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Abstract	  	  Much	  of	  our	  current	  understanding	  regarding	  trauma,	  mechanisms	  of	  healing,	  and	  treatment	  strategies	  have	  evolved	  as	  a	  result	  of	  injuries	  suffered	  during	  armed	  conflict.	  	  While	  our	  understanding	  of	  these	  processes	  has	  advanced	  during	  and	  since	  these	  conflicts,	  treatment	  methods	  of	  traumatic	  wound	  healing	  have	  failed	  to	  progress	  significantly	  in	  the	  last	  forty	  years.	  	  The	  overall	  objective	  of	  this	  research	  was	  to	  test	  the	  hypothesis	  that	  the	  immune	  regulating	  hormone	  Androstenediol	  (AED)	  modulates	  the	  host’s	  immune	  system	  to	  promote	  wound	  healing	  under	  conditions	  where	  it	  has	  been	  inhibited	  by	  stress	  and	  infection.	  	  In	  an	  effort	  to	  characterize	  the	  effects	  of	  Androstenediol	  on	  healing	  following	  trauma,	  this	  research	  focused	  on	  strategies	  to	  evaluate	  which	  levels	  of	  trauma,	  immunosuppressive	  agents,	  and	  Androstenediol	  are	  required	  to	  reverse	  inhibition	  of	  healing.	  	  Sprague-­‐Dawley	  rats	  were	  assessed	  for	  their	  response	  to	  trauma	  and	  intervention	  through	  assessment	  of	  white	  blood	  cell	  levels,	  cytokine	  and	  chemokine	  expression,	  and	  quantification	  of	  wound	  closure.	  	  While	  these	  studies	  did	  provide	  some	  trends	  reflecting	  modulation	  of	  cell	  counts	  and	  protein	  expression	  following	  AED	  treatment	  in	  immune-­‐suppressed	  animals,	  measurement	  of	  wound	  closure	  failed	  to	  reveal	  a	  significant	  response.	  
Introduction	  	   The	  immune	  system	  uses	  a	  variety	  of	  mechanisms	  to	  communicate	  and	  coordinate	  a	  synchronized	  response	  to	  a	  range	  of	  both	  perceived	  and	  real	  threats	  to	  the	  health	  of	  the	  host.	  	  These	  threats	  include	  foreign	  viruses,	  bacteria,	  parasites,	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oncogenic	  host	  cells,	  autoimmune	  disease	  and	  damage	  from	  trauma.	  	  The	  mechanisms	  by	  which	  the	  innate	  and	  adaptive	  immune	  responses	  are	  coordinated	  to	  respond	  to	  these	  threats	  occur	  through	  different	  pathways,	  including	  direct	  cell-­‐to-­‐cell	  interactions	  and	  secretion	  of	  signaling	  proteins.	  	  These	  signaling	  cascades	  most	  frequently	  result	  in	  the	  activation	  of	  formerly	  naïve	  cells,	  recruitment	  of	  phagocytic	  and	  cytotoxic	  cells,	  and	  as	  a	  result,	  resolution	  of	  the	  threat,	  and	  if	  applicable,	  initiation	  of	  the	  healing	  process.	  	  Both	  external	  and	  internal	  influences	  can	  stimulate,	  inhibit,	  disable,	  or	  misdirect	  this	  coordination	  of	  the	  immune	  system	  thus	  resulting	  in	  a	  furtherance	  of	  the	  infectious	  or	  traumatic	  process	  and	  further	  inhibition	  of	  resolution	  and	  healing.	  	  	  In	  clinical	  medicine,	  one	  of	  the	  most	  common	  mechanisms	  of	  inhibiting	  the	  immune	  system	  and	  healing	  process	  are	  through	  the	  use	  of	  glucocorticoids.	  	  In	  addition	  to	  those	  glucocorticoids	  given	  for	  the	  treatment	  of	  a	  broad	  variety	  of	  human	  ailments,	  the	  human	  body	  is	  capable	  of	  producing	  the	  same	  potent	  immunosuppressants.	  	  It	  is	  well	  known	  that	  the	  human	  body	  is	  driven	  to	  produce	  glucocorticoids	  in	  excess	  in	  response	  to	  stressors.	  	  As	  with	  many	  if	  not	  all	  of	  the	  systems	  in	  human	  physiology,	  there	  exists	  a	  balance.	  	  Studies	  have	  shown	  that	  men	  and	  women,	  who	  are	  known	  to	  express	  different	  sex	  steroids	  at	  difference	  ages,	  experience	  an	  increase	  or	  counter	  to	  their	  own	  endogenous	  steroids	  in	  response	  to	  infection	  and	  or	  trauma.	  	  Science	  has	  sought	  for	  some	  time	  to	  exploit	  these	  differences	  by	  studying	  the	  mechanisms	  of	  sex	  steroids	  and	  their	  ability	  to	  create	  an	  environment	  that	  supports	  the	  resolution	  of	  infection	  or	  trauma	  while	  enabling	  the	  healing	  process.	  	  Androstenediol,	  the	  immediate	  derivative	  of	  the	  powerful	  sex	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steroid	  DHEA,	  has	  been	  examined	  extensively	  for	  its	  ability	  to	  modulate	  the	  immune	  system.	  	  It	  has	  been	  characterized	  for	  having	  effects	  in	  resistance	  to	  damage	  from	  ionizing	  radiation,	  bacterial	  and	  viral	  infection,	  and	  following	  hemorrhage	  and	  trauma	  [1-­‐3].	  	  In	  studies	  of	  mice	  receiving	  traumatic	  injury,	  androstenediol	  was	  shown	  to	  reverse	  the	  inhibition	  brought	  about	  by	  the	  potent	  glucocorticoid	  methylprednisolone,	  and	  to	  return	  healing	  to	  a	  timeline	  similar	  to	  mice	  receiving	  no	  immunomodulatory	  inhibition	  (Figure	  1).	  	  Similar	  studies	  have	  shown	  that	  the	  close	  derivative	  of	  androstenediol,	  androstenetriol,	  can	  improve	  survival	  in	  several	  animal	  based	  shock-­‐trauma	  models	  [4,	  5].	  	  It	  may	  then	  be	  hypothesized	  that	  given	  both	  the	  healing	  effects	  of	  androstenediol	  in	  mice,	  and	  the	  bioactive	  immunomodulatory	  effects	  of	  androstenetriol	  in	  rats,	  that	  androstenediol	  may	  exhibit	  a	  similar	  immunomodulatory	  effect	  on	  steroid	  inhibited	  wound	  healing	  in	  rats.	  
	  
Figure	  1:	  	  Illustration	  of	  the	  changes	  in	  rate	  of	  wound	  healing	  in	  murine	  model.	  From	  [6].	  
Monday,	  August	  9,	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  F.	  Jerome	  Diskin	  4	  
	  
	  
Purpose	  	  Of	  the	  many	  complications	  of	  battlefield	  injuries,	  stress	  is	  perhaps	  the	  most	  poorly	  understood	  mechanism	  contributing	  to	  the	  morbidity	  and	  mortality	  of	  those	  suffering	  traumatic	  injury.	  	  	  As	  previously	  described,	  a	  number	  of	  biologically	  relevant	  metabolites	  of	  DHEA	  have	  been	  demonstrated	  to	  provide	  significant	  immunomodulation	  to	  the	  benefit	  of	  the	  test	  subjects.	  	  Currently,	  the	  US	  Army	  is	  seeking	  to	  demonstrate	  the	  effects	  of	  improved	  wound	  healing	  in	  a	  model	  simulating	  full-­‐thickness	  wounds	  in	  male	  Sprague	  Dawley	  rats.	  While	  this	  lab	  has	  previously	  demonstrated	  the	  effects	  of	  improved	  wound	  healing	  via	  androstenediol	  in	  mice,	  other	  labs	  have	  shown	  that	  administration	  of	  androstenediol	  following	  trauma/hemorrhage	  reduces	  the	  activity	  of	  pro-­‐apoptotic	  mediators	  [7].	  	  This	  reduction	  in	  pre-­‐apoptotic	  mediators	  may	  have	  a	  role	  in	  improved	  healing	  following	  trauma.	  	  Our	  efforts	  here	  seek	  to	  illustrate	  this	  role	  in	  the	  rat	  model	  and	  to	  characterize	  the	  nature	  of	  the	  immumodulatory	  effects	  through	  analysis	  of	  cytokines,	  chemokines,	  and	  gross	  cellular	  profile	  as	  well	  as	  wound	  image	  analysis.	  	  Specifically,	  the	  following	  experiments	  represent	  the	  pilot	  studies	  conducted	  in	  order	  to	  determine	  the	  experimental	  parameters	  for	  the	  larger	  research	  project.	  
Clinical	  Significance	  	   According	  to	  data	  collected	  by	  the	  World	  Health	  Organization	  [8],	  injury	  deaths	  worldwide	  are	  expected	  to	  continue	  to	  rise	  past	  the	  recorded	  2000	  levels	  of	  more	  than	  5	  million.	  	  Composed	  of	  deaths	  from	  a	  variety	  of	  mechanisms,	  including	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traffic	  injuries,	  falls,	  war,	  and	  acts	  of	  civilian	  violence,	  the	  American	  College	  of	  Surgeons	  Committee	  on	  Trauma	  uses	  a	  trimodal	  division	  of	  injuries	  to	  describe	  their	  individual	  time-­‐course	  [9].	  	  The	  first	  two	  phases	  of	  this	  trimodal	  distribution	  govern	  events	  immediately	  following	  an	  injury	  to	  hours	  later	  and	  offer	  little	  opportunity	  for	  intervention	  beyond	  the	  well-­‐proven	  methods	  of	  pre-­‐hospital	  care	  and	  traditional	  medicine.	  	  These	  patients	  are	  either	  beyond	  saving	  due	  to	  the	  severity	  and	  immediate	  nature	  of	  their	  injuries,	  or	  are	  going	  to	  benefit	  from	  those	  trained	  specifically	  to	  treat	  trauma	  patients	  within	  the	  “Golden	  Hour”.	  	  It	  is	  however,	  the	  patients	  who	  fall	  within	  this	  third	  phase	  that	  persist	  for	  weeks	  to	  months	  that	  allow	  the	  opportunity	  to	  modulate	  the	  immune	  system	  to	  the	  benefit	  of	  the	  patient.	  	  Frequently,	  these	  patients	  succumb	  days	  to	  weeks	  later	  due	  to	  an	  avalanche	  of	  circumstances,	  often	  involving	  an	  either	  over-­‐active	  or	  ineffective	  immune	  system.	  	  While	  medicine	  has	  made	  strident	  progress	  in	  preventing	  further	  illness	  from	  external	  sources,	  our	  tools	  for	  manipulating	  the	  immune	  system	  to	  our	  advantage	  remain	  limited.	  	  The	  careful	  balance	  between	  an	  overzealous	  and	  an	  underperforming	  immune	  system	  can	  mean	  the	  choice	  between	  life	  and	  death.	  	  Thus,	  the	  opportunity	  to	  modulate	  one	  of	  the	  most	  pervasive	  and	  powerful	  systems	  in	  human	  physiology	  during	  a	  time	  of	  compromised	  health	  may	  provide	  the	  tools	  to	  drastically	  improve	  outcomes	  following	  traumatic	  injury.	  	  	  
Mechanisms	  of	  Healing	  	   The	  last	  generation	  of	  science	  has	  brought	  about	  the	  characterization	  of	  many	  important	  physiological	  processes.	  	  Perhaps	  few	  are	  more	  important	  than	  those	  leading	  to	  an	  understanding	  of	  the	  mechanisms	  behind	  the	  healing	  of	  human	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tissue	  and	  the	  processes	  that	  can	  interfere	  with	  normal	  healing.	  	  Normal	  healing	  has	  been	  characterized	  as	  “acute”;	  described	  as	  a	  timely,	  structured,	  and	  efficient	  manner	  of	  healing	  resulting	  in	  the	  closest	  approximation	  of	  undamaged	  tissue	  endowed	  with	  the	  functions	  and	  appearance	  present	  prior	  to	  injury.	  	  This	  close	  approximation	  of	  the	  former	  state	  does	  not	  come	  about	  through	  haphazard	  coincidence,	  but	  through	  carefully	  coordinated	  steps	  regulated	  by	  specific	  cells	  and	  their	  signaling	  mechanisms.	  	  The	  four	  phases	  which	  overlap	  to	  produce	  an	  acute	  healing	  process	  have	  been	  described	  as:	  hemostasis,	  inflammation,	  proliferation,	  and	  remodeling	  [10].	  	  	  The	  hemostatic	  phase	  is	  focused	  on	  the	  restoration	  of	  a	  closed	  circulatory	  system	  following	  trauma	  or	  injury.	  	  As	  is	  commonly	  known,	  this	  process	  is	  primarily	  mediated	  by	  thrombocytes	  and	  is	  initiated	  by	  thrombocyte	  contact	  with	  elements	  of	  the	  extracellular	  matrix.	  	  In	  conjunction	  with	  the	  induction	  of	  the	  clotting	  cascade,	  thrombocytes	  also	  release	  immunomodulatory	  cytokines	  including	  TGF-­‐β	  and	  platelet-­‐derived	  growth	  factor	  (PDGF).	  	  The	  clotting	  cascade	  results	  in	  the	  cleavage	  of	  fibrinogen	  into	  fibrin	  and	  aggregation	  of	  the	  clotting	  agents.	  	  	  Following	  the	  cessation	  of	  hemorrhage	  now	  damaged	  tissue	  presents	  the	  signals	  necessary	  to	  recruit	  the	  messengers	  of	  inflammation	  and	  initiate	  the	  inflammatory	  cascade.	  	  Circulating	  neutrophils	  are	  attracted	  to	  the	  site	  of	  injury	  courtesy	  the	  ligands	  displayed	  on	  endothelial	  cells	  proximal	  to	  the	  site	  of	  injury	  and	  by	  the	  cytokines	  expressed	  by	  thrombocytes	  present	  at	  the	  site	  of	  injury.	  	  Within	  twenty-­‐four	  hours,	  neutrophils	  and	  macrophages	  begin	  their	  initial	  tasks	  of	  clearing	  invasive	  species	  as	  well	  as	  debris.	  	  T	  and	  B	  cells	  then	  join	  the	  process,	  and	  all	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contribute	  to	  the	  inflammatory	  state.	  	  The	  arrival	  and	  subsequent	  activation	  of	  all	  of	  these	  inflammatory	  mediators	  lay	  the	  foundation	  for	  a	  complex	  physiological	  response	  engineered	  to	  clear	  the	  wound	  of	  foreign	  material	  and	  damaged	  tissue,	  thus	  setting	  the	  stage	  for	  proper	  scaring,	  angiogenesis,	  epithelization,	  and	  finally,	  remodeling.	  	  Naturally,	  as	  is	  evident	  in	  many	  wound-­‐healing	  pathologies,	  the	  careful	  equilibrium	  between	  the	  destruction	  of	  damaged	  tissue	  and	  foreign	  material,	  and	  construction	  of	  new	  tissue	  can	  be	  shifted	  in	  favor	  of	  a	  chronic	  wound	  with	  unresolved	  healing	  characteristics	  or	  an	  “overhealed”	  wound	  characterized	  by	  excessive	  production	  of	  new	  tissue.	  	  Frequently,	  these	  misguided	  healing	  pathways	  are	  result	  of	  improper	  cellular	  signaling,	  including	  those	  signaling	  mechanisms	  involving	  cytokines	  and	  chemokines	  expressed	  in	  the	  inflammatory	  phase	  of	  healing.	  	  	  The	  chemical	  signaling	  that	  draws	  the	  cells	  of	  the	  inflammatory	  response	  is	  also	  responsible	  for	  initiating	  the	  fibroblast	  migration	  that	  is	  hallmark	  of	  the	  proliferative	  phase.	  	  Fibroblasts	  are	  rarely	  found	  in	  normal	  tissue;	  growth	  factors	  and	  cytokines	  such	  as	  Fibroblast	  Growth	  Factor	  (FGF),	  PDGF,	  and	  TGF-­‐β	  are	  responsible	  for	  drawing	  in	  and	  activating	  otherwise	  naïve	  fibroblasts	  [11].	  	  The	  recruited	  fibroblasts	  are	  responsible	  for	  deposition	  of	  the	  most	  abundant	  protein	  in	  the	  animal	  kingdom,	  collagen.	  	  The	  deposition	  of	  collagen	  into	  the	  wound	  site	  is	  followed	  by	  a	  complex	  pathway	  of	  modification	  and	  cross-­‐linking	  resulting	  in	  the	  formation	  of	  a	  scar	  matrix.	  	  In	  order	  for	  the	  newly	  deposited	  tissue	  to	  survive,	  cells	  will	  require	  the	  oxygen	  and	  nutrients	  that	  can	  only	  be	  delivered	  by	  the	  vasculature.	  	  Again,	  the	  same	  factors	  that	  drive	  recruitment	  and	  proliferation	  of	  fibroblasts	  work	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in	  conjunction	  with	  low	  oxygen	  tension	  to	  induce	  the	  recruitment	  and	  differentiation	  of	  endothelial	  cells	  and	  their	  precursors.	  	  	  The	  new	  combination	  of	  tissues,	  collagen,	  extracellular	  matrix,	  and	  vasculature	  now	  assumes	  the	  conformation	  of	  “granulation”	  tissue	  and	  waits	  only	  for	  the	  epithelization	  and	  the	  remodeling	  phase	  before	  assuming	  up	  to	  eighty	  percent	  of	  the	  strength	  of	  native	  tissue.	  	  In	  order	  to	  cover	  the	  site	  of	  injury,	  epithelial	  cells	  from	  the	  margins	  of	  the	  wound	  begin	  to	  migrate	  toward	  the	  center.	  	  Through	  the	  signaling	  of	  growth	  factors	  and	  cytokines,	  the	  existing	  marginal	  cells	  dissolve	  their	  bonds	  with	  the	  underlying	  dermis	  and	  migrate	  until	  meeting	  epithelial	  cells	  from	  the	  opposite	  side.	  	  This	  contact	  completes	  the	  migrational	  phase	  and	  induces	  the	  cells	  to	  begin	  proliferating	  into	  the	  differential	  layers	  characteristic	  of	  the	  epidermis.	  	  During	  this	  final	  phase	  of	  healing,	  the	  newly	  deposited	  matrix	  is	  reorganized	  into	  a	  stronger	  medium,	  new	  capillaries	  merge	  into	  larger	  vascular	  structures,	  and	  metabolic	  activity	  finally	  drops,	  resulting	  the	  familiar	  scar	  tissue	  associated	  with	  a	  healed	  injury.	  	  The	  final	  strength	  of	  the	  wound	  site	  is	  largely	  a	  result	  of	  the	  re-­‐orientation	  and	  cross-­‐linking	  of	  collagen	  fibers	  that	  were	  initially	  deposited	  into	  the	  wound	  site.	  	  Additionally,	  the	  more	  elastic	  Type-­‐III	  collagen	  initially	  deposited	  by	  fibroblasts	  is	  replaced	  over	  time	  by	  the	  more	  rigorous	  and	  widespread	  Type-­‐I	  collagen.	  	  The	  final	  remodeling	  of	  the	  epithelial	  and	  dermal	  layers	  may	  take	  several	  months,	  or	  longer	  under	  pathological,	  sub-­‐nutritional,	  or	  stressful	  conditions,	  and	  result	  in	  a	  healed	  wound	  with	  up	  to	  eighty	  percent	  of	  the	  strength	  of	  the	  original	  tissue.	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Th-­‐1	  vs.	  Th-­‐2	  Responses	  in	  Healing	  	   As	  the	  immune	  system	  has	  long	  been	  held	  to	  have	  a	  role	  in	  the	  healing	  process,	  medicine	  has	  also	  sought	  to	  relate	  some	  of	  the	  known	  mechanisms	  in	  the	  immune	  system	  to	  their	  effect	  on	  healing.	  	  One	  of	  the	  moderately	  well	  known	  immune	  mechanisms	  thought	  to	  have	  implications	  on	  healing	  has	  been	  the	  balance	  between	  the	  several	  species	  of	  T	  helper	  cells.	  	  CD4+	  T	  helper	  cells	  (Th	  cells)	  arise	  from	  the	  same	  common	  lymphoid	  progenitor	  as	  the	  more	  aggressive	  CD8+	  cytotoxic	  “killer”	  T-­‐cells	  [12].	  	  However,	  their	  effectiveness	  comes	  not	  from	  “killing”	  or	  simply	  initiating	  apoptosis	  directly	  in	  infected	  cells,	  although	  this	  activity	  has	  been	  demonstrated	  in	  vitro,	  but	  in	  several	  less	  direct	  activities	  that	  have	  more	  widely	  distributed	  effects.	  	  Namely,	  CD4+	  Th	  cell	  direct	  other	  system	  to	  take	  on	  characteristics	  unfavorable	  toward	  invading	  or	  pathogenic	  species	  by	  either	  activating	  phagocytic	  or	  antibody	  producing	  cells.	  	  This	  therefore	  provides	  the	  difference	  in	  distinguishing	  between	  CD4+Th-­‐1	  and	  CD4+Th-­‐2	  cells.	  	  Specifically,	  Th-­‐1	  cells	  are	  associated	  with	  the	  activation	  of	  macrophages	  and	  dendritic	  cells	  (CMI	  or	  cell-­‐mediated	  immunity)	  as	  well	  as	  some	  opsonizing	  antibody	  classes	  produced	  by	  B-­‐cells,	  mostly	  IgG.	  	  Conversely,	  Th-­‐2	  cells	  are	  associated	  almost	  exclusively	  with	  the	  production	  of	  antibodies	  by	  B-­‐cells,	  most	  notable	  the	  M,	  A,	  and	  E	  classes.	  	  As	  some	  pathogens	  have	  evolved	  to	  exploit	  antigen	  presenting	  cells	  such	  as	  macrophages	  and	  dendritic	  cells,	  these	  variations	  in	  characteristics	  have	  dramatic	  implications	  in	  the	  ability	  to	  counter	  disease.	  	  While	  some	  of	  the	  functions	  of	  these	  T-­‐helper	  cells	  are	  dependent	  on	  cell-­‐to-­‐cell	  contact,	  many	  of	  their	  mechanisms	  are	  reliant	  on	  cytokines	  and	  chemokines	  being	  transmitted	  to	  target	  cells.	  	  Th-­‐1	  cells	  have	  been	  associated	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with	  release	  of	  such	  cytokines	  as	  IL-­‐2,	  IL-­‐3,	  IFN-­‐γ,	  TNF-­‐β,	  TNF-­‐α,	  and	  GM-­‐CSF.	  	  Of	  these,	  IFN-­‐γ,	  TNF-­‐β,	  and	  TNF-­‐α	  are	  known	  to	  activate	  otherwise	  naïve	  macrophages	  and	  IL-­‐2	  serves	  as	  a	  positive	  regulator	  of	  T-­‐cells,	  in	  opposition	  of	  the	  effects	  of	  glucocorticoids	  such	  as	  cortisone	  [13].	  	  Conversely,	  Th-­‐2	  cells	  are	  more	  closely	  associated	  with	  the	  release	  of	  IL-­‐3,	  IL-­‐4,	  IL-­‐5,	  and	  IL-­‐10,	  which	  are	  more	  directly	  related	  to	  increased	  activity	  among	  B-­‐cells	  and	  their	  subsequent	  release	  of	  antibodies.	  	  	  Interestingly,	  the	  cytokines	  released	  by	  the	  individual	  Th	  species	  mentioned	  here	  have	  inhibitory	  effects	  on	  the	  other,	  further	  swinging	  the	  pendulum	  in	  favor	  of	  its	  own	  response	  at	  the	  expense	  of	  the	  other.	  	  As	  illustrated	  before,	  the	  inflammatory	  response	  mediates	  the	  recruitment	  of	  a	  wide	  variety	  of	  cell	  types	  expressing	  an	  even	  more	  varied	  collection	  of	  cytokines,	  chemokines,	  and	  other	  signaling	  mediators.	  	  This	  inflammatory	  response	  may	  play	  a	  direct	  role	  in	  defining	  the	  species	  of	  Th	  cells	  present	  at	  the	  site	  of	  injury.	  	  Unlike	  most	  cells	  that	  reach	  final	  differentiation	  following	  proliferation,	  T-­‐helper	  cells	  circulate	  in	  a	  naïve	  state,	  waiting	  for	  the	  appropriate	  stimuli	  to	  drive	  them	  into	  a	  Th-­‐1,	  Th-­‐2,	  or	  more	  exotic	  lineage.	  	  In	  vitro	  
studies	  have	  suggested	  that	  the	  signaling	  milieu	  present	  at	  the	  site	  of	  injury	  and	  
inflammation	  appears	  to	  favor	  the	  Th-­1	  lineage	  [14].	  	  The	  signals	  involved	  in	  driving	  Th-­‐1	  and	  Th-­‐2	  lineages	  are	  poorly	  understood.	  	  However,	  some	  research	  has	  indicated	  that	  select	  cytokines	  will	  favor	  one	  type	  of	  T-­‐helper	  cell	  over	  another.	  	  Specifically,	  IL-­‐12	  and	  IFN-­‐γ	  are	  thought	  to	  promote	  a	  Th-­‐1	  helper	  cell	  lineage,	  while	  Il-­‐4	  and	  Il-­‐6	  are	  expressed	  in	  Th-­‐2	  differentiation.	  	  Naturally,	  the	  cytokines	  thought	  to	  promote	  the	  expression	  of	  one	  species	  have	  also	  been	  observed	  to	  inhibit	  the	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differentiation	  and	  proliferation	  of	  the	  other	  lineage.	  	  The	  signals	  thought	  to	  be	  responsible	  for	  the	  differentiation	  onto	  the	  Th-­‐1	  lineage	  at	  the	  site	  of	  inflammation	  may	  be	  secreted	  by	  a	  number	  of	  sources.	  	  In	  addition,	  signals	  such	  as	  CCL3,	  CCL4,	  and	  CCL5	  have	  been	  shown	  to	  be	  released	  by	  antigen	  presenting	  cells	  such	  as	  dendritic	  cells	  or	  macrophages	  as	  well	  as	  endothelial	  cells.	  	  While	  these	  signals	  do	  not	  themselves	  drive	  a	  Th-­‐1	  response,	  they	  do	  induce	  the	  release	  of	  IL-­‐12	  from	  dendritic	  cells,	  which	  has	  been	  shown	  to	  drive	  naïve	  T	  cells	  into	  Th-­‐1	  differentiation.	  	  While	  this	  illustration	  does	  present	  data	  to	  implicate	  Th-­‐1	  cells	  alone	  in	  injury	  and	  inflammation,	  it	  should	  be	  noted	  that	  as	  with	  most	  responses	  in	  biology,	  there	  exists	  a	  balance	  between	  the	  Th-­‐1	  and	  Th-­‐2	  responses	  that	  should	  eventually	  resolve	  to	  the	  equilibrium	  seen	  in	  normal	  physiology.	  
Role	  of	  Endogenous	  Steroids	  in	  Healing	  	  Stress	  has	  long	  been	  tied	  to	  numerous	  changes	  in	  physiology	  in	  animal	  models	  as	  well	  as	  human	  subjects,	  including	  graduate	  students.	  	  These	  physiological	  changes	  manifest	  in	  many	  ways,	  including	  changes	  in	  body	  mass,	  immune	  cell	  profiles,	  as	  well	  as	  changes	  in	  the	  timeline	  and	  efficacy	  of	  healing.	  	  Many	  mechanisms	  have	  been	  documented	  as	  contributing	  to	  these	  manifestations	  of	  stress	  induction,	  though	  perhaps	  none	  more	  centrally	  understood	  as	  the	  role	  of	  endogenous	  steroids.	  	  While	  the	  moniker	  can	  be	  applied	  to	  sex	  steroids	  and	  mineralocorticoids,	  which	  are	  both	  thought	  to	  contribute,	  the	  primary	  actors	  in	  the	  stress	  response	  are	  the	  glucocorticoids.	  	  So	  named	  due	  to	  their	  origin	  in	  the	  adrenal	  cortex	  and	  their	  regulation	  of	  blood	  glucose,	  the	  glucocorticoids	  cortisol,	  cortisone,	  and	  corticosterone	  have	  diverse	  effects	  in	  physiology.	  	  The	  major	  player	  in	  humans	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however,	  cortisol,	  has	  been	  identified	  as	  having	  the	  most	  widely	  distributed	  and	  powerful	  effects,	  particularly	  on	  wound	  healing.	  	  Due	  to	  the	  complex	  nature	  of	  glucocorticoids	  and	  their	  receptors,	  wide	  variation	  of	  effects,	  and	  contributing	  factors,	  little	  is	  known	  about	  the	  effects	  of	  cortisol	  on	  wound	  healing.	  	  What	  is	  known	  about	  cortisol	  is	  that	  it	  does	  not	  work	  alone;	  indeed	  studies	  have	  shown	  that	  it	  is	  the	  interaction	  with	  immune	  cytokines	  such	  as	  IL-­‐1β,	  IL-­‐1α,	  IL-­‐6,	  IL-­‐8	  and	  TNF-­‐
α	  that	  coordinate	  the	  effects	  of	  stress	  and	  cortisol	  on	  healing,	  most	  likely	  at	  the	  site	  of	  injury	  [15].	  	  	  When	  considering	  the	  induction	  of	  glucocorticoids	  by	  cytokines,	  early	  reports	  suggested	  that	  the	  interaction	  between	  cytokines	  and	  the	  hypothalamo-­‐pituitary-­‐axis	  (Figure	  2)	  took	  place	  in	  the	  brain	  via	  defects	  in	  the	  blood	  brain	  barrier,	  more	  recent	  papers	  have	  suggested	  that	  the	  signaling	  is	  provided	  at	  local	  sites	  of	  inflammation	  or	  injury	  which	  are	  then	  transmitted	  to	  the	  brain	  via	  afferent	  sensory	  nerves	  [16].	  	  Following	  stimulation	  in	  the	  brain,	  the	  classical	  and	  well-­‐demonstrated	  human	  Andrenocortico	  System	  then	  proceeds	  via	  synthesis	  of	  the	  forty-­‐one	  amino	  acid	  corticotrophin	  releasing	  factor	  (CRF)	  in	  the	  hypothalamus.	  	  CRF	  stimulates	  the	  production	  of	  adrenocorticotropic	  hormone	  (ACTH)	  from	  the	  anterior	  pituitary.	  	  ACTH	  then	  drives	  the	  production	  of	  cortisol	  and	  cortisone	  in	  the	  zona	  fasciculate	  of	  the	  adrenal	  cortex.	  	  This	  extremely	  powerful	  modulator	  of	  multiple	  physiologic	  systems	  also	  exhibits	  powerful	  responses	  to	  feedback	  inhibition,	  primarily	  by	  increased	  levels	  of	  cortisone	  and	  ACTH	  receptors	  in	  the	  brain.	  	  Globally,	  this	  activation	  of	  the	  hypothalamo-­‐pituitary-­‐axis	  with	  subsequent	  synthesis	  of	  cortisone	  is	  seen	  as	  itself	  a	  feedback	  mechanism	  in	  response	  to	  a	  pro-­‐
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inflammatory	  state	  [16],	  and	  typically	  favors	  a	  Th-­‐2	  environment	  at	  the	  expense	  of	  Th-­‐1	  cells.	  	  Other	  factors	  responsible	  for	  driving	  the	  increases	  on	  cortisol	  as	  well	  as	  other	  mediators	  are	  widely	  varied	  and	  include	  social,	  environmental,	  and	  nutritional	  effectors	  [15,	  17,	  18].	  	  	  	  These	  stress-­‐to-­‐healing	  relationships	  typically	  correlate	  an	  increase	  in	  endogenous	  cortisol	  levels	  with	  changes	  in	  healing	  efficacy	  and	  timeline.	  	  Further	  research	  has	  also	  demonstrated	  that	  removal	  of	  the	  organs	  responsible	  for	  the	  secretion	  of	  cortisol	  and	  its	  derivatives	  returns	  the	  healing	  process	  to	  a	  near-­‐normal	  process	  .	  	  	  
	  
Figure	  2:	  	  Hypothalamo-­pituitary	  axis	  	  While	  the	  activities	  of	  the	  glucocorticoids	  are	  closely	  related	  between	  the	  sexes,	  the	  very	  nature	  of	  the	  sexual	  dimorphism	  between	  males	  and	  females	  provides	  for	  comparisons	  of	  the	  effects	  of	  sex	  steroids	  on	  response	  to	  infection	  as	  well	  as	  healing.	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Male	  and	  female	  study	  subjects	  in	  both	  human	  and	  animal	  studies	  have	  been	  shown	  to	  react	  differently	  to	  different	  forms	  of	  trauma,	  including	  frank	  trauma,	  burn	  injuries,	  as	  well	  as	  trauma/hemorrhage	  experiments.	  	  These	  studies	  have	  drawn	  relationships	  between	  the	  types	  of	  sex	  steroids	  expressed	  in	  a	  model	  and	  the	  propensity	  to	  recover	  from	  or	  even	  survive	  traumatic	  injury.	  	  Indeed,	  some	  studies	  have	  gone	  so	  far	  as	  to	  demonstrate	  that	  male	  subjects	  are	  more	  likely	  to	  survive	  burn	  injuries	  while	  female	  subjects	  are	  better	  equipped	  to	  recover	  from	  trauma/hemorrhage	  injuries	  [19].	  	  	  While	  the	  relationship	  between	  sex	  steroids	  and	  healing	  may	  seem	  to	  be	  tenuous	  at	  best,	  studies	  have	  shown	  that	  in	  addition	  to	  the	  receptors	  found	  in	  reproductive	  tissues,	  mediators	  of	  the	  immune	  system	  are	  also	  known	  to	  have	  receptors	  for	  sex	  steroids.	  	  T-­‐cells,	  monocytes,	  macrophages	  as	  well	  as	  others	  are	  known	  to	  be	  modulated	  by	  sex	  steroids.	  	  These	  same	  cells	  are	  also	  known	  to	  play	  an	  active	  role	  in	  response	  to	  healing	  following	  trauma	  and	  other	  insults.	  	  Complicating	  the	  issue	  however,	  is	  the	  fact	  that	  many	  of	  these	  mediators	  of	  the	  immune	  system	  respond	  in	  an	  inverse	  manner	  to	  different	  sex	  steroids.	  	  Work	  by	  Bird	  et	  al.	  demonstrated	  that	  estradiol	  and	  testosterone	  promote	  opposite	  effects	  in	  neutrophil	  invasion	  into	  tissues,	  following	  a	  similar	  relationship	  in	  calcium	  influx.	  	  As	  the	  effects	  of	  the	  sex	  steroids	  can	  be	  shown	  to	  have	  effects	  on	  the	  migration	  of	  immunomodulatory	  cells,	  this	  is	  not	  the	  only	  known	  effect	  on	  healing.	  	  The	  effects	  of	  oral	  contraceptives	  on	  coagulation	  and	  inflammation	  are	  well	  known	  within	  research	  and	  medicine.	  	  Conversely,	  research	  studies	  have	  also	  demonstrated	  that	  estradiol	  antagonists	  can	  promote	  a	  less	  coagulable	  state	  [20].	  	  As	  estradiol	  has	  been	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shown	  to	  have	  a	  direct	  impact	  on	  the	  activity	  of	  the	  clotting	  cascade,	  it	  may	  be	  hypothesized	  that	  this	  effect	  may	  eventually	  result	  in	  a	  more	  effective	  foundation	  for	  healing	  by	  providing	  the	  signals	  required	  for	  the	  establishment	  of	  a	  clot	  and	  eventually	  a	  fibrin	  lattice.	  	  However,	  the	  effects	  of	  the	  sex	  steroids	  with	  regard	  to	  the	  immune	  system	  and	  healing	  are	  not	  limited	  to	  the	  aforementioned	  roles.	  	  	  To	  further	  complicate	  this	  scenario,	  the	  already	  discussed	  T-­‐cells	  are	  also	  profoundly	  affected	  by	  the	  levels	  of	  sex	  steroids.	  	  Changes	  in	  the	  immune	  system,	  including	  circulating	  levels	  of	  T-­‐cells,	  are	  well	  known	  to	  occur	  during	  reproductive	  years	  and	  even	  more	  profoundly	  during	  the	  stages	  of	  pregnancy.	  	  Generally	  speaking,	  pregnancy	  is	  thought	  to	  down-­‐regulate	  the	  mechanisms	  responsible	  for	  cell-­‐mediated	  immunity,	  while	  enhancing	  antibody	  concentrations	  and	  up-­‐regulating	  humoral	  immunity	  [21,	  22].	  	  This	  difference	  between	  male	  and	  female	  subjects	  was	  further	  demonstrated	  in	  a	  study	  in	  which	  female	  mice	  receiving	  burns	  under	  anesthesia	  also	  suffered	  a	  40%	  decrease	  in	  CD4+	  T-­‐cells	  when	  compared	  to	  male	  animals	  [23].	  	  Interestingly,	  while	  the	  effects	  of	  a	  burn	  injury	  seem	  to	  provide	  a	  carte	  blanche	  reduction	  in	  the	  levels	  of	  CD4+	  T-­‐cells	  in	  female	  animals,	  Bird	  states	  that	  the	  trauma-­‐hemorrhage	  model	  in	  male	  mice	  drives	  the	  balance	  between	  the	  Th-­‐1	  and	  Th-­‐2	  CD4+	  T-­‐cells	  into	  a	  Th-­‐2	  profile,	  at	  the	  expense	  of	  the	  Th-­‐1	  function.	  	  This	  effect	  was	  ameliorated	  by	  the	  administration	  of	  estradiol.	  	  This	  is	  in	  contrast	  to	  the	  strictly	  trauma	  related	  model	  discussed	  in	  the	  Th-­‐1	  vs.	  Th-­‐2	  section	  and	  several	  publications	  supporting	  the	  discussion.	  	  It	  should	  be	  noted,	  however,	  that	  there	  are	  equally	  compelling	  data	  published	  for	  opposing	  perspectives,	  and	  the	  subject	  awaits	  resolution.	  	  	  
Monday,	  August	  9,	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  F.	  Jerome	  Diskin	  16	  
Much	  of	  the	  research	  regarding	  sex	  steroids	  and	  wound	  healing	  has	  centered	  on	  the	  female	  sex	  steroids,	  most	  likely	  due	  to	  the	  phased	  nature	  of	  the	  steroids	  and	  the	  ability	  to	  study	  different	  levels	  of	  endogenous	  steroids	  simply	  by	  observing	  the	  model	  during	  different	  reproductive	  and	  stage-­‐of-­‐life	  time	  points.	  	  Never	  the	  less,	  the	  effects	  of	  the	  androgens	  cannot	  be	  overlooked.	  	  Structurally	  distinct	  from	  estradiol,	  the	  androgens	  are	  largely	  thought	  to	  have	  opposing	  effects	  when	  compared	  to	  the	  classical	  female	  sex	  steroids.	  	  Work	  examining	  the	  effects	  of	  androgens	  in	  a	  rat	  model	  demonstrated	  that	  dihydrotestosterone	  provided	  a	  wide	  variety	  of	  effects	  including	  delaying	  the	  migration	  of	  epidermal	  keratinocytes	  [24].	  	  Human	  studies	  on	  the	  differences	  between	  male	  and	  female	  subjects	  suffering	  from	  trauma	  are	  of	  course	  subject	  to	  happenstance	  and	  the	  existence	  of	  a	  pre-­‐existing	  study	  mechanism	  in	  place	  to	  measure	  such	  results.	  	  Such	  studies	  have	  sought	  to	  quantify	  the	  extent	  of	  injuries	  and	  provide	  a	  correlation	  between	  the	  expression	  of	  sex	  steroids	  among	  men	  and	  women	  with	  the	  appearance	  of	  well-­‐known	  plasma	  markers	  for	  trauma,	  and	  finally,	  to	  demonstrate	  a	  relationship	  to	  mortality	  and	  morbidity.	  	  These	  studies	  have	  largely	  provided	  inconclusive	  data	  based	  simply	  on	  the	  diversity	  of	  the	  subjects,	  their	  pre-­‐existing	  health	  status,	  injury	  types,	  as	  well	  as	  other	  factors.	  	  Perhaps	  most	  importantly	  though,	  these	  studies	  remind	  that	  the	  sex	  steroids	  are	  indeed	  not	  fixed,	  and	  do	  respond	  to	  trauma	  and	  injury	  as	  the	  other	  steroid	  classes	  may.	  	  In	  a	  study	  of	  female	  subjects	  following	  trauma,	  circulating	  levels	  of	  estradiol	  were	  found	  to	  have	  changes	  in	  as	  few	  as	  12	  hours	  following	  injury	  [25].	  	  Still	  further	  complications	  of	  the	  issues	  surrounding	  the	  effects	  of	  sex	  steroids	  on	  trauma	  and	  healing	  are	  the	  phased	  nature	  of	  sex	  steroid	  expression	  within	  the	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cycle	  of	  menstrual	  activity	  as	  well	  as	  the	  lifetime	  of	  a	  test	  subject.	  	  	  While	  there	  is	  known	  modulation	  of	  the	  levels	  of	  sex	  steroids	  following	  trauma	  and/or	  injury	  the	  levels	  at	  the	  time	  of	  injury	  due	  to	  life	  cycle	  or	  menstrual	  cycle	  may	  have	  additional	  impact	  on	  the	  reaction	  to	  injury.	  	  Human	  females	  of	  childbearing	  age,	  human	  females	  post-­‐menopause,	  as	  well	  as	  men,	  all	  have	  similar	  levels	  of	  circulating	  estradiol.	  	  However,	  it	  may	  be	  the	  status	  of	  the	  body	  and	  it’s	  ability	  to	  react	  to	  injury	  with	  the	  production	  of	  additional	  steroids	  that	  make	  the	  difference	  in	  responding	  to	  insult.	  In	  addition	  to	  the	  complications	  created	  by	  the	  differences	  between	  males	  in	  females	  in	  the	  expression	  of	  steroids	  and	  subsequent	  effects	  on	  healing,	  there	  also	  exist	  differences	  in	  steroid	  expression	  between	  the	  species	  considered	  in	  these	  studies.	  	  Most	  of	  the	  illustrations	  in	  this	  paper	  refer	  to	  the	  steroid	  activity	  in	  humans;	  however,	  the	  steroid	  mechanisms	  in	  rodent	  models	  are	  considered	  to	  be	  significantly	  different.	  	  Researchers	  in	  the	  1950’s	  first	  documented	  the	  predominance	  of	  corticosterone	  expression	  in	  rodent	  plasma,	  coupled	  with	  the	  almost	  non-­‐existent	  expression	  of	  cortisol	  and	  concluded	  that	  rodents	  fail	  to	  express	  the	  critical	  enzyme	  17α-­‐hydroxylase	  [26,	  27].	  	  These	  conclusions	  have	  been	  both	  supported	  and	  refuted	  in	  a	  variety	  of	  studies	  since	  then.	  	  In	  addition,	  other	  authors	  have	  postulated	  that	  the	  expression	  of	  17α-­‐hydroxylase	  may	  be	  temporal,	  increasing	  and	  decreasing	  at	  different	  points	  in	  life	  [28].	  	  This	  however	  does	  not	  change	  the	  fact	  that	  rat	  and	  mouse	  express	  primarily	  corticosterone,	  while	  humans	  are	  known	  to	  primarily	  express	  cortisol	  [29].	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Thus	  the	  process	  for	  healing	  following	  trauma	  or	  other	  injury	  can	  and	  is	  modulated	  by	  endogenously	  produced	  steroids,	  including	  glucocorticoids,	  sex	  steroids,	  and	  likely	  mineralocorticoids.	  	  These	  effects	  vary	  from	  general	  suppression	  of	  the	  immune	  system,	  and	  associated	  delay	  and	  inhibition	  of	  the	  healing	  process	  to	  promotion	  of	  certain	  parts	  of	  the	  immune	  system	  and	  even	  some	  enhancement	  of	  healing.	  	  These	  effects	  are	  dependant	  on	  the	  general	  health	  of	  the	  subject,	  age,	  levels	  of	  stress,	  sexual	  maturity,	  and	  other	  factors	  yet	  to	  be	  realized.	  	  Generally	  speaking,	  the	  sex	  steroid	  estradiol	  seems	  to	  have	  a	  beneficial	  effect	  on	  recovery	  in	  a	  trauma/hemorrhage	  model	  in	  both	  male	  and	  female	  subjects,	  though	  the	  mechanisms	  are	  still	  unknown.	  	  Conversely,	  others	  have	  reported	  that	  the	  androgens	  have	  a	  suppressive	  effect	  on	  the	  immune	  system,	  perhaps	  preventing	  an	  overzealous	  response	  to	  disease	  or	  traumatic	  injuries,	  while	  still	  others	  have	  reported	  an	  increase	  in	  wound	  inflammation	  in	  response	  to	  androgens	  [30,	  31].	  	  In	  the	  application	  of	  AED	  (Figure	  3),	  it	  seems	  likely	  that	  any	  beneficial	  effects	  of	  the	  drug	  would	  come	  from	  its	  ability	  to	  present	  itself	  as	  a	  stable	  analog	  of	  other	  sex	  steroids,	  perhaps	  estradiol	  (Figure	  4),	  which	  with	  it	  bears	  a	  strong	  structural	  resemblance.	  	  The	  effects	  perhaps	  demonstrate	  this	  strong	  structural	  resemblance	  in	  that	  both	  estradiol	  and	  androstenediol	  induce	  in	  PPAR-­‐γ	  [32,	  33].	  
	  
Figure	  3:	  	  Androst-­5-­ene-­3,beta-­17,beta-­diol	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Figure	  4:	  Estradiol	  	  
Catabolism	  of	  Steroids	  in	  Rats	  	   As	  with	  other	  mammals,	  rats	  metabolize	  steroids	  via	  the	  P450	  isoenzymes.	  	  Previous	  studies	  have	  described	  the	  process	  by	  which	  steroids	  are	  hydroxylated	  to	  less	  active	  metabolites	  and	  eventually	  to	  polar	  products	  for	  excretion	  in	  a	  two-­‐phase	  process	  [34].	  	  As	  there	  exists	  a	  sexual	  dimorphism	  in	  the	  expression	  of	  endogenous	  steroids,	  studies	  have	  demonstrated	  that	  there	  also	  exists	  a	  sexual	  dimorphism	  in	  the	  metabolism	  of	  both	  endogenous	  and	  exogenous	  steroids	  in	  mammals	  [35].	  	  As	  one	  might	  expect,	  the	  efficiency	  with	  which	  mammals	  express	  these	  isoenzymes	  and	  thus	  metabolize	  steroids	  are	  affected	  by	  age,	  gross	  health,	  and	  in	  female	  subjects,	  by	  ovulation	  status	  and/or	  pregnancy.	  	  Metabolic	  rates	  tend	  to	  decline	  with	  age,	  and	  in	  post-­‐menopausal	  females.	  	  	  Other	  external	  forces	  can	  affect	  the	  metabolism	  of	  these	  steroid	  families	  as	  well.	  	  The	  presence	  of	  toxins,	  which	  receive	  preferential	  attention	  over	  the	  steroid	  families,	  may	  delay	  or	  inhibit	  metabolism	  of	  the	  steroids.	  	  In	  addition,	  there	  has	  been	  a	  great	  deal	  of	  attention	  paid	  to	  the	  affect	  of	  peroxisome	  proliferators	  on	  the	  activity	  of	  P450	  enzymes.	  	  These	  structurally	  diverse	  chemical	  compounds	  are	  thought	  to	  bind	  with	  a	  variety	  of	  nuclear	  receptors	  in	  order	  to	  alter	  DNA	  transcription	  and	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eventually	  protein	  expression	  patterns.	  	  Specifically,	  these	  compound/receptor	  complexes	  have	  been	  shown	  to	  alter	  the	  expression	  of	  P450	  enzymes,	  resulting	  in	  alterations	  to	  the	  levels	  of	  enzyme	  expression	  as	  well	  as	  alterations	  to	  the	  levels	  of	  metabolites	  or	  precursors	  produced	  or	  altered	  by	  the	  enzymes	  [36].	  	  This	  information	  is	  important	  to	  this	  research	  in	  particular	  as	  previous	  studies	  have	  identified	  an	  interaction	  between	  peroxisome	  proliferator	  activated	  receptors	  (PPAR’s)	  and	  sex	  steroids	  including	  androstenediol,	  estrogen,	  and	  testosterone	  [37-­‐39].	  	  	  
Effects	  of	  Methylprednisolone	  on	  Healing	  	   As	  a	  class,	  glucocorticoids	  have	  been	  widely	  associated	  with	  suppression	  of	  the	  immune	  system	  such	  that	  they	  are	  routinely	  employed	  to	  curb	  human	  diseases	  such	  as	  autoimmune	  disorders,	  cancers,	  as	  well	  as	  injuries	  suffered	  as	  the	  result	  of	  traumatic	  injury.	  	  The	  side	  effects	  of	  glucocorticoid	  use	  are	  equally	  as	  numerous	  as	  the	  diseases	  they	  are	  used	  to	  treat,	  including	  weight	  gain,	  redistribution	  of	  body	  fat,	  anxiety,	  as	  well	  as	  sleeplessness	  and	  other	  physiological	  alterations.	  	  In	  particular,	  glucocorticoids	  (both	  endogenous	  and	  exogenous)	  have	  been	  demonstrated	  to	  delay	  and/or	  alter	  normal	  wound	  healing.	  	  The	  mechanisms	  behind	  the	  activity	  of	  exogenous	  glucocorticoids	  such	  as	  methylprednisolone	  in	  the	  delay	  in	  wound	  healing	  are	  still	  unknown	  today.	  	  	  Early	  efforts	  by	  researchers	  working	  in	  traumatic	  spinal	  cord	  injury	  revealed	  that	  trauma	  resulted	  in	  a	  dramatic	  increase	  in	  the	  presence	  of	  free	  fatty	  acid	  metabolites,	  particularly	  arachidonic	  acid.	  	  The	  presumed	  sources	  of	  this	  precursor	  to	  inflammation	  were	  the	  damaged	  cell	  membranes	  themselves	  [40].	  	  The	  results	  of	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this	  research	  led	  the	  authors	  to	  conclude	  that	  methylprednisolone	  was	  responsible	  for	  amelioration	  of	  the	  inflammation	  cascade	  through	  its	  activity	  as	  an	  antioxidant.	  	  Work	  since	  then	  has	  characterized	  the	  mechanism	  of	  methylprednisolone	  as	  acting	  though	  cytoplasmic	  receptors	  in	  order	  to	  modify	  transcription	  and	  protein	  synthesis,	  thus	  resulting	  in	  inhibiting	  leukocyte	  diapedesis	  to	  the	  site	  of	  inflammation	  as	  well	  as	  inhibiting	  mediators	  of	  the	  inflammatory	  response	  and	  interfering	  with	  antibody	  responses	  and/or	  complement.	  	  Other	  authors	  have	  sought	  to	  demonstrate	  a	  relationship	  between	  the	  use	  of	  glucocorticoids	  and	  changes	  in	  the	  metabolism	  of	  L-­‐Arginine	  through	  the	  up-­‐regulated	  expression	  of	  Arginase	  [11,	  41].	  	  As	  the	  proper	  metabolism	  of	  Arginine	  is	  essential	  to	  proper	  immune	  response	  as	  well	  as	  collagen	  synthesis,	  the	  response	  is	  predictable.	  	  In	  general,	  the	  influence	  of	  glucocorticoids	  has	  been	  seen	  to	  delay	  the	  healing	  of	  open	  wounds,	  to	  produce	  weaker	  replacement	  tissue,	  and	  to	  increase	  the	  incidence	  of	  infection.	  	  As	  with	  most,	  if	  not	  all	  systems	  in	  physiology	  in	  medicine,	  injury	  and	  illness	  require	  a	  balanced	  immune	  system.	  	  Too	  much	  inflammation	  and	  healing	  cannot	  occur,	  frequently	  following	  by	  further	  compromised	  conditions	  of	  health.	  	  Conversely,	  too	  little	  inflammation,	  and	  the	  proper	  influx	  of	  mediators	  are	  not	  supported	  at	  sites	  of	  injury	  or	  illness,	  and	  foreign	  agents	  are	  allowed	  to	  persist.	  	  Thus	  in	  some	  instances	  it	  is	  appropriate	  to	  support	  the	  immune	  system,	  while	  in	  others,	  the	  immune	  system	  and	  inflammation	  must	  be	  countered.	  	  
Rat	  as	  a	  Model	  in	  Healing	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The	  rat	  as	  a	  model	  for	  interpreting	  the	  mysteries	  of	  science	  and	  medicine	  has	  been	  in	  use	  for	  hundreds	  of	  years.	  	  Today,	  various	  rat	  models	  are	  available	  and	  are	  used	  in	  the	  study	  of	  trauma,	  autoimmune	  disease,	  cancer,	  cardiovascular	  disease,	  neurological	  disorders,	  sexual	  function	  and	  dysfunction,	  metabolic	  disease	  as	  well	  as	  other	  maladies.	  	  The	  rat	  genome	  has	  been	  sequenced	  [42],	  revealing	  a	  homology	  similar	  to	  the	  other	  available	  mammalian	  sequences,	  mice	  and	  men.	  	  Due	  to	  the	  wide	  availability	  of	  numerous	  knock-­‐out	  models	  and	  vast	  amounts	  of	  physiologic	  data,	  the	  NIH	  said	  in	  1999	  that	  “in	  many	  ways,	  the	  rat	  model	  is	  the	  most	  appropriate	  model	  of	  human	  disease”	  [43].	  	  The	  NIH	  report	  goes	  forward	  to	  state	  that	  at	  the	  time	  of	  publication,	  there	  existed	  over	  500,000	  scientific	  publications	  based	  on	  rat	  models,	  with	  approximately	  250	  strains	  of	  genetically	  modified	  rats	  for	  experimental	  use.	  	  Over	  ten	  years	  later,	  these	  statistics	  have	  certainly	  been	  exceeded	  with	  a	  PubMed	  search	  identifying	  over	  700,000	  publications	  associated	  with	  the	  search	  term	  “rat”.	  	  More	  specifically	  to	  this	  work,	  the	  rat	  has	  been	  used	  in	  the	  research	  of	  cutaneous	  wound	  healing	  as	  far	  back	  as	  1919	  [44].	  	  In	  the	  first	  of	  a	  series	  of	  two	  papers	  completed	  in	  1919,	  Akaiwa	  produced	  experimental	  data	  illustrating	  the	  changes	  in	  healing	  patterns	  as	  a	  result	  of	  the	  size	  and	  depth	  of	  the	  wound	  induced	  in	  the	  animals	  [44,	  45].	  	  Decades	  later,	  work	  associated	  with	  wound	  healing	  in	  the	  rat	  model	  turned	  to	  examining	  the	  mechanisms	  behind	  healing	  as	  well	  as	  various	  treatment	  method	  to	  promote	  healing.	  	  	  Today,	  the	  rat	  model	  is	  recognized	  as	  advantageous	  due	  to	  the	  size,	  relative	  inexpensive,	  availability,	  and	  increased	  metabolic	  rate	  of	  the	  animal	  when	  compared	  to	  larger	  models	  [46].	  	  At	  the	  same	  time,	  rats	  provide	  for	  the	  proper	  surface	  area	  to	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induce	  and	  evaluate	  wounds	  and	  wound	  healing	  in	  a	  realistic	  scale.	  	  In	  addition,	  the	  animals	  are	  resistant	  to	  different	  physiologic	  insults	  and	  infections	  and	  are	  relatively	  easy	  to	  handle.	  	  Despite	  the	  problems	  in	  comparing	  “loose	  skinned”	  animals	  such	  as	  rats	  to	  “tight	  skinned”	  animals	  such	  as	  humans,	  the	  benefits	  of	  shared	  dermal	  structures,	  healing	  mechanisms,	  and	  dermal	  thermoregulation	  make	  for	  a	  good,	  however	  not	  perfect,	  approximation	  of	  human	  physiology,	  the	  ultimate	  goal.	  	  The	  disadvantages	  of	  the	  rat	  model	  are	  mostly	  based	  on	  presence	  of	  the	  subcutaneous	  paniculus	  carnosus	  muscle	  layer,	  which	  contributes	  to	  healing	  by	  aiding	  in	  contraction	  and	  collagen	  formation	  in	  a	  way	  that	  is	  not	  representative	  of	  human	  physiology	  [47].	  	  For	  this	  reason,	  the	  pig	  is	  commonly	  recognized	  as	  a	  superior	  model,	  despite	  it’s	  own	  poor	  representation	  of	  contraction	  and	  healing	  in	  a	  humanoid	  timescale.	  
Cytokines	  in	  Healing	  vs.	  Wound	  Closure	  	   The	  process	  of	  wound	  healing	  has	  been	  illustrated	  above	  as	  a	  carefully	  coordinated	  process	  that	  requires	  a	  close	  synchronization	  of	  multiple	  mediators	  to	  facilitate	  the	  final	  return	  of	  normal	  structure	  and	  function.	  	  This	  coordination	  obviously	  requires	  a	  complex	  mechanism	  of	  communication	  in	  order	  to	  correctly	  direct	  the	  appropriate	  mediators	  in	  a	  temporal	  and	  space	  sensitive	  manner	  (Figure	  5).	  	  The	  mediators	  capable	  of	  generating	  these	  signaling	  cascades	  are	  products	  of	  the	  cells	  present	  at	  the	  time	  of	  injury	  as	  well	  as	  those	  recruited	  for	  their	  various	  responsibilities,	  namely	  those	  cells	  of	  the	  immune	  system.	  	  There	  has	  been	  a	  great	  deal	  of	  research	  done	  to	  facilitate	  a	  better	  understanding	  of	  the	  relationship	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between	  these	  cells,	  especially	  their	  products,	  and	  the	  evolution	  of	  the	  wound	  in	  a	  normal	  wound	  healing	  process.	  
	  
Figure	  5:	  	  Phase	  Diagram	  of	  Healing	  Process	  	   The	  first	  cells	  to	  introduce	  themselves	  and	  their	  products	  to	  the	  site	  of	  injury	  are	  those	  of	  the	  readily	  available	  innate	  immune	  system.	  	  Neutrophils	  are	  among	  the	  first	  cells	  present	  following	  an	  injury,	  and	  while	  their	  primary	  role	  is	  to	  phagocytize	  damaged	  and	  foreign	  tissue,	  the	  secretion	  of	  GM-­‐CSF	  has	  also	  been	  of	  recent	  interest.	  	  Perhaps	  the	  most	  central	  of	  the	  innate	  immune	  cells	  recruited	  to	  the	  site	  of	  injury	  are	  the	  macrophages.	  	  Research	  in	  animal	  models	  has	  shown	  that	  treatment	  with	  anti-­‐macrophage	  serum,	  anti-­‐macrophage	  monoclonal	  antibodies,	  and	  steroids	  all	  impair	  wound	  debridement	  and	  induce	  fibroplasia,	  while	  the	  introduction	  of	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macrophages	  directly	  into	  the	  wound	  site	  increase	  wound-­‐breaking	  strength	  and	  increases	  collagen	  synthesis	  [48].	  	  Macrophages	  are	  known	  to	  secrete	  several	  cytokines,	  including	  TNF-­‐α,	  IL-­‐1,	  IL-­‐6,	  TGF-­‐α	  and	  TGF-­‐β,	  PDGF,	  and	  insulin-­‐like	  growth	  factor	  one	  (IGF-­‐1).	  	  These	  cytokines	  elicit	  different	  responses	  among	  fibroblasts;	  however,	  the	  overwhelming	  trend	  is	  to	  promote	  fibroblast	  migration	  and	  proliferation.	  	  In	  contrast,	  macrophages	  are	  also	  known	  oxygen	  radicals	  and	  inducible	  nitric	  oxide	  synthase	  (iNOS),	  both	  of	  which	  act	  in	  an	  antimicrobial	  function	  as	  well	  as	  are	  damaging	  to	  host	  tissue.	  	  	  The	  innate	  immune	  system	  is	  however,	  not	  the	  only	  contributor	  to	  wound	  healing.	  	  T-­‐cells	  also	  migrate	  to	  the	  site	  of	  inflammation	  or	  injury	  relatively	  late	  in	  the	  process.	  	  While	  this	  timeline	  suggests	  that	  perhaps	  T-­‐cells	  are	  less	  important	  in	  the	  migration	  and	  proliferation	  of	  fibroblasts,	  and	  thus	  the	  wound	  healing	  process,	  research	  has	  shown	  us	  otherwise.	  	  Globally,	  the	  removal	  of	  the	  thymus	  or	  treatment	  with	  antibodies	  against	  all	  T-­‐cells	  decreases	  wound	  breaking	  strength	  and	  collagen	  content.	  	  Specific	  studies	  against	  T-­‐cell	  subsets	  have	  indicated	  that	  perhaps	  regulatory	  T-­‐cells	  may	  play	  a	  role	  in	  the	  progression	  of	  a	  normal	  healing	  process,	  while	  CD8+	  T-­‐cells	  may	  impair	  normal	  wound	  healing.	  	  CD4+	  T-­‐cells	  also	  displayed	  a	  correlation	  with	  increased	  wound	  breaking	  strength,	  implying	  that	  CD4+	  T-­‐cells	  may	  also	  have	  an	  upregulatory	  role	  in	  wound	  healing	  [49].	  	  Since	  histological	  studies	  have	  suggested	  that	  the	  predominant	  form	  of	  CD4+	  T-­‐cells	  in	  the	  healing	  wound	  are	  the	  Th-­‐1	  type	  [50],	  the	  Th-­‐1	  type	  cytokines	  are	  those	  most	  likely	  to	  upregulate	  wound	  healing.	  The	  Th-­‐1	  cytokines	  are	  typified	  by	  interleukin-­‐2	  (IL-­‐2),	  but	  also	  include	  IFN-­‐γ,	  TNF-­‐β,	  and	  interleukin-­‐8	  (IL-­‐8).	  	  While	  a	  direct	  link	  between	  these	  Th-­‐
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1	  cytokines	  and	  fibroblast	  activity	  has	  not	  been	  clearly	  demonstrated,	  the	  improvement	  in	  wound	  strength	  cannot	  be	  ignored	  and	  more	  research	  may	  be	  warranted.	  	  Indeed,	  some	  have	  suggested	  that	  it	  is	  through	  the	  indirect	  activity	  of	  Th-­‐1	  cells	  on	  macrophages	  that	  wound	  healing	  is	  improved.	  	  The	  relationship	  between	  the	  Th-­‐1	  cytokine	  IFN-­‐γ	  and	  the	  upregulation	  of	  macrophage	  activity	  thus	  resulting	  in	  increased	  fibroblast	  activity	  has	  been	  suggested	  by	  some	  [51].	  	  Despite	  the	  obvious	  importance	  of	  fibroblasts	  in	  wound	  healing,	  the	  remodeling	  of	  the	  epithelial	  surface	  cannot	  be	  completed	  without	  the	  assistance	  of	  keratinocytes.	  	  Keratinocytes	  are	  known	  to	  express	  the	  CXCR2	  receptor	  for	  IL-­‐8	  (and	  GRO-­‐α)	  [52].	  	  Thus	  the	  secretion	  of	  IL-­‐8	  by	  CD4+	  Th-­‐1	  T-­‐cells	  may	  also	  mediate	  the	  healing	  process	  via	  keratinocytes.	  However,	  as	  will	  be	  discussed,	  keratinocytes	  are	  not	  the	  only	  cells	  expressing	  IL-­‐8.	  	  Activated	  fibroblasts	  also	  secrete	  IL-­‐8,	  perhaps	  thus	  promoting	  the	  re-­‐epithelization	  by	  keratinocytes.	  	  Thus,	  cytokines	  can	  have	  a	  profound	  role	  in	  affecting	  the	  recruitment,	  activation	  and	  secretion	  of	  cells	  both	  native	  to	  and	  drawn	  to	  the	  site	  of	  inflammation	  and/or	  injury.	  	  These	  cytokines	  most	  likely	  play	  a	  role	  in	  the	  regulation	  of	  production	  of	  the	  epidermal	  tissue,	  the	  underlying	  extra-­‐cellular	  matrix	  (ECM),	  as	  well	  as	  angiogenesis.	  	  Removal	  or	  abrogation	  of	  these	  cytokines	  has	  been	  demonstrated	  to	  alter	  the	  wound	  healing	  process,	  as	  has	  removal	  of	  the	  cells	  promoting	  cytokine	  production.	  	  
Characteristics	  of	  Chemokines	  
CD4+	  TH-­‐1	  Type	  Chemokines	  	  
Introduction	  to	  IL-­‐2	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Interleukin-­‐2	  is	  and	  has	  been	  one	  of	  the	  most	  extensively	  studied	  and	  characterized	  chemokines	  to	  date.	  	  IL-­‐2	  was	  the	  first	  chemokine	  identified	  to	  display	  the	  classic	  characteristics	  of	  a	  hormone	  signaling	  complex	  [53].	  	  Originating	  from	  human	  chromosome	  4q28-­‐28,	  the	  153	  amino	  acid	  precursor	  for	  IL-­‐2	  is	  generated	  from	  four	  exons	  including	  a	  20	  amino-­‐acid	  secretory	  sequence[54,	  55].	  	  Post-­‐translational	  modifications	  result	  in	  a	  mature	  protein	  of	  133	  amino	  acids.	  	  Originally	  identified	  as	  a	  soluble	  factor	  contributing	  to	  the	  activation	  and	  proliferation	  of	  T	  cells[56],	  IL-­‐2	  was	  initially	  identified	  as	  TCGF	  (T-­‐Cell	  Growth	  Factor).	  	  Through	  characterized	  early,	  initial	  cell	  theory	  suggested	  that	  chemokines	  like	  IL-­‐2	  were	  less	  important	  to	  cell	  proliferation	  than	  activators	  such	  as	  foreign	  antigen.	  	  It	  was	  found	  later	  that	  IL-­‐2	  is	  not	  only	  secreted	  by	  active	  T	  lymphocytes,	  but	  is	  required	  for	  activation	  and	  cell	  cycle	  progression	  of	  naive	  T	  cells.	  	  In	  addition,	  IL-­‐2	  has	  been	  implicated	  in	  activation	  induced	  cell	  death	  [57].	  	  A	  15.5kd	  protein	  with	  variable	  glycosylation,	  IL-­‐2	  is	  known	  to	  bind	  to	  a	  heterotrimeric	  receptor	  including	  the	  ever-­‐present	  common	  gamma	  chain.	  
Biosynthesis	  of	  IL-­‐2	   	  As	  one	  of	  the	  prototypic	  positive	  modulators	  of	  T-­‐cell	  activity,	  IL-­‐2	  is	  unique	  in	  that	  in	  addition	  to	  activating	  naïve	  T-­‐cells,	  it	  is	  also	  produced	  by	  the	  same	  activated	  T-­‐cells,	  creating	  a	  positive	  activation	  loop[12].	  	  Antigen	  recognition	  by	  the	  T-­‐cell	  induces	  an	  incomplete	  synthesis	  of	  IL-­‐2,	  which	  must	  be	  completely	  enabled	  by	  the	  co-­‐stimulatory	  signal	  B7	  binding	  to	  the	  T-­‐cell	  CD28	  receptor.	  	  This	  co-­‐stimulation	  stabilizes	  IL-­‐2	  mRNA	  and	  increases	  it	  synthesis	  20-­‐30	  fold.	  	  	  The	  mechanism	  by	  which	  IL-­‐2	  and	  co-­‐stimulation	  both	  allow	  for	  increased	  production	  of	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IL-­‐2	  may	  take	  place	  at	  either,	  or	  both,	  translation	  or	  post-­‐translational	  modification.	  	  Translation	  of	  the	  IL-­‐2	  gene	  is	  regulated	  by	  NFAT,	  with	  several	  factors,	  including	  TCF-­‐8	  contributing	  to	  the	  modulation	  of	  transcription.	  	  In	  addition,	  most	  IL-­‐2	  mRNA	  produced	  goes	  unmodified,	  and	  thus	  is	  not	  secreted	  from	  the	  nucleus,	  indicating	  yet	  another	  mechanism	  for	  controlling	  the	  levels	  of	  IL-­‐2	  activity.	  	  Biosynthesis	  of	  IL-­‐2	  has	  been	  shown	  to	  differ	  among	  various	  age	  groups,	  with	  those	  over	  60	  years	  old	  showing	  nearly	  half	  of	  the	  levels	  of	  IL-­‐2	  and	  IL-­‐2R	  mRNA	  than	  in	  those	  under	  40	  years	  of	  age	  [58].	  	  This	  change	  was	  correlated	  to	  a	  similar	  difference	  in	  IL-­‐2	  secretion,	  T-­‐cells	  displaying	  IL-­‐2R,	  as	  well	  as	  IL-­‐2R	  density	  of	  T-­‐cell	  surfaces.	  	  This	  data	  may	  contribute	  to	  some	  of	  the	  well-­‐known	  differences	  in	  inflammatory	  responses	  between	  different	  age	  groups.	  	  
Targets	  of	  IL-­‐2	   	  The	  IL-­‐2	  receptor	  is	  best	  characterized	  in	  its	  role	  in	  the	  adaptive	  immune	  response	  as	  a	  cell	  surface	  receptor	  expressed	  almost	  exclusively	  on	  activated	  T-­‐cells.	  	  Perhaps	  less	  well	  understood	  is	  the	  role	  of	  the	  soluble	  IL-­‐2	  receptor	  in	  such	  physiologic	  mechanisms	  such	  as	  clotting,	  cell	  proliferation	  and	  healing.	  	  In	  order	  to	  better	  facilitate	  IL-­‐2	  activity,	  antigen	  recognition	  by	  T-­‐cells	  promotes	  synthesis	  of	  the	  alpha	  chain	  of	  the	  IL-­‐2	  receptor,	  allowing	  the	  T-­‐cell	  to	  respond	  to	  lower	  levels	  of	  IL-­‐2	  than	  with	  the	  lower	  affinity	  beta/gamma	  IL-­‐2	  receptor.	  	  This	  upregulation	  of	  T-­‐cell	  activity	  has	  been	  linked	  to	  a	  finite	  quantity	  of	  IL-­‐2	  binding	  to	  receptors,	  allowing	  for	  an	  “all-­‐or-­‐nothing”	  response	  [53,	  59].	  	  Receptor	  expression	  has	  been	  shown	  to	  be	  modulated	  by	  other	  factors	  such	  as	  IL-­‐3,	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐6	  as	  well.	  	  Work	  done	  by	  Gaya	  et	  al.	  has	  shown	  that	  IL-­‐2	  receptor	  expression	  can	  be	  inhibited	  in	  a	  dose	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dependent	  manner	  by	  IL-­‐4	  in	  the	  first	  two	  hours	  of	  T-­‐cell	  incubation	  following	  exposure	  to	  antigen	  [60].	  	  IL-­‐2	  is	  known	  to	  activate	  many	  components	  of	  the	  immune	  systems	  such	  as	  B-­‐cells,	  T-­‐cells,	  monocytes,	  oligodendroglial	  cells,	  and	  NK-­‐cells.	  IL-­‐2	  activity	  has	  also	  been	  demonstrated	  to	  drive	  changes	  in	  T-­‐cell	  populations	  via	  the	  Stat-­‐5	  and	  PI3K	  pathways[61].	  	  	  In	  addition	  to	  its	  activity	  stimulating	  T-­‐cell	  expansion,	  IL-­‐2	  has	  been	  demonstrated	  to	  modulate	  other	  surface	  receptors	  in	  various	  cell	  lines[61].	  Along	  with	  its	  role	  in	  the	  immune	  system,	  IL-­‐2	  receptors	  have	  also	  been	  discovered	  on	  intestinal	  epithelial	  cells	  [62],	  and	  in	  human	  proximal	  tubular	  endothelial	  cells	  [63].	  	  IL-­‐2	  has	  also	  been	  applied	  in	  some	  cases	  to	  fight	  various	  forms	  of	  cancer.	  	  Given	  its	  propensity	  to	  activate	  certain	  T-­‐cell	  populations,	  studies	  are	  underway	  to	  evaluate	  the	  use	  of	  IL-­‐2	  in	  battling	  both	  solid	  and	  blood	  borne	  cancers.	  
Predicted	  Response	  of	  IL-­‐2	  to	  Treatment	  	   As	  the	  response	  to	  trauma	  and	  inflammation	  at	  the	  site	  of	  injury	  has	  been	  characterized	  as	  a	  primarily	  Th-­‐1	  type	  response,	  it	  may	  seem	  a	  simple	  step	  to	  conclude	  that	  IL-­‐2	  levels	  are	  most	  likely	  elevated	  during	  the	  immune	  response.	  	  However,	  this	  is	  not	  universally	  true	  and	  the	  introduction	  of	  endogenous	  steroids	  with	  or	  without	  the	  addition	  of	  androstenediol	  should	  at	  least	  further	  complicate	  the	  prediction	  of	  response.	  	  Human	  trauma	  studies	  tracking	  cytokine	  levels	  in	  critically	  ill	  patients	  indicate	  that	  patients	  affected	  only	  by	  trauma	  do	  not	  display	  systemically	  elevated	  levels	  of	  IL-­‐2,	  while	  uninjured	  patients	  suffering	  from	  infection	  do	  present	  with	  systemically	  elevated	  IL-­‐2	  [64].	  	  This	  may	  be	  an	  example	  of	  where	  cytokines	  that	  are	  expressed	  locally	  in	  response	  to	  injury	  or	  inflammation	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are	  not	  expressed	  systemically,	  while	  the	  response	  to	  a	  potentially	  widespread	  threat	  such	  as	  infection	  elicits	  a	  widespread	  response.	  	  However,	  the	  widespread	  distribution	  of	  systemic	  IL-­‐2	  is	  also	  seen	  in	  autoimmune	  disease,	  thus	  explaining	  the	  use	  of	  IL-­‐2	  receptor	  antagonists	  and	  broad-­‐spectrum	  glucocorticoids	  in	  treating	  autoimmune	  disease.	  	  This	  of	  course	  provides	  the	  data	  for	  understanding	  the	  relationship	  between	  methylprednisolone	  and	  IL-­‐2.	  	  Early	  work	  into	  the	  relationship	  between	  cytokines	  and	  glucocorticoids	  revealed	  complicated	  and	  profound	  reductions	  in	  the	  levels	  of	  IL-­‐2.	  	  This	  reduction	  was	  linked	  to	  separate	  mechanisms	  at	  differing	  doses,	  most	  reducing	  IL-­‐2	  levels	  by	  inhibiting	  synthesis	  directly	  [65].	  	  The	  last	  controllable	  variable	  in	  this	  equation	  is	  the	  administration	  of	  androstenediol	  and	  the	  effects	  on	  IL-­‐2.	  	  Studies	  evaluating	  the	  levels	  of	  IL-­‐2	  in	  murine	  splenocytes	  indicate	  a	  modest	  increase	  in	  production	  in	  response	  to	  AED	  [66].	  	  	  Still	  other	  studies	  demonstrated	  that	  a	  trauma-­‐hemorrhage	  model	  followed	  by	  cecal	  ligation	  and	  puncture	  to	  induce	  sepsis	  produced	  a	  drop	  in	  IL-­‐2	  levels	  that	  was	  attenuated	  by	  AED	  [67].	  Other	  sex	  steroids	  have	  differing	  effects	  on	  the	  production	  of	  IL-­‐2	  among	  lymphocytes.	  	  Research	  into	  the	  effects	  of	  post-­‐menopausal	  administration	  of	  estrogen	  replacement	  produced	  profoundly	  reduced	  levels	  of	  IL-­‐2	  from	  lymphocytes	  in	  culture.	  	  While	  the	  effects	  at	  the	  site	  of	  injury	  may	  be	  different,	  the	  combined	  effects	  of	  injury,	  methylprednisolone,	  with	  or	  without	  AED	  are	  likely	  to	  result	  in	  little	  or	  no	  effects	  on	  systemically	  measured	  IL-­‐2.	  
Introduction	  to	  IL-­‐8	   	  Originally	  purified	  and	  characterized	  in	  1987	  [68],	  IL-­‐8	  was	  initially	  assigned	  the	  moniker	  of	  monocyte-­‐derived	  neutrophil	  chemotactic	  factor	  (MDNCF).	  	  IL-­‐8	  was	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considered	  a	  tissue-­‐derived	  factor	  with	  similar	  chemotactic	  properties	  as	  previously	  characterized	  factors	  such	  as	  anaphylatoxin	  C5a,	  platelet	  activating	  factor,	  or	  leukotriene	  B4.	  	  Initial	  work	  demonstrated	  that	  exposure	  to	  IL-­‐8	  caused	  neutrophils	  to	  migrate	  to	  the	  extravascular	  space	  and	  caused	  neutrophil	  changes	  in	  shape,	  adherence,	  movement,	  secretion	  of	  enzymes	  as	  well	  as	  changes	  in	  the	  respiratory	  burst	  mechanism	  [69].	  	  Different	  then	  from	  other	  known	  cytokines,	  IL-­‐8	  showed	  no	  common	  homology	  to	  such	  other	  immune	  system	  regulators	  such	  as	  IL-­‐1,	  TNF,	  IFN	  or	  GM-­‐CSF.	  	  IL-­‐8	  was	  shown	  to	  evolve	  from	  a	  99	  amino	  acid	  precursor	  including	  a	  typical	  20	  amino	  acid	  secretion	  sequence	  [70].	  	  Further	  characterization	  of	  the	  gene	  and	  subsequent	  gene	  products	  revealed	  several	  forms	  of	  IL-­‐8,	  with	  the	  most	  common	  form	  found	  to	  be	  72	  amino	  acids	  [71].	  	  Despite	  the	  differences	  in	  IL-­‐8	  from	  known	  immunogenic	  factors	  such	  as	  IL-­‐1	  or	  GM-­‐CSF,	  IL-­‐8	  did	  indeed	  show	  a	  remarkable	  amount	  of	  similarity	  to	  Β-­‐thromboglobulin	  [72],	  both	  eventually	  characterized	  as	  CXC	  type	  chemokines.	  	  Stronger	  similarities	  in	  activity	  have	  been	  demonstrated	  between	  IL-­‐8	  and	  a	  cleavage	  product	  of	  B-­‐thromboglobulin	  that	  have	  been	  further	  linked	  to	  the	  relative	  positions	  of	  4	  cysteine	  residues[73].	  	  Interleukin-­‐8	  has	  been	  associated	  with	  a	  wide	  variety	  of	  human	  diseases	  and	  has	  broad	  implications	  for	  targeted	  therapy.	  	  Interleukin-­‐8	  has	  been	  associated	  with	  such	  human	  diseases	  as	  ovarian	  cancer	  [74],	  breast	  cancer	  [75],	  psoriasis	  [76],	  and	  asthma	  [77],	  	  as	  well	  as	  various	  autoimmune	  diseases.	  	  One	  of	  the	  most	  unique	  characteristics	  of	  Interleukin-­‐8	  is	  its	  physiologic	  longevity.	  	  While	  most	  studies	  of	  inflammatory	  cytokines	  illustrate	  effectiveness	  in	  hours,	  IL-­‐8	  was	  shown	  to	  be	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present	  in	  immunomodulatory	  levels	  at	  time	  points	  greater	  than	  ninety-­‐six	  hours	  [78,	  79].	  
Biosynthesis	  of	  IL-­‐8	   	  A	  product	  of	  human	  chromosome	  four,	  the	  synthesis	  of	  interleukin	  8	  has	  been	  documented	  in	  many	  different	  cell	  types.	  	  From	  macrophages	  [68],	  to	  fibroblasts	  [80],	  endothelial	  cells	  [80,	  81],	  epithelial	  cells	  [82],	  	  and	  hepatocytes	  [83],	  IL-­‐8	  synthesis	  has	  been	  demonstrated	  in	  response	  to	  a	  number	  of	  different	  stimuli,	  including	  LPS	  [12],	  endotoxin,	  IL-­‐1,	  implant	  debris	  [84]	  and	  even	  hyperosmolarity	  [79].	  	  Interestingly,	  while	  macrophages	  respond	  most	  frequently	  to	  stimuli	  such	  as	  LPS,	  immunogenic	  agents	  such	  as	  IL-­‐2,	  IL-­‐6	  or	  interferons	  fail	  to	  produce	  IL-­‐8	  in	  macrophages	  [69].	  	  Expression	  of	  IL-­‐8	  mRNA	  has	  been	  shown	  to	  correlate	  with	  an	  increase	  in	  NFkB	  activity	  [85],	  raising	  the	  possibility	  that	  NFkB	  plays	  a	  role	  in	  the	  expression	  of	  IL-­‐8.	  	  However,	  still	  other	  studies	  involving	  suppressed	  NfκB	  have	  suggested	  that	  Ap-­‐1,	  rather	  than	  NFkB	  contribute	  to	  synthesis	  of	  IL-­‐8	  [86].	  	  While	  these	  reports	  seem	  at	  odds	  with	  each	  other,	  they	  may	  indeed	  suggest	  converging	  response	  mechanisms	  reacting	  to	  traumatic	  vs.	  infectious	  stimuli.	  	  Response	  to	  antigen	  typically	  results	  in	  a	  rapid	  synthesis	  of	  interleukin-­‐8,	  with	  mRNA	  detectable	  within	  one	  hour	  [69].	  	  Once	  secreted,	  interleukin-­‐8	  is	  thought	  to	  form	  a	  dimer,	  similar	  to	  other	  known	  chemokines	  [87].	  	  Given	  the	  nature	  of	  IL-­‐8	  and	  its	  recognition	  as	  a	  major	  mediator	  in	  infection,	  trauma,	  and	  human	  disease	  it	  should	  come	  as	  no	  surprise	  that	  methods	  to	  inhibit	  the	  production	  and	  activity	  of	  IL-­‐8	  have	  long	  been	  sought	  after.	  	  Various	  agents	  such	  as	  DMSO	  [78],	  fluticasone	  propionate	  and	  salmeterol	  [88],	  L-­‐arginine	  [89],	  and	  even	  monoclonal	  antibodies	  [90]have	  been	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shown	  to	  interfere	  with	  IL-­‐8	  production,	  signaling,	  and/or	  activation	  of	  target	  cells,	  thus	  reducing	  the	  inflammatory	  cascade	  in	  many	  cases.	  
Targets	  of	  IL-­‐8	  	   Complicating	  our	  understanding	  regarding	  the	  effects	  of	  IL-­‐8	  on	  cell	  behavior	  are	  the	  receptors	  known	  to	  recognize	  IL-­‐8.	  	  The	  receptors	  known	  as	  CXCR1,	  also	  known	  as	  IL-­‐8Rα,	  and	  CXCR2,	  also	  known	  as	  IL-­‐8Rβ,	  are	  commonly	  known	  to	  recognize	  chemokines	  containing	  two	  N-­‐terminal	  cysteine	  residues	  separated	  by	  another	  amino	  acid,	  thus	  designated	  CXC	  chemokines.	  	  This	  characteristic	  sequence	  is	  also	  commonly	  preceded	  a	  glutamic	  acid-­‐leucine-­‐argenine	  (ELR)	  sequence.	  	  The	  many	  factors	  matching	  this	  profile	  bind	  to	  the	  CXC	  receptors	  with	  varying	  affinity	  and	  in	  difference	  combinations,	  with	  only	  two	  known	  CXC	  cytokines	  binding	  both	  CXCR1	  and	  CXCR2	  receptors,	  and	  the	  remainder	  binding	  only	  to	  CXCR2	  [91].	  	  The	  CXC	  receptors,	  either	  one	  or	  both,	  have	  been	  shown	  to	  be	  displayed	  on	  a	  number	  of	  different	  cells	  types,	  including	  CD8+	  T-­‐cells,	  mast	  cells,	  as	  well	  as	  endothelial	  and	  epithelial	  cells.	  	  However,	  the	  CXC	  receptors	  are	  most	  commonly	  recognized	  for	  their	  role	  in	  modulating	  the	  innate	  immune	  system	  through	  their	  expression	  on	  neutrophils,	  monocytes	  and	  other	  myeloid	  cells.	  	  Both	  of	  the	  human	  CXC	  receptors	  map	  to	  chromosome	  two,	  and	  lead	  to	  the	  expression	  of	  a	  characteristic	  7-­‐transmembrane	  domain,	  g-­‐protein	  modulated	  receptor,	  with	  features	  similar	  in	  structure	  to	  the	  rhodopsin	  superfamily	  [92].	  	  The	  CXC	  receptors	  have	  also	  been	  found	  to	  be	  expressed	  in	  other	  primates,	  chickens,	  rabbits,	  cows,	  mice,	  and	  rats,	  indicating	  a	  highly	  conserved	  role	  across	  nature.	  	  The	  CXCR1	  receptor	  is	  known	  to	  recognize	  only	  IL-­‐8	  and	  granulocyte	  chemotactic	  protein-­‐2	  (CXCL6).	  	  IL-­‐8	  is	  also	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recognized	  by	  CXCR2,	  which	  recognizes	  CXCL6	  in	  addition	  to	  the	  remainder	  of	  the	  other	  CXC	  chemokines	  including	  several	  of	  the	  GRO	  chemokines.	  	  Both	  of	  these	  receptors	  seem	  to	  act	  through	  the	  classic	  g-­‐protein	  coupled	  signaling	  cascade,	  marked	  by	  a	  change	  in	  free	  calcium	  and	  granule	  enzyme	  release.	  	  Much	  work	  has	  been	  done	  trying	  to	  uncover	  the	  seemingly	  redundant	  roles	  of	  two	  CXC	  receptors,	  with	  some	  overlap	  for	  ligand	  and	  similar,	  if	  not	  identical	  signaling	  mechanisms.	  	  However,	  inhibition	  studies	  have	  revealed	  that	  CXCR1	  seems	  tied	  to	  superoxide	  anion	  production	  and	  increases	  in	  phospholipase-­‐d1,	  while	  CXCR2	  is	  related	  to	  increases	  in	  phospholipase-­‐d2	  expression.	  	  The	  downstream	  results	  of	  CXCR2	  signaling	  are	  less	  well	  understood,	  but	  the	  differences	  in	  signaling	  mechanisms	  may	  lead	  to	  functional	  differences	  in	  the	  CXC	  receptors.	  	  	  
Predicted	  Response	  of	  IL-­‐8	  to	  Treatment	  	   The	  primary	  role	  of	  IL-­‐8	  as	  a	  chemotactic	  factor	  for	  the	  recruitment	  and	  activation	  of	  neutrophils	  makes	  it	  one	  of	  the	  better	  understood	  cytokines.	  	  Despite	  their	  differing	  roles,	  the	  activity	  of	  IL-­‐8	  expression	  shares	  some	  of	  the	  features	  of	  the	  previously	  discussed	  IL-­‐2,	  including	  high	  local	  expression	  following	  trauma	  and	  inflammation.	  	  However,	  unlike	  the	  results	  we	  have	  seen	  in	  IL-­‐2,	  there	  is	  research	  showing	  ten-­‐fold	  and	  five-­‐fold	  increases	  in	  plasma	  levels	  of	  IL-­‐8	  among	  critically	  ill	  septic	  and	  non-­‐septic	  patients	  respectively	  [93],	  thus	  setting	  the	  stage	  for	  measuring	  changes	  after	  treatment	  on	  a	  widespread	  scale	  and	  providing	  an	  indication	  for	  the	  expected	  response	  on	  IL-­‐8	  levels	  to	  trauma.	  	  When	  exposed	  to	  glucocorticoid	  treatment,	  IL-­‐8	  responds	  much	  like	  other	  mediators	  in	  the	  immune	  system,	  namely	  by	  displaying	  a	  profound	  reduction	  in	  circulating	  protein	  levels.	  	  Autoimmune	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models	  such	  as	  multiple	  sclerosis	  and	  rheumatoid	  arthritis	  as	  well	  as	  non-­‐autoimmune	  models	  such	  as	  exercise-­‐induced	  inflammation	  and	  clinical	  patient	  care	  studies	  exhibit	  both	  systemic	  and	  local	  increases	  in	  IL-­‐8	  levels.	  	  One	  of	  the	  most	  common	  treatments	  employed	  in	  these	  models	  as	  well	  as	  in	  clinical	  medicine	  is	  the	  administration	  of	  glucocorticoids,	  including	  methylprednisolone.	  	  In	  these	  cases,	  methylprednisolone	  has	  been	  demonstrated	  to	  provide	  profound	  reductions	  in	  the	  levels	  of	  many	  cytokines,	  including	  IL-­‐8	  [94,	  95].	  	  While	  the	  mechanisms	  behind	  much	  of	  these	  changes	  are	  poorly	  understood,	  at	  least	  some	  of	  these	  studies	  have	  implicated	  a	  reduced	  synthesis	  of	  IL-­‐8	  by	  monocytes	  as	  a	  cause.	  	  Perhaps	  due	  to	  the	  high	  profile	  of	  other	  pro-­‐inflammatory	  cytokines,	  there	  is	  precious	  little	  information	  with	  regard	  to	  the	  interaction	  between	  androstenediol	  and	  interleukin-­‐8.	  	  However,	  since	  there	  have	  been	  comparisons	  between	  AED	  and	  estrogen,	  especially	  with	  regard	  to	  the	  possibility	  of	  a	  common	  signaling	  mechanism,	  we	  are	  not	  without	  guidance.	  	  In	  addition	  to	  the	  commonly	  known	  pathologies	  of	  IL-­‐8	  in	  inflammation	  such	  as	  exercise-­‐induced	  inflammation,	  IL-­‐8	  has	  also	  been	  implicated	  in	  genetic	  illnesses	  such	  as	  cystic	  fibrosis.	  	  In	  both	  of	  these	  circumstances,	  estradiol	  has	  been	  indicated	  as	  a	  suppressor	  of	  IL-­‐8.	  	  With	  regard	  to	  inflammation	  in	  an	  exercise-­‐induced	  model	  of	  inflammation,	  estradiol	  was	  demonstrated	  to	  reduce	  synthesis	  of	  IL-­‐8	  mRNA	  in	  skeletal	  muscle	  cells.	  	  In	  the	  latter	  example,	  estradiol	  was	  shown	  to	  reduce	  the	  synthesis	  of	  IL-­‐8	  in	  a	  dose	  dependant	  manner	  formerly	  induced	  by	  toll-­‐like	  receptor	  agonists	  [96].	  	  Given	  these	  shared	  effects	  on	  the	  expression	  of	  IL-­‐8	  from	  various	  sources	  and	  presumably	  from	  differing	  mechanisms,	  it	  seems	  likely	  that	  the	  effects	  of	  significant	  trauma	  should	  induce	  an	  increase	  in	  the	  expression	  of	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IL-­‐8,	  which	  should	  also	  be	  detectable	  in	  plasma.	  	  However,	  as	  both	  treatment	  protocols	  involve	  at	  least	  one	  suppressor	  of	  IL-­‐8,	  it	  also	  seems	  likely	  that	  IL-­‐8	  will	  be	  reduced,	  perhaps	  to	  undetectable	  levels,	  in	  all	  but	  subjects	  receiving	  trauma	  plus	  vehicle	  only.	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CD4+	  TH-­‐2	  Type	  Chemokines	  	  
Introduction	  to	  IL-­‐6	  	   As	  yet	  another	  of	  the	  earlier	  cytokines,	  IL-­‐6	  had	  already	  been	  identified	  through	  multiple	  experiments	  and	  had	  received	  monikers	  such	  as	  B-­‐cell	  stimulatory	  factor-­‐2,	  IFN-­‐β2,	  26-­‐kDa	  protein,	  hybridoma/plasmacytoma	  growth	  factor,	  and	  HSF	  [97].	  	  The	  primary	  experiments	  responsible	  for	  the	  identification	  of	  the	  protein	  that	  would	  eventually	  become	  known	  as	  IL-­‐6	  involved	  the	  activation	  of	  B-­‐cells	  in	  the	  presence	  of	  T-­‐cells.	  	  Researchers	  correctly	  hypothesized	  that	  there	  must	  be	  some	  soluble	  mediator	  responsible	  for	  the	  activation	  of	  B-­‐cells	  in	  the	  presence	  of	  activated	  T-­‐cells.	  	  	  Structurally,	  IL-­‐6	  is	  a	  185	  amino	  acid	  sequence,	  composed	  of	  a	  four-­‐helix	  bundle	  linked	  by	  loop	  structures	  with	  an	  additional	  mini	  helix	  near	  the	  N-­‐terminus	  [98].	  	  IL-­‐6	  plays	  a	  number	  of	  different	  roles	  in	  physiology,	  including	  the	  T-­‐cell	  dependant	  activation	  of	  B-­‐cells,	  the	  activation	  of	  the	  acute	  phase	  response,	  and	  changes	  in	  bone	  synthesis.	  	  IL-­‐6	  is	  capable	  of	  binding	  both	  cell	  membrane	  receptors	  as	  well	  as	  a	  soluble	  IL-­‐6	  receptor.	  	  Binding	  of	  IL-­‐6	  to	  the	  membrane	  bound	  receptor	  requires	  the	  IL-­‐6	  receptor	  alpha	  subunit	  in	  addition	  to	  the	  ubiquitously	  expressed	  glycoprotein	  gp130.	  	  Binding	  of	  IL-­‐6	  to	  the	  heterodimeric	  receptor	  complex	  has	  been	  demonstrated	  to	  drive	  signal	  transduction	  via	  both	  the	  MAP	  Kinase	  and	  JAK-­‐STAT	  signaling	  pathways,	  resulting	  in	  altered	  transcription	  and	  protein	  synthesis	  depending	  on	  the	  cell	  type	  receiving	  the	  stimulus	  [99].	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The	  soluble	  IL-­‐6	  receptor	  represents	  a	  50-­‐55kD	  ligand	  binding	  protein	  that	  is	  either	  a	  cleavage	  product	  or	  a	  splicing	  product	  of	  the	  original	  80kD	  membrane	  bound	  receptor	  subunit.	  	  With	  the	  ubiquitous	  expression	  of	  gp130	  in	  nearly	  all	  cell	  types,	  the	  synthesis	  of	  the	  soluble	  receptor	  allows	  IL-­‐6	  to	  stimulate	  cell	  signaling	  in	  nearly	  any	  cell	  type.	  	  Alternatively,	  in	  the	  absence	  of	  the	  gp130	  subunit	  the	  soluble	  receptor	  subunit	  may	  act	  as	  an	  agonist,	  preventing	  signaling	  by	  IL-­‐6	  by	  sequestering	  otherwise	  available	  IL-­‐6	  molecules.	  	  	  Due	  to	  the	  widespread	  nature	  of	  IL-­‐6	  expression	  both	  in	  normal	  and	  abnormal	  physiology,	  science	  has	  produced	  an	  antibody	  designed	  to	  interfere	  with	  both	  the	  membrane	  bound	  and	  soluble	  versions	  of	  the	  IL-­‐6	  receptor.	  	  This	  (tocilizumab)	  has	  been	  approved	  in	  Japan,	  Europe	  and	  the	  US	  primarily	  for	  the	  treatment	  of	  rheumatoid	  arthritis.	  	  In	  addition,	  IL-­‐6	  has	  been	  researched	  extensively	  in	  predicting	  mortality	  and	  morbidity.	  	  Today’s	  methods	  of	  predicting	  the	  clinical	  outcomes	  in	  patients	  have	  not	  changed	  in	  decades.	  	  Many	  studies	  have	  sought	  to	  advance	  current	  clinical	  tools	  in	  identifying	  patients	  at	  risk	  of	  severe	  morbidity	  or	  mortality	  following	  a	  wide	  variety	  of	  insults.	  	  Many	  of	  these	  studies	  have	  focused	  on	  measuring	  soluble	  factors	  and	  have	  sought	  to	  identify	  a	  relationship	  between	  these	  factors	  and	  patient	  outcome.	  	  Needless	  to	  say,	  these	  studies	  are	  complicated	  by	  the	  broad	  spectrum	  of	  patient	  health	  histories,	  mechanisms	  of	  illness	  and/or	  injury,	  and	  treatment	  pathways.	  	  Thus,	  many	  of	  these	  studies	  have	  fallen	  short	  of	  providing	  conclusive	  measurements	  to	  be	  correlated	  with	  predicting	  patient	  outcomes	  and	  providing	  interventions	  to	  alter	  undesired	  outcomes.	  	  Nonetheless,	  measuring	  IL-­‐6	  has	  been	  a	  target	  to	  measure	  following	  burns,	  trauma,	  hemorrhage,	  sepsis,	  or	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combinations	  of	  these	  insults.	  	  Some	  studies	  have	  drawn	  impressive	  relationships	  between	  the	  levels	  of	  IL-­‐6	  in	  blood,	  and	  mortality,	  with	  correlations	  illustrating	  that	  higher	  levels	  of	  IL-­‐6	  are	  indicative	  of	  a	  increased	  risk	  of	  death	  [100].	  	  I	  have	  yet	  to	  find	  evidence	  of	  research	  involving	  the	  administration	  of	  IL-­‐6	  receptor	  antibodies	  as	  a	  counter	  to	  rising	  IL-­‐6	  levels	  following	  trauma	  or	  other	  insult	  correlated	  with	  mortality.	  	  	  Perhaps	  most	  interesting,	  IL-­‐6	  synthesis	  was	  affected	  by	  the	  administration	  of	  estrogen	  in	  vitro	  and	  in	  vivo	  [101].	  	  In	  this	  study,	  the	  authors	  demonstrated	  that	  in	  human	  bone	  marrow	  stromal	  cells,	  synthesis	  of	  IL-­‐6	  was	  increased	  10,000-­‐fold	  following	  administration	  of	  a	  mixture	  of	  IL-­‐1	  and	  TNFα.	  	  The	  synthesis	  of	  IL-­‐6	  and	  the	  expression	  of	  IL-­‐6	  mRNA	  were	  then	  both	  reduced	  in	  a	  dose	  dependant	  manner	  following	  administration	  of	  17β-­‐estradiol	  and	  a	  combination	  of	  IL-­‐1	  and	  TNFα,	  when	  compared	  to	  cells	  receiving	  only	  the	  IL-­‐1	  and	  TNFα.	  	  With	  the	  expression	  of	  this	  powerful	  immunological	  mediator	  altered	  by	  sex	  steroids,	  or	  their	  metabolites,	  it	  may	  not	  be	  a	  long	  leap	  to	  hypothesize	  that	  additional	  sex	  steroid	  may	  be	  able	  to	  also	  affect	  the	  synthesis	  of	  IL-­‐6	  in	  a	  number	  of	  different	  tissues.	  
Biosynthesis	  of	  IL-­‐6	  	   The	  gene	  coding	  for	  the	  IL-­‐6	  protein	  consists	  of	  five	  exons	  and	  four	  introns	  found	  on	  human	  chromosome	  seven	  and	  is	  characterized	  as	  having	  a	  structure	  homologous	  to	  G-­‐CSF	  [102].	  	  Production	  of	  IL-­‐6	  has	  been	  most	  commonly	  associated	  with	  T-­‐cell	  mediated	  activation	  of	  B-­‐cells.	  However,	  synthesis	  of	  IL-­‐6	  has	  also	  been	  demonstrated	  in	  macrophages,	  fibroblasts,	  synovial	  cells,	  endothelial	  cells,	  glial	  cells,	  and	  keratinocytes	  [99].	  	  In	  addition,	  IL-­‐6	  expression	  has	  been	  documented	  in	  a	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number	  of	  different	  types	  of	  cancer	  cells,	  including	  cardiac	  myxoma,	  certain	  bladder	  cell	  cancers	  and	  certain	  cervical	  cancers	  [102].	  	  Obviously,	  the	  synthesis	  of	  IL-­‐6	  by	  such	  a	  broad	  selection	  of	  cell	  types	  illustrates	  the	  broad	  implications	  of	  IL-­‐6	  and	  its	  affects	  at	  multiple	  targets.	  	  Similarly,	  this	  also	  means	  that	  identifying	  the	  relationship	  between	  the	  synthesis	  by	  specific	  cells	  and	  the	  response	  by	  specific	  targets	  is	  nearly	  impossible	  in	  an	  in	  vivo	  model.	  	  	  Naturally,	  the	  biosynthesis	  of	  IL-­‐6	  in	  these	  many	  different	  types	  of	  cells	  is	  stimulated	  by	  many	  different	  input	  ligands.	  	  Some	  of	  the	  common	  factors	  responsible	  for	  stimulating	  the	  biosynthesis	  and	  release	  of	  IL-­‐6	  are	  IL-­‐1,	  TNF,	  PDGF,	  pathogen	  associated	  molecular	  patterns	  (PAMPs),	  and	  LPS	  [99,	  102].	  	  In	  addition	  to	  the	  most	  recognized	  form	  of	  IL-­‐6,	  some	  authors	  have	  shown	  that	  IL-­‐6	  mRNA	  can	  be	  produced	  in	  at	  least	  two	  different	  mRNA	  isoforms	  of	  IL-­‐6	  by	  alternative	  splicing.	  	  These	  alternative	  forms	  of	  transcription	  of	  the	  IL-­‐6	  gene	  appeared	  as	  fragments	  with	  58	  bp	  deletions	  and	  114	  bp	  deletions	  of	  exon	  5	  and	  exon	  3	  respectively	  [103].	  	  The	  activity	  of	  these	  alternative-­‐splicing	  variants	  is	  the	  subject	  of	  much	  speculation.	  	  While	  the	  structure	  of	  the	  protein	  remains	  largely	  intact,	  there	  are	  specific	  regions	  missing	  that	  have	  been	  related	  to	  either	  the	  alpha-­‐receptor	  subunit	  or	  the	  gp130	  receptor	  subunit	  that	  bring	  the	  binding	  affinity	  to	  these	  ligands	  into	  question.	  	  Nevertheless,	  the	  existence	  of	  alternative	  isoforms	  of	  the	  IL-­‐6	  protein	  already	  produced	  by	  a	  wide	  variety	  of	  cells	  and	  implicated	  in	  a	  number	  of	  normal	  and	  abnormal	  physiological	  process	  muddies	  an	  already	  complicated	  picture.	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Targets	  of	  IL-­‐6	  	   While,	  as	  mentioned,	  the	  gp130	  subunit	  of	  the	  IL-­‐6	  receptor	  in	  expressed	  in	  many	  tissue	  types	  and	  aids	  in	  the	  signal	  transduction	  of	  other	  signaling	  molecules,	  the	  expression	  of	  the	  alpha-­‐receptor	  subunit	  is	  far	  more	  exclusive	  and	  is	  the	  key	  to	  any	  selectivity	  in	  IL-­‐6	  signaling.	  	  Membrane	  bound	  IL-­‐6	  receptors	  have	  been	  identified	  in	  hepatocytes,	  B-­‐cells,	  osteoblasts,	  T-­‐cells,	  chondrocytes,	  pulmonary	  epithelial	  cells,	  skeletal	  muscle,	  fibroblasts,	  as	  well	  as	  other	  cells.	  	  Conversely,	  the	  soluble	  IL-­‐6	  receptor	  allows	  for	  IL-­‐6	  to	  bind	  with	  the	  possibility	  of	  a	  complete	  cytokine/receptor	  complex	  in	  any	  cell	  also	  expressing	  gp130	  [104],	  although	  it	  should	  be	  noted	  that	  some	  studies	  have	  postulate	  that	  the	  soluble	  IL-­‐6	  receptor	  acts	  as	  an	  antagonist;	  sequestering	  IL-­‐6	  for	  breakdown	  and	  thus	  reducing	  the	  response	  elicited	  by	  IL-­‐6.	  	  Binding	  of	  the	  complete	  IL-­‐6/receptor	  complex	  results	  in	  intracellular	  tyrosine	  phosphorylation	  as	  part	  of	  the	  JAK/STAT	  signal	  transduction	  cascade	  [97].	  	  The	  dimer	  formed	  by	  STAT3	  then	  is	  widely	  known	  to	  translate	  to	  the	  nucleus	  and	  initiate	  transcription.	  	  Naturally,	  the	  resulting	  transcription	  would	  be	  dependant	  on	  the	  cell	  type	  and	  the	  genetic	  information	  exposed	  for	  initiation	  of	  said	  transcription.	  	  	  IL-­‐6	  in	  its	  role	  as	  a	  pro-­‐inflammatory	  cytokine	  also	  initiates	  reactions	  that	  promote	  a	  correction	  of	  the	  pro-­‐inflammatory	  state.	  Research	  manuscripts	  have	  indicated	  that	  the	  exposure	  of	  microglial	  cells	  to	  IL-­‐6	  and	  TNF-­‐α	  results	  in	  the	  upregulation	  of	  IL-­‐10	  mRNA	  and	  the	  increased	  release	  of	  IL-­‐10	  by	  these	  cells	  [105].	  	  Alternate	  studies	  in	  monocytes	  have	  indicated	  that	  IL-­‐10	  enhances	  degradation	  of	  IL-­‐6	  mRNA,	  resulting	  in	  a	  decreased	  translation	  to	  IL-­‐6	  protein	  [106].	  	  Overall,	  more	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is	  known	  about	  the	  final	  results	  of	  IL-­‐6	  signaling	  than	  the	  specific	  cascades	  producing	  these	  results.	  	  IL-­‐6	  is	  though	  to	  promote	  normal	  physiologic	  signaling,	  to	  be	  a	  major	  mediator	  of	  pro-­‐inflammatory	  reactions,	  and	  to	  promote	  the	  uncontrolled	  growth	  and	  proliferation	  of	  oncogenic	  cells.	  	  	  
Predicted	  Response	  of	  IL-­‐6	  to	  Treatment	  	   As	  IL-­‐6	  has	  been	  identified	  and	  researched	  extensively	  as	  a	  marker	  for	  mortality	  and	  morbidity	  following	  trauma	  and/or	  infection,	  there	  is	  indeed	  a	  plethora	  of	  information	  available	  with	  regard	  the	  effects	  of	  some	  common	  modulatory	  factors.	  	  Perhaps	  the	  most	  well	  known	  characterization	  of	  the	  role	  of	  IL-­‐6	  in	  critical	  injury	  comes	  from	  Remick	  et	  al.	  [100].	  	  In	  it,	  the	  authors	  convincingly	  demonstrate	  the	  use	  of	  IL-­‐6	  as	  a	  predictor	  of	  mortality	  in	  mice	  following	  a	  sepsis	  model.	  	  In	  human	  studies	  of	  trauma	  patients,	  IL-­‐6	  has	  been	  identified	  as	  having	  a	  positive	  correlation	  with	  severity	  of	  injury	  [93,	  107].	  	  Thus	  IL-­‐6	  exists	  as	  a	  common	  indicator	  of	  severe	  trauma	  and	  is	  detectable	  in	  plasma	  following	  trauma	  and	  or	  infection.	  	  These	  studies	  have	  suggested	  that	  there	  is	  a	  threshold	  value	  for	  IL-­‐6	  above	  which	  mortality	  is	  threatened.	  	  However,	  as	  with	  the	  other	  cytokines	  discussed	  thus	  far,	  IL-­‐6	  is	  also	  subject	  to	  the	  widespread	  and	  powerful	  effects	  of	  methylprednisolone.	  	  Both	  in	  vivo	  and	  in	  vitro	  models	  have	  demonstrated	  the	  reduction	  of	  IL-­‐6	  levels	  at	  the	  site	  of	  injury	  as	  well	  as	  in	  the	  systemic	  circulation	  following	  treatment	  with	  methylprednisolone[108,	  109].	  	  The	  characterization	  of	  effects	  by	  Almawi	  et	  al.	  illustrated	  a	  total	  abrogation	  of	  mRNA	  in	  a	  dose	  dependant	  manner	  among	  human	  peripheral	  blood	  mononuclear	  leukocytes.	  	  These	  observations	  were	  made	  in	  the	  presence	  of	  fully	  functional	  receptors,	  thus	  leading	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to	  the	  conclusion	  that	  methylprednisolone	  acts	  at	  the	  level	  of	  transcription,	  though	  the	  possibility	  of	  interference	  at	  additional	  sites	  is	  a	  possibility.	  	  Conversely,	  studies	  in	  a	  spinal	  cord	  injury	  model	  among	  rats	  demonstrated	  a	  site-­‐specific	  elevation	  in	  IL-­‐6	  that	  was	  also	  reduced	  with	  administration	  of	  methylprednisolone,	  illustrating	  both	  the	  local	  and	  systemic	  production	  as	  well	  as	  the	  reduction	  of	  that	  production	  by	  glucocorticoids.	  	  	  As	  IL-­‐6	  has	  been	  considered	  one	  of	  the	  most	  important	  cytokines	  in	  predicting	  outcome	  following	  illness	  or	  trauma,	  there	  is	  fairly	  good	  data	  with	  regard	  to	  the	  effects	  of	  androstenediol	  on	  IL-­‐6.	  	  The	  most	  convincing	  studies	  illustrate	  a	  reduction	  in	  elevated	  IL-­‐6	  levels	  following	  a	  two-­‐hit	  model	  of	  trauma-­‐hemorrhage	  and	  sepsis	  in	  rats	  that	  also	  correlates	  with	  an	  increase	  in	  survival	  against	  subjects	  not	  receiving	  AED	  treatment	  [67,	  110].	  	  Thus	  it	  seems	  likely	  that	  IL-­‐6	  levels	  should	  be	  increased	  with	  trauma,	  and	  also	  likely	  that	  the	  administration	  of	  methylprednisolone,	  while	  simulating	  stress,	  may	  reduce	  IL-­‐6	  levels,	  perhaps	  even	  to	  baseline	  levels.	  	  Furthermore,	  the	  administration	  of	  AED	  should	  further	  reduce	  the	  levels	  of	  IL-­‐6	  when	  compared	  to	  subjects	  not	  receiving	  AED.	  
Introduction	  to	  IL-­‐10	   	  Initially	  recognized	  for	  its	  inhibition	  of	  T-­‐helper	  cells,	  IL-­‐10	  has	  become	  known	  as	  a	  major	  element	  in	  the	  modulation	  of	  the	  immune	  system	  and	  the	  differentiation	  of	  naïve	  immune	  cells	  [111].	  	  As	  more	  has	  become	  known	  about	  IL-­‐10,	  its	  action	  has	  been	  found	  to	  be	  a	  direct,	  massive	  inhibition	  of	  monocytes	  and	  macrophages,	  which	  results	  in	  the	  subsequent	  inhibition	  of	  Th	  and	  NK	  cells	  [112].	  	  Specifically,	  the	  activity	  of	  IL-­‐10	  has	  been	  shown	  to	  inhibit	  the	  synthesis	  of	  IL-­‐1,	  IL-­‐2,	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IL-­‐3,	  IL-­‐6,	  IL-­‐8,	  IL-­‐12	  and	  IFN-­‐γ	  in	  humans	  [113].	  	  The	  absence	  of	  normal	  IL-­‐10	  levels	  is	  found	  frequently	  in	  cases	  of	  chronic	  inflammatory	  disease	  and	  autoimmunity.	  	  X-­‐ray	  crystallographic	  analysis	  has	  characterized	  the	  signaling	  peptide	  as	  a	  non-­‐covalent	  homodimer	  of	  178	  amino	  acids	  each	  and	  with	  a	  structure	  similar	  to	  IFN-­‐γ.	  	  	  Studies	  using	  protein	  mimics	  of	  IL-­‐10	  have	  demonstrated	  that	  short	  peptide	  sequences	  of	  the	  IL-­‐10	  peptide	  are	  able	  to	  initiate	  IL-­‐10-­‐like	  responses,	  leading	  to	  questions	  as	  to	  the	  relationship	  between	  the	  structure	  and	  the	  function	  of	  the	  intact	  IL-­‐10	  protein.	  	  The	  IL-­‐10	  gene	  is	  most	  commonly	  expressed	  in	  T-­‐cells	  and	  in	  monocytes/macrophages.	  	  Located	  in	  chromosome	  one	  in	  mice	  and	  men,	  transcription	  of	  the	  IL-­‐10	  gene	  results	  in	  an	  mRNA	  product	  approximately	  2kb	  long.	  	  	  The	  structurally	  similar	  human	  IL-­‐22	  has	  been	  shown	  in	  recent	  work	  to	  bind	  to	  a	  receptor	  complex	  consisting	  in	  part	  of	  the	  IL-­‐10	  receptor.	  	  This	  has	  also	  lead	  to	  questions	  regarding	  the	  possible	  cross	  reactivity	  of	  IL-­‐10	  and	  similar	  proteins	  with	  heterogeneous	  receptor	  complexes.	  	  While	  probably	  fortunate	  for	  research	  and	  unfortunate	  for	  human	  health,	  mammals	  are	  not	  the	  only	  organisms	  expressing	  the	  IL-­‐10	  gene	  in	  nature.	  	  IL-­‐10	  gene	  homologues	  are	  expressed	  in	  several	  viruses	  known	  to	  infect	  humans	  and	  other	  mammals,	  including	  Epstein-­‐Barr	  virus,	  Equine	  Herpes	  virus	  II,	  pox	  virus	  Orf,	  and	  human	  cytomegalovirus	  [112].	  	  These	  IL-­‐10	  homologues	  have	  been	  identified	  as	  having	  a	  structural	  homology	  of	  up	  to	  a	  frighteningly	  84%.	  	  Needless	  to	  say,	  this	  implicates	  IL-­‐10	  like	  proteins	  and	  IL-­‐10	  receptors	  in	  the	  furtherance	  of	  disease	  in	  humans	  and	  other	  mammals.	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Biosynthesis	  of	  IL-­‐10	   	  As	  previously	  described,	  the	  IL-­‐10	  gene	  is	  transcribed	  from	  an	  approximately	  2kb	  mRNA	  and	  processed	  into	  a	  protein	  of	  approximately	  178	  amino	  acids.	  	  Translation	  of	  the	  post-­‐translational	  mRNA	  produces	  one	  half	  of	  the	  IL-­‐10	  dimer	  required	  for	  biological	  activity.	  	  The	  monomer	  presents	  as	  a	  structure	  of	  six	  alpha	  helices,	  contains	  four	  cysteine	  residues,	  of	  which	  only	  one	  is	  conserved	  among	  members	  of	  the	  IL-­‐10	  family	  of	  cytokines,	  suggesting	  that	  disulfide	  bonds	  are	  not	  important	  in	  the	  conformation	  of	  the	  monomer	  or	  dimerization	  of	  the	  superstructure.	  	  The	  monomer	  is	  characterized	  by	  the	  V-­‐shaped	  structure,	  which	  is	  hypothesized	  to	  aid	  in	  the	  dimerization	  of	  the	  final	  active	  molecule.	  Research	  characterizing	  the	  massive,	  rapid	  release	  of	  IL-­‐10	  in	  response	  to	  certain	  stimuli	  has	  suggested	  that	  there	  are	  alternative	  methods	  for	  modulating	  levels	  of	  IL-­‐10	  in	  vivo.	  	  	  Researchers	  have	  hypothesized	  that	  IL-­‐10	  is	  continuously	  synthesized	  at	  some	  constitutive	  level,	  and	  that	  it	  is	  post-­‐transcriptional	  mechanisms	  that	  are	  responsible	  for	  controlling	  overall	  IL-­‐10	  levels.	  	  This	  would	  allow	  for	  a	  faster	  modulation	  of	  IL-­‐10	  levels	  rather	  than	  simple	  resolution	  through	  transcriptional	  control	  [112].	  	  The	  biosynthesis	  has	  been	  characterized	  as	  a	  response	  or	  counterbalance	  to	  inflammation	  through	  synthesis	  by	  Th-­‐2	  cells	  in	  order	  to	  downregulate	  the	  inflammatory	  role	  of	  Th-­‐1	  cells.	  	  IL-­‐10	  has	  been	  shown	  to	  serve	  several	  functions	  in	  this	  role.	  	  Primarily	  as	  a	  stimulator	  of	  B-­‐cell	  activation	  to	  increase	  sensitivity	  to	  antigen,	  IL-­‐10	  has	  also	  been	  demonstrated	  to	  play	  roles	  in	  suppressing	  Th-­‐1	  response	  following	  the	  induction	  of	  anergenic	  activity	  as	  well	  as	  perhaps	  being	  a	  constitutive	  element	  in	  balancing	  inflammation	  against	  abnormal	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physiology	  in	  such	  autoimmune	  diseases	  such	  as	  experimental	  autoimmune	  encephalomyelitis,	  IDDM,	  and	  rheumatoid	  arthritis	  [112].	  
Targets	  of	  IL-­‐10	  	   As	  already	  demonstrated,	  IL-­‐10	  has	  a	  broad	  effect	  on	  a	  number	  different	  cell	  types,	  including	  T-­‐cell,	  B-­‐cells,	  monocytes/macrophages	  as	  well	  as	  NK	  cells.	  	  The	  possibility	  of	  receptor	  sites	  for	  such	  a	  diverse	  and	  powerful	  cytokine	  must	  be	  considered.	  	  	  Especially	  in	  view	  of	  	  the	  fact	  that	  although	  IL-­‐10	  is	  first	  thought	  to	  act	  as	  a	  dimer,	  but	  has	  also	  been	  shown	  to	  act	  in	  protein	  subunits	  and	  is	  expressed	  by	  additional	  organisms.	  	  Like	  other	  cytokine	  receptors,	  the	  IL-­‐10	  receptor	  is	  also	  a	  dimer,	  composed	  of	  alpha	  and	  beta	  subunits,	  which	  constitute	  the	  receptor	  and	  signaling	  roles	  of	  the	  IL-­‐10	  receptor	  respectively.	  	  In	  contrast	  to	  IL-­‐6,	  there	  have	  been	  no	  reports	  of	  a	  soluble	  receptor	  for	  IL-­‐10	  in	  vivo,	  although	  in	  vitro	  experiments	  have	  been	  able	  to	  synthesize	  a	  soluble	  IL-­‐10α	  subunit.	  	  Studies	  have	  shown	  that	  T-­‐cells	  downregulate	  expression	  of	  one	  subunit	  of	  the	  IL-­‐10	  receptor	  in	  response	  to	  activation,	  while	  macrophages	  actually	  upregulate	  IL-­‐10	  receptor	  expression	  in	  response	  to	  antigen	  or	  other	  activating	  stimuli.	  	  The	  expression	  of	  the	  alpha	  subunit	  has	  also	  been	  demonstrated	  to	  be	  induced	  in	  non-­‐immune	  system	  cells,	  such	  as	  fibroblasts,	  epidermal	  cells,	  keratinocytes,	  and	  colonic	  epithelium	  in	  response	  to	  such	  stimuli	  as	  lipopolysaccharide	  (LPS),	  glucocorticoids	  and	  other	  compounds	  [112].	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Predicted	  Response	  of	  IL-­‐10	  to	  Treatment	  	   The	  role	  of	  IL-­‐10	  in	  modulating	  the	  immune	  system	  following	  trauma	  and	  or	  infection	  is	  generally	  characterized	  as	  a	  “brake”	  on	  the	  pro-­‐inflammatory	  mediators	  of	  the	  immune	  system.	  	  Reviewing	  the	  human	  data	  for	  IL-­‐10	  levels	  among	  critically	  ill	  patients	  provides	  a	  reminder	  as	  to	  both	  the	  balance	  sought	  by	  the	  immune	  system	  
and	  the	  temporal	  nature	  of	  cytokine	  expression.	  	  This	  conclusion	  is	  born	  from	  the	  results	  of	  both	  traumatic	  and	  non-­‐traumatic	  patient	  studies	  and	  their	  expression	  of	  IL-­‐10	  during	  their	  treatment.	  	  While	  perhaps	  expecting	  to	  see	  a	  reduction	  in	  the	  levels	  of	  the	  anti-­‐inflammatory	  cytokine	  IL-­‐10	  among	  non-­‐survivors	  (thus	  providing	  an	  overly	  pro-­‐inflammatory	  pathologic	  state),	  studies	  frequently	  illustrate	  IL-­‐10	  levels	  at	  or	  above	  levels	  found	  among	  healthy	  volunteers	  [64,	  114].	  	  The	  most	  striking	  differences	  in	  these	  values	  were	  presented	  when	  comparing	  critically	  ill	  trauma	  patients	  with	  critically	  ill	  patients	  suffering	  from	  non-­‐traumatic	  sepsis.	  	  In	  comparing	  the	  values	  between	  survivors	  and	  non-­‐survivors	  within	  these	  groups,	  the	  authors	  illustrated	  little	  difference	  in	  the	  trauma	  groups,	  while	  the	  sepsis	  group	  displayed	  a	  ten-­‐fold	  difference	  between	  survivors	  and	  non-­‐survivors	  with	  the	  non-­‐survivors	  having	  the	  higher	  value.	  	  This	  may	  either	  illustrate	  an	  overly	  Immunosuppressed	  state,	  thus	  allowing	  the	  pathogen	  to	  thrive	  and	  ultimately	  overcome	  the	  host,	  or,	  it	  may	  illustrate	  a	  futile	  effort	  to	  apply	  a	  brake	  to	  a	  pathologic	  pro-­‐inflammatory	  state.	  	  Only	  by	  evaluating	  the	  rest	  of	  the	  patient’s	  blood	  values	  can	  this	  determination	  be	  made.	  	  	  This	  is	  course	  also	  dependent	  on	  the	  temporal	  value	  of	  the	  cytokine	  messaging	  system.	  	  The	  previously	  discussed	  IL-­‐10	  values	  among	  traumatic	  and	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non-­‐traumatic	  patients	  were	  obtained	  at	  48	  hours	  post-­‐admission	  to	  the	  ICU.	  	  This	  of	  course	  gives	  no	  indication	  as	  to	  the	  overall	  temporal	  pattern	  of	  the	  illness	  and	  thus	  is	  fairly	  useless	  in	  evaluating	  the	  temporal	  nature	  of	  IL-­‐10	  in	  this	  study.	  	  It	  does	  however	  serve	  as	  a	  reminder	  that	  the	  expression	  of	  cytokines	  are	  temporal	  in	  nature	  and	  may	  ultimately	  be	  dependent	  on	  the	  expression	  of	  other	  cytokines.	  	  With	  regard	  to	  the	  trauma	  patients,	  admission	  to	  the	  ICU	  following	  surgery	  or	  other	  interventions	  to	  stabilize	  the	  patient	  likely	  occurs	  within	  a	  fairly	  close	  timeline	  between	  individuals.	  	  With	  the	  knowledge	  that	  the	  IL-­‐10	  values	  are	  the	  same	  or	  similar	  between	  survivors	  and	  non-­‐survivors	  of	  the	  traumatic	  injury	  group,	  IL-­‐10	  may	  be	  discounted	  as	  a	  value	  for	  predicting	  mortality.	  	  However,	  the	  further	  knowledge	  that	  the	  otherwise	  healthy	  group	  presents	  with	  IL-­‐10	  values	  nearly	  twice	  that	  of	  the	  entire	  trauma	  group	  indicates	  an	  imbalance	  that	  may	  be	  significant.	  	  	  When	  considering	  the	  reaction	  of	  IL-­‐10	  to	  administration	  of	  glucocorticoids	  such	  as	  methylprednisolone,	  one	  might	  expect	  to	  see	  an	  increase	  as	  glucocorticoids	  are	  known	  for	  their	  anti-­‐inflammatory	  properties.	  	  This	  is	  indeed	  the	  case,	  but	  the	  reasons	  for	  this	  are	  not	  yet	  clear.	  	  There	  are	  indeed	  examples	  citing	  increases	  in	  circulating	  IL-­‐10	  following	  administration	  of	  methylprednisolone	  [115].	  	  However,	  as	  glucocorticoids	  like	  methylprednisolone	  are	  known	  to	  downregulate	  other	  cytokines,	  most	  likely	  at	  the	  level	  of	  transcription,	  the	  mechanisms	  in	  the	  regulation	  of	  IL-­‐10	  remains	  unclear.	  	  One	  groups	  has	  postulated	  that	  the	  reason	  for	  increased	  circulating	  IL-­‐10	  may	  be	  at	  least	  partially	  due	  to	  decreased	  expression	  of	  the	  IL-­‐10	  receptor.	  	  These	  authors	  demonstrated	  not	  only	  that	  the	  IL-­‐10	  receptor	  is	  expressed	  on	  CD4+	  and	  CD8+	  T-­‐cells,	  NK	  cells,	  monocytes	  and	  neutrophils,	  but	  also	  that	  a	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seven	  day	  course	  resulted	  in	  a	  significant	  reduction	  in	  the	  expression	  of	  the	  IL-­‐10	  receptor	  on	  these	  same	  cells	  [116].	  	  This	  of	  course	  raises	  the	  question	  as	  to	  whether	  the	  decrease	  in	  receptor	  expression	  is	  due	  to	  an	  active	  removal	  of	  the	  receptors,	  or	  merely	  the	  failure	  to	  synthesize	  new	  receptors	  once	  IL-­‐10	  has	  been	  bound	  and	  the	  receptor/ligand	  complex	  has	  been	  internalized.	  	  Furthermore,	  this	  casts	  into	  possibility	  the	  question	  as	  to	  whether	  there	  is	  not	  increased	  IL-­‐10	  synthesis	  following	  glucocorticoid	  administration,	  but	  merely	  higher	  circulating	  levels	  due	  to	  a	  lack	  of	  available	  receptors.	  	  This	  would	  in	  turn	  cast	  further	  doubt	  on	  the	  possibility	  of	  IL-­‐10	  to	  act	  as	  an	  anti-­‐inflammatory	  cytokine	  as	  it	  cannot	  bind	  receptors	  and	  thus	  produce	  its	  anti-­‐inflammatory	  signaling	  cascade.	  	  For	  the	  sake	  of	  simplicity,	  we	  must	  now	  merely	  acknowledge	  that	  glucocorticoid	  administration	  increases	  IL-­‐10	  levels	  as	  part	  of	  an	  already	  anti-­‐inflammatory	  process.	  	  	  Unfortunately,	  there	  is	  a	  similar	  poor	  understanding	  regarding	  the	  effects	  of	  androstenediol	  on	  IL-­‐10	  levels.	  	  Work	  in	  rats	  treated	  with	  a	  sepsis	  model	  and	  a	  sepsis/trauma/hemorrhage	  (STH)	  model	  showed	  increases	  in	  IL-­‐10	  in	  the	  STH	  model	  that	  were	  reduced	  by	  the	  administration	  of	  IL-­‐10	  [110].	  These	  results	  were	  demonstrated	  both	  in	  plasma	  levels	  of	  IL-­‐10	  and	  in	  IL-­‐10	  mRNA	  from	  liver	  biopsy.	  	  Thus,	  while	  trauma	  in	  humans	  produced	  a	  profound	  drop	  in	  IL-­‐10	  levels	  following	  only	  trauma	  and	  no	  significant	  difference	  in	  the	  sepsis	  only	  group	  [64],	  the	  rat	  model	  of	  sepsis	  only	  produced	  no	  significant	  increase	  while	  the	  trauma/hemorrhage	  and	  sepsis	  model	  produced	  increased	  levels	  that	  were	  reduced	  by	  IL-­‐10.	  	  Therefore,	  when	  considering	  a	  rat	  model,	  we	  should	  expect	  traumatic	  injury	  to	  increase	  IL-­‐10	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levels.	  	  Treatment	  with	  methylprednisolone	  may	  increase	  IL-­‐10	  levels,	  while	  further	  treatment	  with	  androstenediol	  may	  reduce	  circulating	  levels	  of	  IL-­‐10.	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Materials	  and	  Methods	  	  
Specific	  Studies	  	   Based	  on	  the	  previously	  illustrated	  hypothesis,	  background	  information,	  and	  mechanisms,	  the	  specific	  studies	  to	  be	  completed	  were	  designed.	  	  In	  order	  to	  assess	  the	  mechanisms	  behind	  the	  suppression	  of	  wound	  healing	  by	  corticosteroids	  and	  subsequent	  restorative	  features	  of	  androstenediol,	  we	  sought	  to	  conduct	  preliminary	  experiments	  to	  determine	  the	  ratios	  of	  wound	  size,	  glucocorticoid	  dose,	  and	  androstenediol	  dose	  that	  would	  provide	  the	  best	  illustration	  of	  the	  data.	  We	  thus	  began	  with	  groups	  of	  ten	  male	  Sprague	  Dawley	  rats	  six	  to	  eight	  weeks	  old	  and	  weighing	  between	  two-­‐hundred	  twenty-­‐five	  and	  two-­‐hundred	  fifty	  grams.	  	  The	  animals	  in	  each	  group	  of	  six	  or	  ten	  were	  to	  be	  divided	  into	  animals	  receiving	  experimental	  treatments	  and	  those	  receiving	  the	  vehicle	  control	  only.	  	  	  The	  animals	  were	  received	  into	  the	  University	  Department	  of	  Animal	  Resources	  and	  were	  allowed	  to	  acclimate	  for	  at	  least	  seven	  days	  prior	  to	  the	  initiation	  of	  the	  study.	  	  On	  the	  day	  before	  wounding	  (Day-­‐1),	  animals	  were	  assessed	  for	  general	  health;	  the	  animals	  were	  then	  weighed	  and	  animals	  received	  either	  an	  injection	  of	  synthetic	  glucocorticoid	  or	  vehicle	  while	  under	  anesthetic	  using	  isoflurane	  in	  oxygen	  delivered	  via	  anesthetic	  chamber.	  Animals	  were	  then	  returned	  to	  housing.	  	  On	  the	  day	  of	  wounding	  (Day	  0),	  animals	  were	  again	  weighed,	  then	  anesthetized	  using	  isoflurane	  in	  oxygen	  delivered	  via	  anesthetic	  chamber.	  The	  animals	  received	  prophylactic	  analgesia	  (0.1mg/kg	  buprenorphine,	  IP),	  then	  the	  dorsum	  of	  each	  animal	  was	  shaved	  and	  anesthesia	  depth	  confirmed	  by	  absence	  of	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response	  to	  painful	  stimulus.	  	  The	  wounding	  site	  cleansed	  with	  iodophore	  and	  dried.	  	  Two	  circular	  full	  thickness	  wounds	  were	  induced	  on	  the	  shaved	  dorsum	  adjacent	  the	  spine.	  	  Experimental	  animals	  received	  either	  an	  injection	  of	  androstenediol,	  or	  vehicle	  only.	  	  In	  order	  to	  determine	  the	  effects	  of	  the	  experimental	  applications,	  animals	  were	  assessed	  at	  time	  points	  specific	  to	  each	  group	  and	  their	  expected	  response.	  	  During	  these	  periodic	  assessments,	  animals	  were	  again	  weighed	  and	  photographed	  for	  wound	  image	  data	  measurements.	  	  On	  further	  specific	  time	  points,	  blood	  was	  drawn	  from	  the	  tail	  vein	  into	  a	  syringe	  pre-­‐loaded	  with	  EDTA	  for	  use	  in	  several	  assays,	  including	  ELISA,	  Multiplex	  Analysis,	  FACS	  Analysis,	  and	  VetScan	  measurements.	  	  During	  all	  of	  these	  periodic	  assessments	  and	  blood	  draws,	  animals	  were	  anesthetized	  using	  isoflurane	  in	  oxygen	  delivered	  via	  anesthetic	  chamber	  and	  assessed	  for	  response	  to	  painful	  stimuli.	  	  On	  day	  21,	  the	  animals	  were	  sacrificed	  by	  Euthasol	  injection	  done	  under	  isoflurane	  anesthesia.	  Prior	  to	  euthanasia	  and	  when	  the	  animals	  are	  under	  deep	  anesthesia,	  blood	  was	  drawn	  from	  the	  tail	  vein	  or	  by	  direct	  cardiac	  puncture.	  
Study	  Groups	  	   The	  following	  study	  groups	  represent	  a	  selection	  of	  approximately	  25%	  of	  the	  animal	  groups	  studied	  during	  the	  course	  of	  this	  research	  project.	  	  Groups	  listed	  in	  this	  document	  were	  selected	  to	  provide	  a	  sense	  of	  the	  timeline	  and	  strategies	  employed	  to	  generate	  the	  desired	  results	  within	  the	  parameters	  of	  the	  research	  protocol.	  	  While	  the	  general	  approach	  to	  each	  group	  was	  similar,	  changes	  were	  made	  in	  the	  dose	  of	  glucocorticoids,	  type	  of	  glucocorticoids,	  dose	  of	  healing	  promoter	  (AED	  or	  AET),	  size	  of	  wound,	  vehicles	  and/or	  injection	  sites	  (Table	  1).	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Depomedrol/AED	  Group	  Beginning	  248376A	  	   In	  early	  July	  2009,	  we	  were	  well	  into	  the	  study	  groups	  employed	  to	  determine	  the	  parameters	  of	  the	  larger	  experiment.	  	  The	  group	  beginning	  248376A	  was	  indicative	  of	  the	  previous	  groups	  and	  represented	  a	  baseline	  of	  the	  procedures	  and	  compounds	  used	  throughout	  the	  experiment.	  	  The	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  12mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  6mm	  full-­‐thickness	  wounds,	  taken	  by	  6mm	  biopsy	  punch,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  a	  mixture	  of	  DMSO	  and	  ethanol	  in	  two	  subcutaneous	  injection	  sites	  near	  the	  wound	  sites	  of	  the	  animal.	  	  Androstenediol	  (AED)	  treatment	  animals	  received	  the	  DMSO/ethanol,	  which	  then	  also	  contained	  AED	  at	  a	  dose	  of	  .25mg/kg	  in	  the	  same	  location	  as	  the	  control	  animals.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  3,	  6,	  and	  9.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	  
Depomedrol/AET	  Group	  Beginning	  248680	  	   The	  immediately	  following	  group	  was	  designated	  to	  begin	  248680.	  	  The	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  Following	  several	  weeks	  of	  experiments	  to	  determine	  the	  parameters	  of	  the	  master	  study	  using	  AED,	  we	  hypothesized	  that	  perhaps	  the	  rats	  would	  not	  respond	  as	  well	  to	  the	  AED	  treatment	  as	  the	  mice	  from	  the	  previous	  experiment	  might.	  	  Thus	  we	  decided	  to	  try	  a	  course	  of	  the	  alternative	  derivative,	  androstenetriol.	  	  In	  addition,	  we	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had	  found	  that	  the	  combination	  of	  DMSO	  and	  ethanol	  were	  producing	  epidermal	  ulcerations	  at	  the	  site	  of	  injection.	  	  Thus,	  in	  this	  group	  we	  also	  elected	  to	  try	  beta-­‐cyclodextrin	  as	  the	  delivery	  vehicle.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  12mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  6mm	  full-­‐thickness	  wounds,	  taken	  by	  6mm	  biopsy	  punch,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  beta-­‐cyclodextrin	  in	  two	  subcutaneous	  injection	  sites	  near	  the	  wound	  sites	  of	  the	  animal.	  	  Androstenetriol	  (AET)	  treatment	  animals	  received	  the	  beta-­‐cyclodextrin,	  which	  then	  also	  contained	  AET	  at	  a	  dose	  of	  .25mg/kg	  in	  the	  same	  location	  as	  the	  control	  animals.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AET	  injection	  consistent	  with	  their	  group	  on	  days	  3,	  6,	  and	  9.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	  
Depomedrol/AED	  Group	  Beginning	  252251	  	   Immediately	  following	  our	  foray	  into	  the	  AET	  trial,	  we	  returned	  to	  experimenting	  with	  AED.	  	  However,	  in	  this	  group,	  we	  decided	  to	  try	  to	  increase	  the	  administration	  of	  AED	  by	  injecting	  at	  additional	  sites.	  	  In	  addition,	  we	  decided	  that	  additional	  trauma	  may	  upregulate	  the	  immune	  response	  and	  may	  thus	  increase	  the	  response	  of	  the	  immune	  system	  to	  AED.	  	  The	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  12mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  12mm	  full-­‐thickness	  wounds,	  taken	  by	  measurement	  and	  hand-­‐cut,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  Control	  animals	  then	  received	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vehicle,	  consisting	  of	  beta-­‐cyclodextrin	  in	  four	  subcutaneous	  injection	  sites	  near	  the	  wound	  sites	  of	  the	  animal.	  	  Androstenediol	  (AED)	  treatment	  animals	  received	  the	  beta-­‐cyclodextrin,	  which	  then	  also	  contained	  AED	  at	  a	  dose	  of	  .25mg	  per	  injection	  site	  in	  the	  same	  location	  as	  the	  control	  animals	  (for	  a	  total	  injection	  of	  1mg	  AED).	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  3	  and	  9.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	  
Depomedrol/AED	  Group	  Beginning	  252968	  	   In	  September	  of	  2009,	  we	  were	  continuing	  with	  AED	  while	  we	  also	  proceeded	  with	  modulating	  other	  parameters	  of	  the	  experiment.	  	  At	  this	  time,	  we	  felt	  that	  additional	  trauma	  may	  further	  the	  presentation	  of	  the	  desired	  results.	  	  Thus,	  the	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  12mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  14mm	  full-­‐thickness	  wounds,	  taken	  by	  measurement	  and	  hand-­‐cut,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  beta-­‐cyclodextrin	  in	  a	  single	  intraperitoneal	  injection	  site.	  	  androstenediol	  (AED)	  treatment	  animals	  received	  3ml	  of	  beta-­‐cyclodextrin	  containing	  AED	  at	  the	  single	  intraperitoneal	  injection	  site	  as	  well.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  3,	  6,	  9	  and	  16.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	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Depomedrol/AED	  Group	  Beginning	  254682	  	   In	  October	  of	  2009,	  we	  were	  concerned	  about	  the	  concentration	  of	  AED	  in	  the	  beta-­‐cyclodextrin.	  	  In	  addition,	  we	  were	  unconvinced	  that	  the	  frequency	  of	  AED	  doses	  were	  sufficient	  to	  provide	  the	  biochemical	  momentum	  required	  to	  facilitate	  the	  desired	  results.	  	  Thus	  in	  this	  groups	  we	  decided	  to	  increase	  the	  frequency	  of	  injection.	  	  The	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  12mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  14mm	  full-­‐thickness	  wounds,	  taken	  by	  measurement	  and	  hand-­‐cut,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  beta-­‐cyclodextrin	  in	  four	  subcutaneous	  injection	  sites	  near	  the	  wound	  sites	  of	  the	  animal.	  	  Androstenediol	  (AED)	  treatment	  animals	  received	  2ml	  of	  AED	  in	  beta-­‐cyclodextrin	  in	  the	  same	  locations	  as	  the	  control	  animals.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  1	  through	  9.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	  
Depomedrol/AED	  Group	  Beginning	  258339	  	   In	  November	  of	  2009,	  we	  continued	  with	  our	  hypothesis	  that	  additional	  trauma	  would	  enhance	  the	  difference	  in	  wound	  healing	  between	  the	  vehicle	  and	  AED	  groups.	  	  In	  addition,	  we	  decided	  that	  less	  inhibition	  of	  the	  immune	  system	  might	  make	  the	  results	  more	  apparent.	  	  The	  animals	  were	  received	  and	  acclimated	  as	  illustrated	  in	  the	  previous	  sections.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  8mg	  methylprednisolone.	  	  On	  Day	  0,	  each	  animal	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received	  two	  14mm	  full-­‐thickness	  wounds,	  taken	  by	  measurement	  and	  hand-­‐cut,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  In	  addition,	  each	  animal	  received	  a	  laparatomy	  4cm	  in	  length.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  beta-­‐cyclodextrin	  in	  a	  tail	  vein	  injection.	  	  androstenediol	  (AED)	  treatment	  animals	  received	  .3ml	  of	  AED	  in	  beta-­‐cyclodextrin,	  also	  in	  the	  tail	  vein.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  3	  through	  9.	  	  The	  animals	  were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  21.	  
Cortisone/AED	  Group	  Beginning	  261328	  	   January	  of	  2010,	  we	  had	  concerns	  that	  the	  profound	  immunosupression	  initiated	  by	  methylprednisolone	  could	  not	  be	  overcome	  in	  this	  particular	  animal	  model.	  	  In	  addition,	  questions	  as	  to	  the	  true	  dose	  of	  AED	  in	  the	  cyclodextrin	  vehicle	  continued	  to	  perplex.	  	  Thus	  we	  tried	  an	  alternative	  glucocorticoid,	  cortisone,	  and	  returned	  to	  the	  original	  vehicle	  DMSO	  and	  ethanol.	  	  On	  Day-­‐1,	  each	  animal	  was	  weighed,	  and	  received	  an	  IM	  injection	  of	  48mg/kg	  cortisone.	  	  On	  Day	  0,	  each	  animal	  received	  two	  14mm	  full-­‐thickness	  wounds,	  taken	  by	  measurement	  and	  hand-­‐cut,	  on	  either	  side	  of	  the	  spine,	  in	  the	  upper	  dorsal	  aspect.	  	  In	  addition,	  each	  animal	  received	  a	  laparatomy	  4cm	  in	  length.	  	  Control	  animals	  then	  received	  vehicle,	  consisting	  of	  DMSO/ethanol	  in	  two	  subcutaneous	  injection	  sites	  near	  the	  wounds.	  	  Androstenediol	  (AED)	  treatment	  animals	  received	  .4ml	  of	  AED	  in	  DMSO/ethanol,	  also	  near	  the	  wounding	  sites.	  	  Following	  Day	  0,	  animals	  then	  received	  either	  a	  vehicle	  or	  AED	  injection	  consistent	  with	  their	  group	  on	  days	  3,	  6,	  and	  9.	  	  The	  animals	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were	  sampled	  for	  blood	  during	  the	  course	  of	  the	  experiment	  via	  tail	  vein	  and	  were	  terminated	  on	  Day	  9.	  	  Group	   Wound	   Steroid	   Dose	   Mediator	   Dose	   Vehicle	   Sites	  248376A	   2x6mm	   Depo	   12mg	   AED	   24mg	   DMSO/ETOH	   2xSC	  248680	   2x6mm	   Depo	   12mg	   AET	   24mg	   DMSO/ETOH	   2xSC	  252251	   2x12mm	   Depo	   12mg	   AED	   16mg	   Cyclodextrin	   4xSC	  252968	   2x14mm	   Depo	   12mg	   AED	   30mg	   Cyclodextrin	   1xIP	  258339	   2x14mm	  +Lap	   Depo	   8mg	   AED	   3mg	   Cyclodextrin	   1xIV	  261328	   2x14mm	  +Lap	   Cort.	   48mg/kg	   AED	   32mg	   DMSO/ETOH	   2xSC	  
Table	  1:	  	  Animal	  Groups	  and	  Treatments	  	  
Sample	  Preparation	  	   The	  analysis	  of	  blood	  samples	  was	  critical	  to	  the	  investigation	  into	  the	  mechanisms	  employed	  by	  the	  drug	  in	  question,	  and	  second	  only	  in	  importance	  to	  the	  wound	  sizes	  during	  the	  healing	  process.	  	  Blood	  samples	  were	  taken	  by	  tail	  vein	  under	  inhaled	  anesthesia	  at	  various,	  specified	  time	  points.	  	  The	  samples	  were	  taken	  for	  either	  use	  in	  a	  single	  assay,	  or	  more	  commonly,	  for	  use	  in	  several	  assays	  in	  tandem.	  	  In	  some	  cases,	  the	  samples	  were	  divided	  into	  groups	  to	  undergo	  individual	  analysis	  at	  later	  time	  points,	  in	  other	  cases;	  a	  single	  sample	  was	  subject	  to	  more	  than	  one	  single	  assay	  immediately	  flowing	  harvest.	  	  For	  example,	  a	  single	  blood	  sample	  could	  be	  assayed	  by	  VetScan	  for	  total	  cell	  counts;	  since	  the	  VetScan	  technique	  removes	  only	  a	  small	  quantity	  of	  blood	  from	  the	  sample	  tube	  without	  contaminating	  the	  rest,	  the	  same	  sample	  could	  then	  be	  centrifuged	  to	  separate	  blood	  plasma	  from	  red	  blood	  cells.	  	  These	  populations	  could	  then	  be	  separated	  via	  pipette	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for	  further	  analysis	  (ELISA	  and	  FACS).	  	  The	  sample	  preparation	  for	  each	  of	  the	  specific	  assays	  follows.	  
VetScan	  	   Animals	  to	  be	  sampled	  were	  placed	  under	  anesthetic	  by	  isoflurane	  in	  oxygen	  via	  anesthetic	  chamber.	  	  Animals	  were	  determined	  to	  be	  insensitive	  to	  pain	  and	  were	  transferred	  to	  a	  heated	  pad	  to	  maintain	  body	  temperature	  during	  the	  procedure.	  	  The	  tail	  was	  cleaned	  with	  alcohol	  preparation	  and	  blood	  was	  accessed	  in	  the	  tail	  vein	  via	  aseptic	  technique.	  	  Samples	  of	  at	  least	  150µl	  were	  collected	  from	  the	  tail	  vein	  and	  deposited	  in	  a	  microtubule	  pre-­‐loaded	  with	  the	  anticoagulant	  EDTA.	  	  In	  the	  instance	  that	  the	  blood	  sample	  was	  to	  serve	  both	  VetScan	  and	  ELISA	  samples,	  with	  or	  without	  FACS	  analysis,	  sample	  volume	  was	  about	  600µl.	  	  Samples	  were	  not	  refrigerated	  but	  were	  kept	  at	  room	  temperature	  until	  analysis,	  usually	  immediately	  after	  the	  last	  sample	  was	  taken.	  	  Sample	  tubes	  were	  loaded	  into	  the	  VetScan	  machine.	  	  The	  instruments	  were	  programmed	  to	  read	  the	  blood	  sample	  according	  to	  the	  species,	  and	  to	  characterize	  the	  blood	  cells.	  The	  VetScan	  HM2	  is	  a	  self	  contained,	  fully	  automated	  tool	  for	  the	  complete	  blood	  count	  of	  cells	  in	  whole	  blood.	  	  The	  VetScan2	  measures	  White	  Blood	  Cells	  and	  their	  subpopulations	  by	  volumetric	  impedance.	  	  Following	  dilution	  of	  1:32,000	  with	  two	  different	  forms	  of	  diluent,	  electrically	  neutral	  blood	  cells	  pass	  through	  an	  electrically	  charged	  aperture,	  applying	  a	  minimal	  charge	  to	  each	  cell.	  	  Each	  cell	  accepts	  a	  charge	  in	  a	  manner	  directly	  proportional	  to	  its	  size.	  	  Diluted	  blood	  is	  then	  forced	  through	  yet	  another	  aperture,	  large	  enough	  to	  accommodate	  only	  one	  cell	  at	  a	  time.	  	  Charges	  are	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measured	  at	  this	  aperture	  and	  according	  to	  the	  size	  of	  the	  charge,	  lymphocytes,	  monocytes,	  and	  granulocytes	  are	  distinguished	  from	  one	  another.	  
ELISA	  	   Blood	  was	  taken	  as	  illustrated	  above	  for	  VetScan.	  	  In	  the	  instance	  in	  which	  blood	  was	  to	  serve	  only	  for	  ELISA	  and/or	  FACS	  analysis,	  only	  500µl	  was	  taken.	  	  Microtubes	  containing	  whole	  blood	  in	  EDTA	  were	  loaded	  into	  a	  centrifuge	  and	  centrifuged	  to	  separate	  the	  intact	  cells	  from	  proteins	  suspended	  in	  the	  blood	  plasma.	  	  The	  supernatant	  from	  the	  microtubes	  was	  pipetted	  off	  above	  the	  buffy	  coat,	  and	  was	  loaded	  into	  between	  one	  and	  three	  fresh,	  sterile	  microtubes,	  depending	  on	  the	  quantity	  of	  blood	  plasma	  available.	  	  The	  microtubes	  were	  labeled	  with	  the	  subject	  number	  and	  date,	  and	  were	  then	  flash-­‐frozen	  in	  liquid	  nitrogen.	  	  Frozen	  samples	  were	  loaded	  into	  a	  -­‐80˚C	  freezer	  for	  later	  use.	  	  At	  the	  time	  of	  assay,	  samples	  were	  removed	  from	  the	  freezer,	  and	  placed	  in	  ice	  at	  room	  temperature.	  	  R&D	  ELISA	  assay	  kits	  were	  used	  for	  all	  protein	  characterization.	  	  Kits	  used	  were	  in	  date	  and	  sealed	  prior	  to	  use.	  	  Kits	  were	  opened	  and	  inspected	  to	  ensure	  the	  stability	  and	  quality	  of	  the	  individual	  reagents.	  	  According	  to	  the	  directions	  provided	  with	  the	  kit,	  the	  reagents	  and	  assay	  plate	  were	  prepared	  for	  introduction	  of	  the	  samples.	  	  Samples	  were	  processed	  according	  to	  the	  instructions	  provided	  and	  assayed	  at	  the	  completion	  of	  the	  incubation	  steps.	  
Wound	  Image	  Data	  Analysis	  	   In	  order	  to	  accurately	  characterize	  the	  healing	  process	  between	  different	  treatment	  groups,	  our	  lab	  sought	  to	  employ	  the	  use	  of	  wound	  planimetry	  to	  provide	  
Monday,	  August	  9,	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  F.	  Jerome	  Diskin	  61	  
an	  objective,	  unbiased	  quantitative	  measure	  of	  the	  size	  of	  the	  wounds.	  	  Animal	  subjects	  were	  photographed	  using	  a	  digital	  camera	  at	  predefined	  time-­‐points.	  	  At	  the	  time	  of	  photography,	  the	  animals	  were	  sedated	  using	  inhaled	  anesthetics.	  	  Animals	  were	  placed	  on	  a	  level,	  well-­‐lit	  surface,	  in	  a	  prone	  position,	  and	  were	  photographed	  by	  the	  digital	  camera	  placed	  at	  a	  fixed,	  predetermined	  height.	  	  Wounds	  were	  measured	  using	  the	  Image	  J	  software	  program	  as	  available	  from	  the	  National	  Institutes	  of	  Health.	  	  Photos	  were	  opened	  in	  Image	  J,	  the	  scale	  was	  set	  in	  the	  program	  by	  drawing	  a	  line	  on	  the	  scale	  in	  the	  photograph	  and	  then	  setting	  the	  photo	  scale	  to	  match	  the	  photo.	  	  Wounds	  were	  then	  traced	  by	  tracing	  the	  outline	  of	  the	  open	  wound.	  	  If	  no	  open	  wound	  was	  visible	  due	  to	  scabbing,	  the	  outline	  of	  the	  scab	  was	  traced.	  	  Typically,	  once	  the	  scab	  fell	  off,	  there	  was	  a	  center	  area	  of	  open	  wound,	  surrounded	  by	  intact	  tissue	  in	  the	  late	  stages	  of	  healing,	  then	  surrounded	  by	  undisturbed	  tissue.	  	  In	  all	  cases	  where	  it	  could	  be	  visualized,	  only	  the	  open	  wound	  was	  measured.	  	  Wound	  that	  had	  closed	  completely	  were	  not	  measured,	  and	  no	  tracing	  measurement	  was	  generated.	  	  These	  closed	  wounds	  were	  typically	  characterized	  by	  pink	  tissue	  in	  the	  outline	  of	  the	  former	  open	  wound,	  surrounded	  by	  white,	  undisturbed	  tissue.	  	  The	  tracing	  and	  area	  calculations	  were	  displayed	  in	  a	  quantitative	  data	  summary,	  which	  was	  then	  overlaid	  across	  the	  bottom	  region	  of	  the	  photo.	  	  Once	  the	  wounds	  were	  measured	  and	  data	  displayed,	  a	  screen	  shot	  was	  then	  taken	  and	  saved	  into	  Adobe	  Acrobat	  PDF	  file	  format	  for	  data	  entry	  and	  storage.	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Delivery	  Methods	  	  
Vehicles	   	  During	  the	  course	  of	  these	  experiments,	  it	  became	  clear	  that	  the	  vehicle	  used	  to	  deliver	  androstenediol	  to	  the	  animals	  and	  their	  circulation	  were	  compromised	  by	  complications	  including	  damage	  to	  the	  animal	  model,	  aggregation	  of	  the	  target	  drug	  in	  vivo,	  aggregation	  of	  the	  target	  drug	  in	  the	  delivery	  instrument,	  or	  a	  simple	  failure	  of	  the	  vehicle	  to	  deliver	  biologically	  significant	  levels	  of	  the	  target	  drug	  to	  the	  animal	  model.	  	  Below	  are	  the	  profile	  and	  rational	  for	  selecting	  the	  various	  vehicles.	  	  	  
DMSO	  and	  Ethanol	  	  Commonly	  employed	  for	  the	  delivery	  of	  compounds	  not	  soluble	  in	  polar	  solvent,	  DMSO/Ethanol	  was	  employed	  as	  the	  first	  vehicle.	  	  We	  found	  that	  the	  solvent	  was	  superior	  in	  providing	  a	  completely	  dissolved	  mixture	  of	  AED	  that	  delivered	  completely	  into	  tissue.	  	  However,	  despite	  the	  documented	  anti-­‐inflammatory	  properties	  of	  both	  DMSO	  and	  ethanol	  [78],	  we	  found	  that	  the	  solvent	  induced	  ulcers	  in	  the	  skin	  at	  the	  site	  of	  delivery.	  	  This	  was	  unexpected	  as	  other	  animal	  models	  have	  employed	  this	  vehicle	  without	  similar	  side	  effects.	  	  As	  the	  solvent	  has	  not	  only	  the	  propensity	  to	  modulate	  the	  very	  system	  we	  sought	  to	  monitor,	  but	  also	  induced	  additional	  wounding,	  we	  sought	  out	  alternate	  methods	  of	  delivering	  the	  drugs.	  
Cremophor	  EL	   	  Yet	  another	  widely	  popular	  solvent	  for	  the	  delivery	  of	  non-­‐polar	  compounds	  has	  been	  Cremophor.	  	  Popular	  because	  it	  has	  the	  ability	  to	  solubilize	  non-­‐polar	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compounds	  in	  an	  aqueous	  solution,	  we	  had	  hopes	  that	  this	  would	  solve	  our	  delivery	  problems.	  	  However,	  as	  Cremophor	  is	  best	  known	  for	  stabilizing	  emulsions,	  we	  found	  that	  we	  had	  a	  compound	  that	  would	  not	  pass	  through	  the	  needle	  size	  necessary	  to	  introduce	  the	  mixture	  to	  the	  model.	  	  Furthermore,	  we	  also	  found	  that	  it	  was	  extremely	  difficult	  to	  dissolve	  in	  the	  necessary	  concentration	  of	  AED.	  	  Also,	  due	  to	  the	  opaque	  nature	  of	  Cremophor,	  it	  was	  impossible	  to	  tell	  when	  the	  target	  drug	  had	  become	  fully	  suspended	  in	  the	  vehicle.	  	  	  
Beta-­‐cyclodextrin	  	   Our	  most	  recent	  foray	  into	  the	  search	  for	  a	  suitable	  delivery	  vehicle	  brought	  to	  our	  attention	  the	  oligosaccharide	  beta-­‐cyclodextrins.	  	  Beta-­‐cyclodextrins	  are	  currently	  used	  in	  pharma,	  food	  products,	  and	  other	  chemical	  applications.	  	  Given	  their	  unique	  cage-­‐like	  structure,	  it	  was	  hypothesized	  that	  we	  could	  load	  β-­‐cyclodextrin	  with	  molecules	  of	  AED,	  which	  would	  then	  be	  protected	  from	  an	  aqueous	  solution	  and	  thus	  protected	  from	  precipitation.	  	  While	  there	  has	  been	  some	  difficulty	  in	  determining	  how	  much	  AED	  exists	  in	  the	  beta-­‐cyclodextrin	  and	  how	  much	  becomes	  biologically	  available,	  this	  currently	  remains	  our	  best	  option	  in	  the	  rat	  model.	  
Injection	  Sites	  	  Due	  to	  the	  various	  methods	  approached	  to	  deliver	  androstenediol	  and	  our	  efforts	  to	  provide	  the	  best	  route	  for	  a	  biologically	  active	  drug,	  we	  experimented	  with	  several	  delivery	  routes.	  	  Several	  of	  these	  were	  mandated	  by	  the	  fact	  that	  some	  vehicles	  could	  carry	  only	  a	  small	  concentration	  of	  AED	  and	  in	  order	  to	  deliver	  the	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desired	  amount,	  we	  were	  forced	  to	  increase	  the	  volume	  of	  the	  total	  infusion.	  	  Obviously,	  there	  are	  limits	  to	  volume	  that	  can	  be	  introduced	  under	  the	  skin	  that	  may	  not	  have	  implications	  elsewhere.	  	  This	  section	  details	  the	  advantages	  and	  disadvantages	  of	  each	  approach	  in	  our	  work.	  
Intramuscular	   	  Due	  to	  the	  highly	  vascular	  nature	  of	  muscle	  tissue,	  intramuscular	  injections	  are	  commonly	  applied	  in	  both	  human	  and	  veterinary	  medicine.	  	  The	  sites	  are	  generally	  considered	  to	  accept	  a	  greater	  volume	  than	  subcutaneous	  sites,	  although	  perhaps	  less	  volume	  than	  an	  intraperitoneal	  injection.	  	  In	  addition,	  human	  studies	  of	  some	  compounds	  have	  illustrated	  that	  intramuscular	  injections	  lead	  to	  higher	  peak	  plasma	  concentrations,	  and	  thus	  better	  availability	  [117].	  	  Conversely,	  there	  seem	  to	  be	  fewer	  complications	  in	  the	  intramuscular	  site	  injection	  than	  in	  the	  intraperitoneal	  site,	  though	  perhaps	  more	  risk	  than	  that	  associated	  with	  the	  subcutaneous	  injection.	  	  As	  several	  large	  muscle	  groups	  often	  serve	  as	  targets	  for	  intramuscular	  injections,	  there	  exists	  the	  risk	  associated	  with	  striking	  or	  damaging	  one	  of	  the	  large	  nerve	  tracts	  often	  associated	  with	  the	  larger	  muscle	  groups.	  	  In	  addition,	  the	  use	  of	  intramuscular	  injection	  sites	  reduces	  the	  ability	  to	  assess	  the	  aggregation	  of	  target	  drug	  in	  the	  animal	  model,	  as	  we	  saw	  somewhat	  frequently	  in	  our	  experiments.	  
Intravenous	  	   The	  intravenous	  delivery	  of	  drug	  presents	  some	  of	  the	  greatest	  advantages	  as	  well	  as	  some	  of	  the	  greatest	  challenges	  to	  our	  work.	  	  	  The	  site	  allows	  for	  the	  delivery	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of	  a	  significant	  volume	  without	  compromising	  the	  health	  of	  the	  model	  as	  well	  as	  provides	  the	  most	  direct	  method	  for	  guaranteeing	  the	  provision	  of	  a	  biologically	  significant	  amount	  of	  the	  target	  drug.	  	  In	  addition,	  as	  has	  been	  suggested	  in	  the	  use	  of	  androstenediol	  as	  well	  as	  others,	  this	  route	  provides	  the	  most	  direct	  and	  diverse	  exposure	  for	  the	  metabolism	  that	  may	  be	  required	  for	  full	  biological	  activity.	  	  Conversely,	  the	  technical	  aspects	  of	  securing	  a	  patent	  vein	  in	  an	  anesthetized	  animal	  and	  frequency	  of	  drug	  delivery	  provide	  challenges.	  	  Inhaled	  anesthetics	  are	  well	  known	  to	  induce	  vasoconstriction	  (sometimes	  intentionally)	  thus	  reducing	  blood	  flow	  to	  the	  extremities	  such	  as	  a	  tail	  vein	  and	  making	  such	  injection	  sites	  difficult	  to	  cannulate	  at	  best.	  	  Also,	  the	  repeated	  introduction	  of	  a	  needle	  into	  the	  rodent	  tail	  vein	  as	  sometimes	  required	  by	  the	  volume	  of	  drug	  or	  by	  experimental	  parameters	  will	  cause	  repeated	  trauma	  to	  the	  extremity,	  making	  later	  venous	  access	  more	  difficult	  in	  addition	  to	  inducing	  further	  trauma	  and	  affecting	  the	  immune	  system	  that	  is	  being	  measured.	  	  
Intraperitoneal	  	   Like	  the	  other	  methods,	  the	  intraperitoneal	  injection	  site	  has	  both	  advantages	  as	  well	  as	  serious	  risks.	  	  This	  site	  presents	  perhaps	  the	  best	  opportunity	  to	  introduce	  large	  volumes	  of	  drug	  and	  vehicle	  into	  the	  animal	  without	  risking	  harm.	  	  In	  addition,	  if	  the	  activity	  of	  AED	  is	  indeed	  mediated	  by	  activation	  in	  the	  lymphatic	  system,	  the	  intraperitoneal	  site	  offers	  widespread	  access	  to	  the	  lymph	  nodes	  of	  the	  abdominal	  cavity	  and	  surrounding	  structures	  such	  as	  the	  spleen.	  	  Also,	  the	  intraperitoneal	  site	  also	  offered	  us	  the	  opportunity	  to	  introduce	  a	  larger	  needle	  gauge,	  as	  there	  are	  fewer	  compact	  structures	  as	  in	  muscle	  tissue	  and	  more	  room	  to	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work	  than	  at	  a	  subcutaneous	  site.	  	  This	  allowed	  us	  to	  mediate	  some	  of	  the	  vehicle	  issues	  that	  we	  were	  challenged	  with.	  	  However,	  the	  risks	  of	  injection	  so	  close	  to	  structures	  prone	  to	  induce	  sepsis	  or	  other	  life-­‐threatening	  illness	  in	  a	  small	  animal	  present	  their	  own	  challenges.	  	  The	  opportunity	  to	  lacerate	  or	  otherwise	  damage	  abdominal	  organs	  make	  this	  a	  risky	  procedure.	  	  In	  addition,	  the	  risk	  of	  drug	  aggregation	  or	  encapsulation	  resulting	  in	  a	  massive	  immune	  response	  to	  the	  abdominal	  cavity	  presents	  additional	  risk.	  	  While	  some	  of	  these	  challenges	  and	  risks	  do	  exists	  to	  a	  smaller	  extent	  at	  other	  injection	  sites,	  mistakes	  or	  missteps	  elsewhere	  result	  in	  death	  less	  frequently.	  	  However,	  this	  is	  a	  commonly	  used	  technique,	  and	  if	  performed	  carefully,	  and	  with	  some	  experience,	  can	  be	  used	  successfully.	  
Subcutaneous	  	   The	  subcutaneous	  injection	  site	  represented	  for	  us	  the	  most	  convenient	  site	  for	  introducing	  drug	  and	  vehicle,	  the	  opportunity	  to	  monitor	  the	  external	  and	  immediately	  internal	  effects	  of	  the	  injection,	  and	  to	  minimize	  the	  complications	  involved	  with	  some	  of	  the	  other	  sites	  and	  techniques.	  	  However,	  this	  convenience	  came	  at	  the	  price	  of	  limiting	  the	  size	  of	  the	  bolus	  that	  could	  be	  introduced	  beneath	  the	  skin,	  thus	  limiting	  the	  amount	  of	  drug	  that	  could	  be	  delivered	  at	  one	  injection	  site.	  	  In	  addition,	  the	  subcutaneous	  injection	  requires	  a	  nominal	  needle	  size,	  placing	  additional	  pressure	  on	  the	  vehicle	  system	  used	  to	  apply	  the	  compound	  and	  the	  extent	  to	  which	  it	  is	  soluble	  and	  able	  to	  pass	  through	  the	  needle	  without	  aggregation.	  	  In	  addition,	  the	  location	  brings	  into	  question	  whether	  the	  drug	  will	  be	  encapsulated	  as	  was	  seen	  with	  some	  vehicles,	  and	  whether	  the	  drug	  will	  be	  offered	  the	  proper	  opportunity	  for	  full	  activation	  and	  widespread	  biological	  availability.	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Results	  	   As	  was	  described	  in	  the	  Specific	  Studies	  section	  with	  regard	  to	  the	  different	  experimental	  groups,	  the	  following	  represents	  the	  results	  of	  the	  temporal	  and	  experimental	  continuum	  as	  we	  sought	  to	  determine	  the	  parameters	  to	  be	  used	  in	  the	  larger	  master	  study.	  	  Thus	  contained	  in	  each	  subsequent	  group	  are	  different	  variables	  such	  as	  drugs,	  dosages,	  vehicle,	  injection	  sites,	  and/or	  types	  and	  amount	  of	  trauma.	  	  Included	  in	  the	  data	  are	  the	  wound	  healing	  data,	  the	  information	  on	  changes	  in	  cell	  count,	  and	  where	  available,	  quantification	  of	  specific	  protein	  data.	  
Depomedrol/AED	  Group	  Beginning	  248376A	  	   The	  rat	  group	  beginning	  248376A	  was	  measured	  and	  given	  Day-­‐1	  treatment	  on	  July	  6,	  2009.	  	  During	  the	  treatment	  course,	  blood	  samples	  were	  taken	  on	  days	  -­‐1,	  3,	  6,	  9,	  and	  day	  21,	  all	  referencing	  the	  day	  of	  wounding	  (Day	  0).	  	  Animals	  were	  also	  photographed	  at	  these	  time	  points.	  	  VetScan	  data	  illustrated	  changes	  in	  white	  blood	  cells	  that	  indicated	  that	  the	  AED	  group	  held	  higher	  counts,	  though	  not	  always	  outside	  the	  overlap	  created	  by	  standard	  deviation	  (Figure	  6).	  	  While	  this	  appears	  promising,	  the	  changes	  relative	  to	  Day-­‐1	  data	  indicate	  that	  the	  total	  white	  blood	  cell	  counts	  dropped	  in	  both	  groups,	  although	  less	  in	  the	  AED	  group.	  As	  the	  predominant	  white	  blood	  cell	  in	  these	  count	  are	  the	  lymphocytes,	  it	  should	  come	  as	  no	  surprise	  that	  the	  lymphocyte	  counts	  reflect	  the	  same	  trend	  (Figure	  7).	  	  Interestingly,	  the	  monocyte	  and	  neutrophil	  counts	  show	  data	  consistent	  with	  changes	  induced	  by	  AED,	  however	  with	  opposite	  trends.	  	  Monocytes	  remain	  at	  the	  same	  or	  similar	  levels	  as	  the	  control	  groups	  through	  Day	  9,	  but	  begin	  to	  separate	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thereafter,	  perhaps	  reflecting	  some	  synergistic	  effects	  of	  both	  the	  AED	  and	  immune	  system	  (Figure	  8).	  	  When	  compared	  to	  the	  Day	  -­‐1	  values,	  the	  monocyte	  counts	  rebound	  from	  the	  initial	  administration	  of	  methylprednisolone	  (Figure	  9).	  	  These	  counts	  then	  decline	  to	  levels	  below	  Day-­‐1	  in	  the	  vehicle	  group,	  while	  in	  the	  AED	  group	  they	  persist	  at	  levels	  at	  least	  three	  times	  baseline	  Day	  -­‐1	  levels.	  While	  these	  levels	  are	  systemic,	  they	  may	  indicate	  enhanced	  healing.	  	  	  Conversely,	  the	  neutrophil	  counts	  illustrated	  by	  the	  VetScan	  granulocyte	  assay	  also	  indicate	  an	  initial	  reduction	  from	  baseline	  levels	  (Day-­‐1),	  which	  then	  rebound	  (Figure	  10).	  	  This	  rebound	  is	  more	  robust	  in	  the	  AED	  group	  and	  persists	  at	  levels	  higher	  than	  the	  vehicle	  group	  throughout	  the	  course	  of	  the	  experiment.	  	  Despite	  the	  perceived	  benefits	  of	  AED	  on	  the	  monocyte	  counts	  and	  the	  granulocyte	  counts,	  and	  their	  known	  beneficial	  effects	  on	  the	  wound	  healing	  process,	  measurements	  of	  wound	  sizes	  during	  the	  course	  of	  the	  experiment	  failed	  to	  yield	  any	  clear	  benefits.	  	  	  The	  trend	  lines	  indicate	  that	  the	  greatest	  difference	  in	  wound	  size	  exists	  around	  time	  point	  Day	  13	  (Figure	  11).	  	  This	  may	  correlate	  with	  the	  early	  rebound	  levels	  in	  monocyte	  and	  granulocyte	  counts	  when	  compared	  to	  the	  vehicle	  group.	  	  However,	  the	  replication	  of	  the	  data	  from	  earlier	  experiments	  that	  showed	  complete	  closure	  in	  the	  AED	  group	  while	  control	  groups	  remained	  open,	  failed	  to	  materialize.	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Figure	  6:	  	  Total	  White	  Blood	  Cell	  Counts	  for	  Rat	  Group	  Beginning	  248376A	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Figure	  8:	  Total	  Monocyte	  Counts	  for	  Rat	  Group	  Beginning	  248376A	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Figure	  10:	  Total	  Granulocyte	  Counts	  for	  Rat	  Group	  Beginning	  248376A	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Depomedrol/AET	  Group	  Beginning	  248680	  	   The	  rat	  group	  beginning	  248680	  was	  measured	  and	  given	  Day-­‐1	  treatment	  on	  July	  13,	  2009.	  	  During	  the	  treatment	  course,	  blood	  samples	  were	  taken	  on	  days	  -­‐1,	  3,	  9,	  and	  day	  16,	  all	  referencing	  the	  day	  of	  wounding	  (Day	  0).	  	  Animals	  were	  also	  photographed	  at	  these	  time	  points.	  	  	  Total	  White	  Blood	  Cell	  counts	  in	  this	  group	  were	  less	  impressive	  than	  with	  the	  previous	  group,	  with	  measurements	  showing	  both	  similar	  total	  levels	  and	  similar	  trending	  in	  the	  AET	  group	  when	  compared	  to	  the	  vehicle	  group	  (Figure	  12).	  	  This	  trend	  was	  also	  reflected	  when	  comparing	  the	  levels	  against	  the	  Day-­‐1	  levels,	  reflecting	  drops	  in	  both	  groups	  (Figure	  13).	  	  Thus	  the	  anticipated	  responses	  in	  lymphocyte	  counts	  were	  also	  seen.	  	  Total	  lymphocyte	  count	  was	  lowered	  dramatically	  (Figure	  14),	  as	  well	  as	  was	  the	  counts	  when	  compared	  to	  Day-­‐1	  baseline	  levels.	  	  The	  trends	  when	  comparing	  the	  AET	  animals	  against	  the	  vehicle	  animals	  were	  indistinguishable.	  	  Monocytes,	  however,	  gave	  the	  impression	  that	  some	  difference	  was	  perceptible	  between	  groups.	  	  When	  comparing	  absolute	  monocyte	  counts,	  very	  little	  difference	  between	  groups	  was	  apparent,	  less	  even	  when	  considering	  the	  standard	  deviation	  between	  values	  (Figure	  15).	  	  However,	  when	  examining	  the	  values	  against	  the	  Day-­‐1	  baseline	  values,	  there	  was	  a	  nearly	  50%	  difference	  in	  favor	  of	  the	  AET	  animals,	  perhaps	  falsely	  encouraging	  given	  the	  lack	  of	  standard	  deviation	  in	  a	  measurement	  of	  percentage.	  	  The	  granulocyte	  counts	  provided	  no	  clear	  direction	  and	  indicated	  conflicting	  trends	  in	  both	  groups	  in	  measuring	  both	  total	  counts	  and	  levels	  against	  the	  Day-­‐1	  baseline	  values	  (Figure	  16).	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Despite	  any	  hope	  offered	  by	  the	  minor	  differences	  illustrated	  by	  the	  major	  mediators	  of	  fibroblast	  activity	  (monocytes),	  wound	  size	  data	  indicated	  no	  difference	  between	  groups,	  with	  day–to-­‐day	  wound	  measurements	  and	  final	  closure	  nearly	  identical	  (Figure	  17).	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Figure	  13:	  Changes	  in	  White	  Blood	  Cell	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  248680	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Figure	  15:	  Total	  Monocyte	  Counts	  for	  Rat	  Group	  Beginning	  248680	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Figure	  17:	  Wound	  Size	  Data	  as	  a	  Percentage	  of	  Day-­1	  Wound	  Size	  in	  Rat	  Group	  Beginning	  248680	  	  	  
Depomedrol/AED	  Group	  Beginning	  252251	  	   The	  rat	  group	  beginning	  252251	  was	  measured	  and	  given	  Day-­‐1	  treatment	  on	  August	  31,	  2009.	  	  During	  the	  treatment	  course,	  blood	  samples	  were	  taken	  on	  days	  -­‐1,	  3,	  9,	  and	  day	  21,	  all	  referencing	  the	  day	  of	  wounding	  (Day	  0).	  	  Animals	  were	  also	  photographed	  at	  these	  time	  points.	  	  The	  white	  blood	  cell	  count	  data	  from	  this	  group	  was	  extremely	  variable,	  with	  no	  perceptible	  trends	  shown	  in	  the	  absolute	  cell	  counting	  (Figure	  18).	  	  White	  blood	  cell	  count	  data	  referenced	  to	  the	  Day-­‐1	  baseline	  values	  indicate	  an	  immediate	  drop	  in	  counts,	  with	  a	  recovery	  to	  near	  baseline	  in	  the	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indicated	  in	  the	  larger	  WBC	  populations.	  	  Absolute	  lymphocyte	  counts	  were	  dropped	  immediately	  from	  Day-­‐1	  baseline	  values,	  and	  showed	  no	  recovery	  or	  difference	  between	  groups	  (Figure	  20).	  	  Similarly,	  values	  referenced	  back	  to	  the	  baseline	  values	  showed	  do	  difference	  between	  groups	  (Figure	  21).	  	  Conversely,	  the	  monocyte	  and	  granulocyte	  groups	  seemed	  to	  provide	  any	  momentum	  for	  the	  changes	  seen	  in	  the	  larger	  WBC	  population.	  	  With	  regard	  to	  the	  monocytes,	  Day	  9	  showed	  significant	  increases	  in	  systemic	  counts	  in	  both	  groups	  (Figure	  22).	  	  Absolute	  values	  showed	  no	  significant	  difference	  in	  the	  values	  between	  the	  AED	  and	  vehicle	  groups,	  while	  the	  percentage	  values	  compared	  to	  Day-­‐1	  baseline	  give	  the	  impression	  of	  a	  difference.	  	  Similarly,	  the	  granulocyte	  counts	  also	  showed	  a	  significant	  systemic	  mobilization	  of	  granulocytes	  on	  Day	  9,	  although	  no	  difference	  was	  seen	  between	  the	  groups	  (Figure	  23).	  	  Values	  referenced	  to	  the	  Day-­‐1	  count	  indicate	  an	  increase	  in	  Day	  9	  among	  the	  vehicle	  animals	  above	  those	  counts	  in	  the	  AED	  animals,	  but	  the	  deviation	  among	  the	  absolute	  values	  seem	  to	  discount	  that	  conclusion.	  	  	  In	  evaluating	  the	  wound	  size	  data,	  the	  effects	  of	  the	  increased	  monocyte	  and	  granulocyte	  counts	  seem	  to	  be	  at	  odds	  with	  the	  better	  healing	  of	  the	  AED	  group	  at	  Days	  3	  through	  13,	  especially	  when	  considering	  that	  the	  vehicle	  groups	  had	  slightly	  higher	  values	  (Figure	  24).	  	  This	  of	  course	  could	  have	  alternative	  meaning	  to	  be	  discussed	  later.	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Figure	  18:	  Total	  White	  Blood	  Cell	  Counts	  for	  Rat	  Group	  Beginning	  252251	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Figure	  20:	  Lymphocyte	  Counts	  for	  Rat	  Group	  Beginning	  252251	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Figure	  22:	  Total	  Monocyte	  Counts	  for	  Rat	  Group	  Beginning	  252251	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Figure	  24:	  Wound	  Size	  Data	  as	  a	  Percentage	  of	  Day-­1	  Wound	  Size	  in	  Rat	  Group	  Beginning	  252251	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Lymphocyte	  counts	  indicated	  a	  curious	  response	  in	  this	  group.	  	  For	  the	  first	  time	  among	  these	  specific	  animal	  groups,	  the	  lymphocyte	  count	  indicated	  a	  recovery	  trend	  from	  the	  initial	  reduction.	  	  This	  trend	  was	  however	  reflected	  in	  both	  the	  AED	  and	  the	  vehicle	  group	  (Figure	  27).	  	  The	  changes	  in	  Day-­‐1	  values	  indicate	  that	  the	  group	  started	  with	  slightly	  higher	  values	  than	  the	  average	  Day-­‐1	  animal,	  and	  that	  the	  two	  groups	  also	  trended	  in	  a	  similar	  fashion	  (Figure	  28).	  	  Again,	  as	  was	  seen	  in	  the	  last	  group,	  the	  monocyte	  and	  granulocyte	  trends	  seem	  to	  provide	  the	  momentum	  for	  changes	  in	  the	  total	  white	  blood	  cell	  counts.	  	  Absolute	  monocyte	  values	  trend	  in	  a	  similar	  manner	  to	  the	  WBC	  counts,	  with	  values	  favoring	  the	  AED	  group	  early	  in	  the	  series,	  then	  dropping	  and	  eventually	  matching	  those	  of	  the	  vehicle	  group	  (Figure	  29).	  	  The	  values	  when	  referenced	  to	  the	  Day-­‐1	  counts	  also	  show	  a	  dramatic	  difference	  favoring	  the	  AED	  group,	  which	  then	  rebound	  to	  less	  than	  baseline	  values	  before	  correcting	  again	  (Figure	  30).	  	  The	  granulocyte	  counts	  also	  trend	  in	  a	  similar	  fashion,	  however,	  without	  the	  drop	  and	  subsequent	  correction	  from	  Day	  16	  to	  Day	  21.	  	  The	  circulating	  granulocyte	  values	  gradually	  build	  in	  both	  groups,	  peaking	  at	  Day	  16,	  with	  increases	  to	  the	  AED	  group,	  before	  returning	  to	  near	  baseline	  values	  on	  Day	  21	  (Figure	  31).	  	  This	  trend	  is	  repeated	  in	  the	  counts	  referenced	  to	  the	  baseline	  Day-­‐1	  values,	  with	  counts	  greatly	  exceeding	  baseline	  counts,	  before	  returning	  to	  near	  normal	  (Figure	  32).	  	  With	  the	  exception	  of	  Day	  16,	  there	  seems	  little	  difference	  in	  the	  number	  of	  circulating	  granulocytes,	  of	  which	  neutrophils	  are	  the	  clear	  majority,	  between	  the	  two	  study	  groups	  (Figure	  32).	  	  In	  contrast	  to	  the	  last	  group	  that	  indicated	  a	  slight	  advantage	  to	  healing	  in	  the	  AED	  group,	  this	  group	  indicates	  the	  opposite	  (Figure	  33).	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Despite	  the	  perceived	  advantages	  illustrated	  when	  the	  values	  are	  compared	  against	  the	  Day-­‐1	  counts,	  the	  standard	  deviations	  indicate	  that	  most	  of	  these	  values	  are	  the	  same	  if	  not	  statistically	  insignificant,	  and	  thus	  these	  trend	  lines	  indicating	  healing	  rate	  are	  most	  likely	  the	  same.	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Figure	  26:	  Changes	  in	  White	  Blood	  Cell	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  252968	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Figure	  28:	  Changes	  in	  Lymphocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  252968	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Figure	  30:	  Changes	  in	  Monocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  252968	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Figure	  32:	  Changes	  in	  Granulocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  252968	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Depomedrol/AED	  Group	  Beginning	  254682	  	   The	  rat	  group	  beginning	  254682	  was	  measured	  and	  given	  Day-­‐1	  treatment	  on	  October	  5,	  2009.	  	  During	  the	  treatment	  course,	  blood	  samples	  were	  taken	  on	  days	  -­‐1,	  3,	  9,	  and	  day	  16,	  all	  referencing	  the	  day	  of	  wounding	  (Day	  0).	  	  Animals	  were	  also	  photographed	  at	  these	  time	  points.	  	  As	  with	  other	  groups,	  the	  total	  white	  blood	  cell	  counts	  dropped	  and	  stayed	  relatively	  low	  through	  the	  course	  of	  the	  experiment	  (Figure	  34).	  	  The	  pattern	  in	  this	  group	  shows	  slight	  differences	  indicating	  minimally	  higher	  levels	  of	  white	  blood	  cells	  in	  the	  AED	  group.	  	  The	  values	  for	  standard	  deviation	  indicate	  that	  these	  counts	  are	  without	  merit.	  	  When	  the	  values	  are	  compared	  to	  the	  Day-­‐1	  baseline	  count,	  there	  is	  a	  similar	  picture	  presented,	  with	  slightly	  higher	  WBC	  counts	  in	  the	  AED	  group	  throughout	  (Figure	  35).	  	  	  As	  with	  the	  last	  few	  groups,	  the	  trends	  in	  lymphocyte	  values	  drop	  from	  Day-­‐1	  values	  and	  fail	  to	  recover.	  	  There	  seems	  no	  apparent	  benefit	  in	  either	  group	  (Figure	  36).	  	  When	  compared	  to	  the	  referenced	  Day-­‐1	  counts,	  the	  drop	  is	  significant	  to	  less	  than	  20%	  of	  normal	  values	  (Figure	  37).	  	  The	  monocyte	  counts	  paint	  a	  different	  picture,	  however,	  especially	  when	  compared	  to	  the	  course	  of	  AED	  administration.	  	  The	  monocyte	  counts	  in	  the	  vehicle	  group	  drop	  following	  the	  administration	  of	  methylprednisolone	  and	  induction	  of	  trauma.	  	  However,	  the	  AED	  group	  sustains	  their	  monocyte	  counts	  and	  even	  shows	  a	  slight	  increase	  from	  the	  baseline	  values.	  	  This	  is	  particular	  interesting	  as	  the	  AED	  administration	  continued	  to	  Day	  9,	  at	  which	  point	  the	  AED	  group	  monocyte	  levels	  drop	  again.	  	  At	  the	  same	  time	  point	  (Day	  16),	  the	  vehicle	  group’s	  monocyte	  counts	  rebound	  above	  baseline.	  	  As	  compared	  to	  the	  average	  Day-­‐1	  values,	  this	  particular	  group	  is	  already	  starting	  at	  less	  than	  70%	  of	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normal.	  	  When	  the	  following	  values	  are	  compared	  as	  a	  percentage	  to	  the	  Day-­‐1	  baseline	  values,	  they	  indicate	  a	  drop	  in	  over	  80%	  within	  the	  vehicle	  group,	  which	  then	  gradually	  recovers	  to	  eventually	  exceed	  the	  Day-­‐1	  values	  (Figure	  39).	  	  In	  this	  analysis,	  however,	  the	  levels	  of	  the	  AED	  monocyte	  counts	  seem	  far	  less	  impressive.	  	  The	  AED	  group	  indicates	  a	  slight	  drop,	  small	  increase,	  followed	  by	  yet	  another	  drop.	  	  Given	  the	  statistical	  significance	  of	  the	  absolute	  values,	  these	  changes	  are	  probably	  non-­‐existent.	  	  However,	  it	  is	  important	  to	  note	  the	  lack	  of	  change	  as	  compared	  to	  the	  drop	  in	  the	  vehicle	  group,	  especially	  when	  compared	  to	  the	  course	  of	  AED	  administration.	  	  The	  granulocyte	  counts	  in	  this	  group	  are	  also	  particularly	  fascinating.	  The	  AED	  group	  displays	  granulocyte	  levels	  that	  exceed	  the	  vehicle	  group’s	  levels	  though	  the	  final	  time	  point,	  Day	  16	  (Figure	  40).	  	  Again	  due	  the	  small	  animal	  group,	  these	  differences	  appear	  to	  be	  meaningless	  in	  all	  but	  one	  time	  point.	  	  The	  trend,	  however,	  should	  not	  be	  ignored.	  	  When	  considering	  this	  same	  data	  referenced	  to	  the	  Day-­‐1	  average	  baseline	  values,	  this	  group	  also	  starts	  below	  “normal”	  baseline	  levels.	  	  These	  counts	  recover	  significantly	  from	  the	  initial	  values	  and	  gain	  momentum	  throughout	  the	  experiment.	  	  This	  change	  is	  significantly	  pronounced	  within	  the	  AED	  group,	  up	  to	  50%	  more	  than	  within	  the	  vehicle	  group	  (Figure	  41).	  	  Thus	  while	  the	  standard	  deviation	  within	  the	  absolute	  cell	  counts	  cast	  this	  data	  into	  question,	  the	  trend	  in	  the	  group	  seems	  to	  indicate	  that	  the	  AED	  groups	  realized	  increases	  in	  both	  monocyte	  and	  granulocyte	  counts	  in	  a	  manner	  consistent	  with	  the	  day	  to	  day	  administration	  of	  AED.	  	  However	  once	  again,	  these	  changes	  failed	  to	  manifest	  in	  any	  changes	  wound	  healing.	  	  Both	  the	  vehicle	  and	  AED	  groups	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proceed	  on	  nearly	  identical	  courses	  with	  the	  AED	  group	  actually	  further	  behind	  the	  vehicle	  group	  in	  final	  healing	  (Figure	  42).	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Figure	  35:	  Changes	  in	  White	  Blood	  Cell	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  254682	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Figure	  37:	  Changes	  in	  Lymphocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  254682	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Figure	  39:	  Changes	  in	  Monocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  254682	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Figure	  41:	  Changes	  in	  Granulocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  254682	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Depomedrol/AED	  Group	  Beginning	  258339	  	   The	  rat	  group	  beginning	  258339	  was	  measured	  and	  given	  Day-­‐1	  treatment	  on	  November	  23,	  2009.	  	  During	  the	  treatment	  course,	  blood	  samples	  were	  taken	  on	  days	  -­‐1,	  3,	  16,	  and	  day	  21,	  all	  referencing	  the	  day	  of	  wounding	  (Day	  0).	  	  Animals	  were	  also	  photographed	  at	  these	  time	  points.	  	  As	  previously	  illustrated,	  animals	  in	  this	  group	  received	  a	  lower	  dose	  of	  methylprednisolone	  as	  well	  as	  the	  induction	  of	  additional	  trauma	  in	  the	  form	  of	  a	  laparatomy.	  	  It	  was	  the	  groups	  hope	  that	  this	  would	  represent	  less	  immunosupression	  in	  the	  face	  of	  additional	  upregulation	  of	  the	  immune	  system	  in	  response	  to	  the	  additional	  trauma,	  thus	  resulting	  in	  a	  better	  response	  to	  the	  AED.	  	  The	  following	  data	  also	  presents	  a	  unique	  perspective	  within	  this	  experiment	  as	  this	  group	  not	  only	  included	  the	  AED	  and	  vehicle	  subsets,	  but	  also	  a	  control	  group	  (PBS/VEH)	  as	  well	  as	  a	  group	  to	  distinguish	  the	  AED	  effects	  from	  those	  of	  the	  methylprednisolone	  effects	  (PBS/AED).	  	  In	  addition,	  because	  of	  the	  unique	  nature	  of	  this	  group,	  it	  was	  selected	  to	  do	  a	  further	  analysis	  of	  the	  function	  of	  the	  immune	  system	  by	  evaluating	  some	  of	  the	  protein	  mediators	  expressed	  under	  various	  circumstances.	  	  	  The	  total	  white	  blood	  cell	  counts	  presumably	  immediately	  illustrate	  the	  effects	  of	  the	  methylprednisolone,	  even	  at	  the	  lower	  dose.	  	  The	  total	  white	  blood	  cell	  counts	  indicate	  that	  both	  the	  groups	  receiving	  the	  methylprednisolone	  drop	  significantly,	  with	  little	  to	  no	  recovery	  in	  either	  the	  AED	  or	  vehicle	  group	  (Figure	  43).	  	  Conversely,	  the	  groups	  not	  receiving	  the	  methylprednisolone	  appeared	  to	  suffer	  no	  changes,	  again	  with	  no	  changes	  attributable	  to	  the	  AED.	  	  Interestingly,	  all	  groups	  presented	  with	  significantly	  lower	  counts	  on	  Day+1,	  perhaps	  due	  to	  the	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effects	  of	  the	  trauma	  itself.	  	  When	  compared	  to	  average	  Day-­‐1	  baseline	  levels,	  the	  Day+1,	  counts	  drop	  well	  over	  80%,	  with	  little	  recovery	  in	  the	  methylprednisolone	  groups,	  and	  recovers	  beyond	  baseline	  levels	  in	  the	  AED	  and	  vehicle	  groups	  not	  receiving	  the	  immunosuppressive	  steroid	  (Figure	  44).	  	  Interestingly,	  this	  same	  data	  indicates	  minor	  increases	  in	  WBC	  count	  in	  the	  DEPO/AED	  group	  above	  that	  of	  the	  DEPO/VEH	  group.	  	  	  Lymphocyte	  counts	  for	  this	  groups	  and	  each	  individual	  subset	  is	  almost	  identical	  to	  the	  white	  blood	  cell	  values.	  	  Following	  trauma,	  all	  T-­‐cell	  groups	  drop	  to	  values	  near	  normal,	  with	  recovery	  only	  in	  the	  groups	  not	  receiving	  the	  methylprednisolone	  (Figure	  45).	  	  Values	  compared	  to	  the	  average	  Day-­‐1	  counts	  also	  follow	  this	  trend.	  	  Immediately	  following	  wounding,	  all	  groups	  display	  a	  lymphocyte	  count	  below	  20%	  of	  normal.	  	  As	  with	  the	  overall	  WBC	  counts,	  the	  groups	  not	  receiving	  methylprednisolone	  recover	  to	  lymphocyte	  levels	  above	  normal,	  with	  the	  AED/VEH	  groups	  doing	  slightly	  better.	  	  Groups	  receiving	  methylprednisolone,	  however,	  remain	  with	  lymphocyte	  levels	  below	  40%	  of	  normal	  (Figure	  46).	  	  	  Efforts	  to	  characterize	  the	  activity	  and	  possible	  activation	  of	  T-­‐lymphocytes	  by	  analyzing	  IL-­‐2	  levels	  resulted	  in	  unreadable	  levels.	  	  The	  IL-­‐2	  ELISA	  assay	  revealed	  an	  accurate	  standard	  curve	  down	  to	  levels	  of	  31	  pg/ml	  (Figure	  47).	  	  However,	  our	  assay	  of	  Day-­‐1	  and	  Day	  +1	  blood	  samples	  in	  group	  beginning	  258339	  failed	  to	  reveal	  any	  detectable	  IL-­‐2	  levels.	  	  Rat	  IL-­‐2	  levels	  are	  typically	  less	  than	  15pg/ml,	  so	  this	  result	  is	  not	  completely	  unexpected.	  	  However,	  we	  would	  presume	  to	  see	  some	  systemic	  expression	  of	  IL-­‐2	  with	  increased	  T-­‐lymphocyte	  activity.	  	  We	  also	  sought	  to	  determine	  some	  level	  of	  T-­‐lymphocyte	  activity	  through	  the	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characterization	  of	  IL-­‐6	  levels.	  	  As	  with	  the	  IL-­‐2	  ELISA,	  we	  found	  the	  standard	  curve	  for	  the	  IL-­‐6	  assay	  to	  provide	  for	  an	  accurate	  reading	  of	  levels	  to	  just	  less	  then	  62	  pg/ml	  (Figure	  48).	  	  Again	  normal	  levels	  of	  IL-­‐6	  in	  rats	  are	  found	  to	  be	  less	  than	  the	  lowest	  detectable	  level	  in	  this	  assay.	  	  While	  this	  assay	  indeed	  provided	  some	  data,	  it	  indicates	  modest	  levels	  of	  IL-­‐6,	  at	  time	  points	  inconsistent	  with	  a	  response	  induced	  by	  trauma	  or	  drugs	  (Figure	  49).	  	  Furthermore,	  without	  any	  clear	  relationship	  between	  treatment	  and	  group,	  it	  seems	  that	  the	  IL-­‐6	  levels	  in	  these	  animals	  did	  not	  respond	  to	  either	  drug	  or	  physical	  damage.	  	  	  Monocyte	  counts	  also	  failed	  to	  add	  any	  clarity	  to	  this	  group	  as	  well.	  	  After	  an	  initial	  drop	  in	  monocyte	  levels	  across	  all	  groups,	  due	  either	  to	  the	  trauma,	  methylprednisolone,	  or	  both,	  monocyte	  levels	  returned	  to	  near	  normal	  levels	  also	  in	  all	  groups	  (Figure	  50).	  	  These	  minor	  changes	  did	  not	  favor	  any	  one	  group	  over	  another,	  and	  they	  did	  not	  seem	  to	  reflect	  any	  identifiable	  trends	  (Figure	  51).	  	  In	  an	  effort	  to	  characterize	  any	  interaction	  between	  monocytes	  and	  T-­‐lymphocytes	  in	  response	  to	  any	  trauma	  or	  drug	  administration,	  we	  sought	  to	  assay	  interleukin-­‐10.	  	  Unfortunately,	  circulating	  IL-­‐10	  levels	  also	  failed	  to	  reveal	  any	  useful	  information.	  	  While	  again	  we	  were	  able	  to	  discern	  a	  useful	  standard	  curve	  (Figure	  52),	  there	  were	  yet	  again	  no	  detectable	  levels	  of	  IL-­‐10	  in	  this	  group	  of	  animals	  for	  time	  points	  Day-­‐1,	  Day+1,	  or	  Day	  +3.	  	  With	  normal	  levels	  typically	  below	  the	  lowest	  detectable	  levels	  for	  this	  assay	  (32	  pg/ml),	  this	  result	  was	  again	  predictable	  for	  the	  baseline	  levels,	  but	  disappointing	  for	  the	  later	  time	  points.	  	  	  In	  this	  group,	  it	  is	  the	  granulocyte/neutrophil	  counts	  that	  finally	  lent	  some	  clarity	  to	  activity	  corresponding	  to	  treatment	  or	  drugs.	  	  Raw	  granulocyte	  counts	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illustrate	  a	  response	  to	  either	  drugs,	  or	  trauma	  or	  both	  but	  Day	  +1,	  with	  a	  recovery	  of	  levels	  shortly	  thereafter	  (Figure	  53).	  	  Perhaps	  most	  interestingly,	  the	  PBS/AED	  group	  indicated	  the	  least	  variation	  among	  any	  of	  the	  subgroups	  surveyed	  while	  the	  DEPO/AED	  group	  showed	  a	  persistent	  advance	  after	  recovering	  from	  the	  initial	  insult.	  	  Trends	  are	  encouraging	  when	  evaluated	  against	  the	  Day-­‐1	  average	  baseline	  values.	  	  When	  evaluating	  the	  DEPO/AED	  group	  against	  the	  DEPO/VEH	  group,	  both	  groups	  show	  an	  increase	  over	  the	  experiment,	  with	  the	  AED	  group	  showing	  higher	  systemic	  granulocyte	  levels	  (Figure	  54).	  	  Strangely,	  PBS/AED	  levels	  not	  only	  failed	  to	  keep	  pace,	  they	  indicated	  a	  continuous	  drop	  in	  levels.	  	  In	  an	  effort	  to	  characterize	  the	  recruitment	  of	  neutrophils,	  the	  circulating	  levels	  of	  IL-­‐8	  were	  assayed.	  	  The	  standard	  curve	  for	  interleukin-­‐8	  revealed	  that	  levels	  should	  be	  detectable	  as	  low	  as	  between	  7	  and	  15	  pg/ml	  (Figure	  55).	  	  As	  was	  the	  case	  with	  the	  raw	  granulocyte	  counts,	  the	  IL-­‐8	  assay	  also	  provided	  some	  interesting	  trends	  (Figure	  56,	  Figure	  58).	  	  While	  circulating	  IL-­‐8	  levels	  failed	  to	  change	  significantly	  in	  either	  of	  the	  groups	  treated	  with	  methylprednisolone,	  both	  the	  PBS/AED	  and	  the	  PBS/VEH	  groups	  expressed	  interesting	  increases	  in	  IL-­‐8	  expression	  from	  Day-­‐1	  to	  Day	  +1.	  	  The	  PBS/AED	  expressed	  the	  most	  clear-­‐cut	  change	  in	  expression	  among	  the	  groups	  assayed.	  	  	  As	  has	  been	  the	  case	  with	  other	  groups,	  the	  androstenediol	  seemed	  to	  provide	  some	  minor	  benefits	  to	  healing	  during	  the	  course	  of	  the	  experiment,	  although	  it	  presented	  no	  overall	  benefit	  with	  regard	  to	  the	  final	  wound	  closure	  (Figure	  58).	  	  It	  should	  not	  be	  unexpected	  that	  the	  subsets	  of	  the	  groups	  illustrated	  the	  most	  accelerated	  healing	  values,	  at	  times	  exceeding	  that	  of	  the	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methylprednisolone	  animals	  by	  as	  much	  as	  40%	  wound	  closure.	  	  Perhaps	  most	  disappointing	  was	  that	  the	  animals	  receiving	  no	  inhibition	  and	  no	  treatment	  at	  all,	  benefitted	  the	  most,	  presented	  as	  the	  most	  closed	  wounds	  when	  measured	  against	  the	  original	  wound	  size	  during	  the	  entire	  course	  of	  the	  experiment.	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Figure	  44:	  Changes	  in	  White	  Blood	  Cell	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  258339	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Figure	  46:	  Changes	  in	  Lymphocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  258339	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Figure	  48:	  Standard	  Curve	  for	  IL-­6	  ELISA	  for	  Rat	  Group	  Beginning	  258339	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Figure	  50:	  Total	  Monocyte	  Counts	  for	  Rat	  Group	  Beginning	  258339	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Figure	  52:	  Standard	  Curve	  for	  IL-­10	  ELISA	  for	  Rat	  Group	  Beginning	  258339	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Figure	  54:	  Changes	  in	  Granulocyte	  Count	  from	  Day-­1	  Average	  in	  Rat	  Group	  Beginning	  258339	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Figure	  56:	  IL-­8	  ELISA	  Values	  for	  Days	  -­1	  and	  Day+1	  for	  Rat	  Group	  Beginning	  258339	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Figure	  58:	  Wound	  Size	  Data	  as	  a	  Percentage	  of	  Day-­1	  Wound	  Size	  in	  Rat	  Group	  Beginning	  258339	  	  















Monday,	  August	  9,	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  F.	  Jerome	  Diskin	  108	  
group	  started	  with	  slightly	  lower	  values	  when	  compared	  to	  the	  average	  Day-­‐1	  counts,	  they	  reached	  levels	  over	  150%	  by	  Day	  6,	  and	  then	  began	  to	  trend	  back	  down.	  	  There	  appears	  to	  be	  no	  discernable	  difference	  between	  the	  treatment	  groups.	  	  	  T-­‐lymphocyte	  levels	  appear	  to	  set	  the	  aforementioned	  features	  in	  the	  total	  white	  blood	  cell	  count	  (Figure	  60).	  	  While	  initially	  presenting	  at	  low	  levels,	  below	  70%	  of	  normal	  (Figure	  61),	  these	  groups	  recover	  and	  then	  exceed	  normal	  levels	  before	  dropping.	  	  The	  monocyte	  counts	  provide	  a	  welcome	  deviation	  from	  the	  previous	  two	  cell	  groups,	  indicating	  the	  same	  trending	  as	  was	  seen	  before,	  but	  showing	  that	  the	  AED	  treatment	  group	  had	  higher	  levels	  of	  circulating	  monocytes	  than	  did	  the	  vehicle	  group	  (Figure	  62).	  	  When	  referencing	  the	  average	  Day-­‐1	  values,	  we	  can	  see	  that	  while	  the	  monocytes	  in	  the	  vehicle	  group	  indicated	  twice	  the	  normal	  levels	  or	  monocytes,	  the	  AED	  treatment	  group	  nearly	  quadrupled.	  	  While	  the	  granulocyte	  data	  a	  fairly	  unimpressive,	  the	  fact	  that	  there	  is	  so	  little	  difference	  between	  groups	  is	  in	  fact	  interesting.	  	  The	  changes	  in	  granulocyte	  levels	  reflect	  those	  seen	  in	  both	  the	  lymphocyte	  and	  total	  WBC	  counts,	  however,	  with	  absolutely	  no	  difference	  between	  the	  treatment	  groups	  (Figure	  63).	  	  Both	  groups	  also	  show	  increases	  in	  granulocyte	  count	  doubling,	  and	  then	  tripling	  before	  beginning	  to	  drop	  again.	  	  	  While	  in	  this	  group	  we	  saw	  differences	  in	  cell	  counting	  that	  were	  not	  patently	  obvious	  in	  other	  treatment	  groups,	  there	  again	  failed	  to	  be	  any	  apparent	  difference	  in	  the	  manner	  or	  timeline	  in	  which	  the	  wound	  healed	  (Figure	  64).	  	  In	  fact,	  these	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treatment	  groups	  presented	  more	  similar	  healing	  timelines	  than	  an	  of	  the	  other	  study	  models.	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Figure	  60:	  Total	  Lymphocyte	  Counts	  for	  Rat	  Group	  Beginning	  261328	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Figure	  62:	  Total	  Monocyte	  Counts	  for	  Rat	  Group	  Beginning	  261328	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Discussion	  	   As	  stated	  previously,	  the	  results	  provided	  above	  represent	  a	  select	  subset	  of	  the	  data	  obtained	  in	  approximately	  twenty	  study	  groups.	  	  Through	  a	  close	  examination,	  we	  can	  see	  that	  through	  the	  process	  of	  induced	  trauma,	  administration	  of	  immunosuppressive	  glucocorticoids,	  and	  immunomodulatory	  sex-­‐steroid	  derivatives,	  we	  have	  indeed	  modified	  the	  presentation	  of	  white	  blood	  cells	  counts,	  and	  also	  altered	  some	  cytokine	  profiles.	  	  These	  processes	  also	  provided	  some	  data	  reflecting	  an	  altered	  healing	  process	  in	  groups	  corresponding	  with	  the	  treatment	  they	  received.	  	  Again	  however,	  while	  we	  did	  see	  some	  trends	  reflecting	  differences	  between	  these	  groups,	  as	  well	  as	  some	  significant	  differences	  during	  the	  healing	  process,	  the	  final	  result(s)	  were	  not	  different	  enough,	  if	  at	  all,	  to	  recognize	  a	  real	  distinction	  in	  the	  healing	  process	  in	  response	  to	  the	  experimental	  drugs.	  	  The	  question	  then	  remains:	  why?	  	  	  Our	  expectation	  was	  that	  the	  administration	  of	  androstenediol	  would	  relieve	  immunosupression	  induced	  by	  the	  prior	  administration	  of	  methylprednisolone,	  thus	  enabling	  the	  host	  to	  heal	  full-­‐thickness	  wounds	  at	  a	  rate	  faster	  than	  those	  not	  receiving	  androstenediol.	  	  As	  stated	  previously,	  this	  hypothesis	  was	  based	  on	  data	  obtained	  in	  a	  previous	  murine	  model	  in	  this	  lab	  [6].	  	  There	  are	  numerous	  reasons,	  perhaps	  too	  many	  to	  examine,	  that	  could	  account	  for	  the	  difference	  in	  results	  obtained	  between	  these	  two	  studies.	  	  There	  are	  however,	  several	  factors	  that	  are	  more	  easily	  identifiable	  which	  play	  a	  significant	  role	  in	  these	  differences.	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The	  first	  and	  perhaps	  most	  significant	  possibility	  is	  the	  immunomodulatory	  drug	  itself.	  	  The	  original	  source	  of	  the	  drug	  and	  the	  vehicle	  it	  was	  administered	  in	  were	  a	  proprietary	  mixture	  then	  and	  are	  now	  unavailable.	  	  We	  were	  of	  course	  able	  to	  procure	  the	  ∆5-­‐androstene-­‐3β,17β-­‐diol	  from	  alternate	  sources.	  	  However,	  we	  had	  no	  assurances	  that	  the	  procedures	  that	  were	  utilized	  allowing	  the	  drug	  to	  become	  soluble	  in	  vehicle	  were	  the	  same	  as	  previously	  employed.	  	  Additionally,	  we	  did	  not	  have	  the	  formulation	  for	  the	  original	  vehicle,	  and	  while	  we	  experimented	  with	  several	  vehicles,	  we	  were	  challenged	  with	  using	  vehicle	  components	  that	  are	  known	  to	  modulate	  the	  immune	  system	  themselves.	  	  Some,	  in	  fact	  (at	  least	  in	  the	  rat)	  induced	  skin	  ulcers	  similar	  to	  those	  seen	  in	  chemical	  burns.	  	  Furthermore,	  some	  vehicle	  solutions	  appeared	  to	  disallow	  the	  drug	  to	  enter	  either	  the	  general	  circulation	  of	  the	  lymph	  system,	  as	  encapsulated	  deposits	  of	  drug	  were	  found	  at	  the	  site	  of	  injection.	  	  While	  we	  found	  great	  success	  in	  the	  use	  of	  β-­‐cyclodextrin,	  the	  victory	  was	  incomplete.	  	  The	  β-­‐cyclodextrin	  allowed	  us	  to	  produce	  a	  completely	  soluble	  form	  of	  the	  drug	  in	  solution.	  	  However,	  we	  struggled	  to	  discern	  how	  much	  of	  the	  drug	  was	  taken	  up	  by	  the	  starch-­‐derived	  cages,	  as	  well	  as	  how	  much	  of	  the	  drug	  was	  made	  available	  to	  the	  host.	  	  These	  results	  illustrate	  the	  difficulties	  in	  formulating	  a	  vehicle	  that	  would	  allow	  the	  drug	  into	  solution	  while	  still	  remaining	  bioavailable	  and	  non-­‐toxic.	  	  	  	   Ignoring	  for	  a	  moment	  the	  possibility	  that	  the	  drug	  administered	  may	  have	  had	  no	  effect	  due	  to	  an	  altered	  formulation	  or	  an	  incompatible	  vehicle,	  we	  did	  see	  some	  impressive	  changes	  in	  the	  quantities	  of	  white	  blood	  cells,	  as	  well	  as	  some	  changes	  in	  the	  expression	  of	  inflammatory	  cytokines	  (Table	  2).	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   Trend	  Difference	  	  Group	  ID	   Lymph.	   Mon.	   Gran.	   IL-­‐8	   Wound	  Healing	  248376A	   ⇓ 	   ⇑ 	   ⇑ 	   N/A	   -­-­	  248680	   ⇓ 	   ⇑ 	   ⇑ 	   N/A	   -­-­	  252251	   ⇓ 	   ⇑⇓ 	   -­-­	   N/A	   ⇑-­	  252968	   ⇓⇑ 	   ⇑⇓ 	   -­-­	   N/A	   ⇓ 	  254682	   ⇓ 	   -­-­	   ⇑ 	   N/A	   -­-­	  258339	   ⇓ 	   -­-­	   ⇑ 	   ⇑ 	   -­-­	  261328	   -­-­	   ⇑ 	   -­-­	   N/A	   -­-­	  
Table	  2:	  Changes	  in	  Cell	  Count	  and	  Cytokine	  Levels	  in	  AED/AET	  Animals	  vs.	  Immunosuppressed	  Animals	  
Only	  	  Perhaps	  most	  surprising	  is	  the	  fact	  that	  some	  of	  these	  white	  blood	  cells,	  namely	  monocytes,	  are	  some	  of	  the	  most	  potent	  mediators	  of	  the	  healing	  process	  available.	  However,	  while	  there	  appears	  to	  be	  little	  difference	  in	  the	  healing	  of	  groups	  with	  increased	  monocyte	  levels	  compared	  to	  those	  with	  flat	  or	  biphasic	  changes	  in	  monocyte	  counts.	  	  Similarly,	  changes	  in	  the	  inflammatory	  cytokine	  IL-­‐8	  also	  did	  not	  seem	  to	  present	  any	  difference	  in	  the	  healing	  process.	  	  So	  then,	  why	  are	  there	  changes	  associated	  with	  these	  drug	  administrations	  reflected	  in	  mediators	  of	  the	  healing	  process,	  with	  no	  actual	  changes	  in	  healing?	  	  We	  are	  assuming	  that	  the	  expression	  of	  systemic	  cell	  types	  and	  protein	  levels	  are	  indicative	  of	  a	  changed	  process	  at	  the	  site	  of	  injury	  or	  inflammation.	  	  While	  indeed	  this	  may	  be	  the	  case,	  the	  opposite	  may	  in	  fact	  be	  true	  where	  as	  the	  relationship	  between	  local	  and	  circulating	  cells	  may	  be	  inverted.	  	  When	  speaking	  of	  cells	  recruited	  from	  the	  periphery,	  the	  introduction	  of	  glucocorticoids	  or	  sex	  steroids	  such	  as	  androstenediol	  may	  in	  fact	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restrict	  cellular	  migration	  to	  the	  site	  of	  injury.	  	  Glucocorticoids	  have	  been	  shown	  to	  decrease	  levels	  of	  activated	  white	  blood	  cells,	  including	  the	  reduced	  expression	  of	  glycosylated	  proteins	  responsible	  for	  the	  migration	  of	  cells	  from	  the	  systemic	  circulation	  into	  the	  site	  of	  injury.	  	  This	  effect	  would	  thus	  increase	  circulating	  levels	  of	  white	  blood	  cells	  by	  allowing	  the	  synthesis	  as	  part	  of	  a	  natural	  or	  pathological	  process	  while	  preventing	  their	  access	  to	  injury.	  	  In	  fact,	  one	  may	  be	  able	  to	  produce	  a	  relationship	  between	  increased	  levels	  of	  circulating	  cells	  and	  reduced	  local	  counts.	  	  In	  addition,	  while	  the	  activity	  of	  white	  blood	  cells	  may	  or	  may	  not	  be	  a	  systemic	  indication	  of	  local	  activity,	  there	  remains	  the	  question	  of	  cytokine	  and	  other	  protein	  messenger	  expression.	  	  IL-­‐8	  is	  a	  well	  known	  recruiter	  of	  neutrophils	  and	  it’s	  expression	  certainly	  correlates	  with	  increased	  systemic	  neutrophil	  counts.	  	  While	  perhaps	  not	  true	  of	  other	  chemokines,	  IL-­‐8	  surely	  must	  act	  systemically	  in	  order	  to	  recruit	  circulating	  granulocytes.	  	  Other	  cytokines	  failed	  to	  present	  themselves	  at	  detectable	  levels,	  which	  may	  be	  a	  result	  of	  trauma	  below	  the	  threshold	  for	  the	  expression	  of	  circulating	  cytokines	  or	  activation	  of	  the	  immune	  system,	  still	  to	  be	  discussed.	  	  Other	  mediators	  not	  discussed	  here	  may	  not	  be	  expressed	  systemically,	  acting	  in	  a	  paracrine	  or	  autocrine	  manner	  locally.	  	  Thus	  increased	  levels	  of	  circulating	  white	  blood	  cells	  may	  not	  be	  an	  indicator	  of	  local	  activity,	  and	  in	  some	  cases,	  in	  fact	  the	  inverse	  may	  be	  predicted.	  	  	  	   Whether	  or	  not	  the	  assays	  utilized	  served	  as	  accurate	  predictors	  of	  activity	  within	  the	  immune	  system	  or	  healing,	  the	  fact	  remains	  that	  healing	  within	  the	  AED	  or	  AET	  groups	  failed	  to	  exceed	  that	  of	  the	  methylprednisolone	  only	  groups.	  	  Most	  other	  studies	  illustrating	  the	  difference	  made	  by	  the	  administration	  of	  β-­‐
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androstenes	  are	  within	  models	  with	  multiple	  insults	  such	  as	  trauma	  and	  hemorrhage,	  trauma	  and	  infection,	  or	  burn	  and	  infection	  etc.	  These	  previous	  studies	  have	  provided	  positive	  data,	  while	  this	  one	  did	  not,	  suggesting	  that	  a	  significant	  upregulation	  of	  the	  immune	  system	  by	  either	  trauma	  or	  infection	  may	  be	  required	  in	  order	  to	  provide	  an	  improved	  outcome.	  	  Within	  these	  study	  groups,	  the	  rats	  were	  specified	  to	  be	  between	  two	  hundred	  twenty-­‐five	  grams	  and	  two	  hundred	  fifty	  grams	  upon	  delivery.	  	  Rats	  normally	  lost	  weight	  during	  the	  course	  of	  the	  experiment,	  presumably	  due	  to	  increased	  metabolism	  following	  administration	  of	  the	  methylprednisolone.	  	  This	  of	  course	  means	  that	  the	  rats	  were	  at	  their	  maximum	  weight	  upon	  delivery	  to	  the	  lab,	  between	  two	  hundred	  twenty-­‐five	  grams	  and	  two	  hundred	  fifty	  grams.	  	  This	  is	  relevant	  in	  calculating	  their	  body	  surface	  area.	  	  Calculating	  the	  body	  surface	  area	  of	  rodents	  can	  be	  very	  difficult,	  however,	  it	  is	  typically	  measured	  by	  inputting	  the	  mass	  into	  a	  standard	  calculation,	  which	  is	  adjusted	  for	  the	  specific	  species	  by	  a	  prefactor.	  	  The	  equation	  given	  for	  the	  Norway	  Rat	  is:	   Surface	  Area	  (sq.cm.)	  =	  9.1	  x	  (Mass	  (g))2/3	  This	  equation	  results	  in	  a	  body	  surface	  area	  of	  324.4cm2,	  or	  32,470mm2.	  	  When	  this	  is	  related	  to	  the	  wound	  sizes	  applied,	  it	  produces	  wound	  sizes	  totaling	  0.17%	  for	  the	  total	  of	  both	  6mm	  wounds,	  0.7%	  for	  the	  total	  of	  both	  12mm	  wounds,	  and	  0.95%	  of	  total	  body	  surface	  area	  for	  both	  14mm	  wounds.	  	  Needless	  to	  say,	  these	  wounds	  represent	  minimal	  trauma,	  and	  may	  not	  be	  significant	  enough	  to	  induce	  the	  immune	  system	  into	  either	  a	  state	  requiring	  correction,	  or	  a	  state	  that	  can	  make	  good	  use	  of	  the	  immunomodulatory	  androstenes.	  	  However,	  the	  previous	  murine	  study	  utilized	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6mm	  wounds	  in	  mice	  with	  approximately	  one	  quarter	  of	  the	  body	  surface	  area	  of	  these	  rats.	  	  The	  wounds	  in	  these	  mice	  then	  approach	  0.7%	  of	  the	  body	  surface	  area,	  comparable	  to	  the	  12mm	  wounds	  in	  the	  rat.	  	  The	  subject	  may	  however	  be	  more	  complex	  as	  the	  increased	  wound	  size	  in	  the	  rat	  failed	  to	  produce	  the	  desired	  results.	  	   Some	  of	  the	  last	  identifiable	  and	  more	  complex	  issues	  to	  be	  examined	  as	  complicating	  factors	  for	  these	  experiments	  involve	  the	  catabolism	  and	  interaction	  of	  the	  administered	  as	  well	  as	  the	  endogenous	  steroids.	  	  Namely,	  is	  the	  catabolism	  of	  androstenediol	  and/or	  methylprednisolone	  different	  in	  the	  rat	  than	  in	  the	  murine	  model?	  	  Secondly,	  could	  the	  metabolites	  of	  these	  drugs	  interfere	  or	  otherwise	  alter	  the	  effects	  of	  the	  other?	  	  Lastly,	  is	  there	  a	  relationship	  between	  trauma,	  inflammation	  and	  the	  catabolism	  of	  these	  drugs	  and	  the	  subsequent	  metabolites?	  	  The	  catabolism	  of	  both	  endogenous	  and	  exogenous	  steroids,	  including	  mineralocorticoids,	  glucocorticoids,	  and	  sex	  steroids,	  is	  commonly	  known	  to	  be	  completed	  primarily	  in	  the	  liver.	  	  This	  is	  not	  to	  say	  that	  these	  steroids	  are	  not	  catabolized	  at	  other	  sites	  in	  the	  body,	  as	  they	  are.	  	  Studies	  seeking	  to	  compare	  the	  existence	  and	  activity	  of	  p450	  enzymes	  (also	  known	  as	  CYP	  enzymes)	  have	  long	  sought	  to	  draw	  relationships	  between	  human	  and	  animal	  models.	  	  Recent	  studies	  in	  fact,	  have	  characterized	  both	  the	  mouse	  and	  the	  male	  rat	  as	  the	  species	  most	  similar	  to	  man	  in	  their	  inhibition	  and	  enzymatic	  activities	  when	  examining	  the	  catabolism	  of	  testosterone	  [118].	  	  This	  is	  of	  course	  a	  broad	  generalization	  both	  due	  to	  the	  difference	  in	  the	  species	  as	  well	  as	  the	  wide	  range	  of	  various	  human	  cytochrome	  p450	  levels	  due	  to	  inter-­‐individual	  variation	  and	  genetic	  polymorphisms.	  	  Due	  to	  the	  broad	  diversity	  of	  p450	  enzymes	  and	  the	  common	  redundancy	  witnessed	  in	  
Monday,	  August	  9,	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  F.	  Jerome	  Diskin	  119	  
important	  biological	  systems,	  it	  seems	  unlikely	  that	  a	  single	  enzyme	  is	  wholly	  responsible	  for	  the	  catabolism	  of	  any	  of	  the	  steroid	  species	  administered	  during	  the	  course	  of	  the	  experiments.	  	  However,	  some	  common	  enzymes	  have	  come	  to	  be	  recognized	  across	  the	  animal	  species	  we	  are	  examining	  here.	  	  P450-­‐7B1,	  a	  potent	  7-­‐
α	  hydroxylase	  has	  been	  observed	  operating	  in	  the	  brain,	  skin,	  prostate,	  and	  the	  liver,	  all	  frequent	  targets	  of	  steroid	  messengers	  [119].	  	  However,	  and	  perhaps	  most	  interesting,	  while	  mice	  are	  able	  to	  carry	  out	  7α-­‐hydroxylation	  in	  lymphocytes,	  human	  are	  not	  [120].	  	  Research	  into	  whether	  rats	  express	  the	  ability	  to	  conduct	  7α-­‐hydroxylation	  in	  lymphocytes	  remains	  unanswered.	  	  In	  addition,	  this	  enzyme	  is	  responsible	  for	  the	  7α-­‐hydroxylation	  of	  circulating	  3β-­‐hydroxysteroids,	  including	  DHEA,	  5-­‐androstene-­‐3β,	  17β-­‐diol	  (AED),	  and	  estradiol	  [121].	  	  Expressed	  at	  human	  chromosome	  eight,	  rat	  chromosome	  2,	  and	  mouse	  chromosome	  3,	  the	  enzyme	  has	  been	  found	  to	  produce	  the	  expected	  metabolites	  from	  these	  precursors	  in	  the	  skin,	  spleen,	  thymus,	  prostate	  and	  joints.	  	  However,	  earlier	  work	  had	  identified	  6β-­‐hydroxylation	  as	  the	  common	  mechanisms	  responsible	  for	  the	  catabolism	  of	  testosterone,	  androstenedione,	  and	  progesterone	  in	  both	  rat	  and	  human	  studies	  [122].	  	  There	  is	  some	  likelihood	  that	  this	  enzyme	  identified	  by	  Waxman	  et	  al.	  [122]	  is	  also	  known	  as	  CYP3A4,	  characterized	  by	  its	  6β-­‐hydroxylation	  of	  testosterone	  and	  inhibition	  by	  itraconazole	  [123].	  	  Thus	  it	  is	  very	  likely	  that	  there	  are	  multiple	  mechanisms	  for	  the	  metabolism	  of	  the	  various	  steroid	  species,	  perhaps	  even	  redundant	  mechanisms	  for	  the	  same	  steroid.	  	  There	  appear	  to	  be	  some	  similarities	  as	  well	  as	  some	  differences	  among	  these	  enzymes	  when	  considering	  the	  different	  animal	  species	  examined	  in	  this	  paper.	  	  Therefore,	  we	  must	  be	  careful	  when	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comparing	  the	  metabolism	  of	  steroid	  species	  between	  these	  organisms	  and	  be	  mindful	  of	  the	  differences	  between	  them.	  While	  the	  identification	  of	  these	  enzymes	  is	  not	  terribly	  important	  for	  this	  work,	  it	  is	  important	  to	  recognize	  that	  there	  are	  likely	  separate	  enzymes	  processing	  the	  drugs	  introduced	  to	  our	  subjects.	  	  And	  while	  this	  difference	  seems	  clear,	  it	  is	  also	  possible	  that	  the	  structural	  nature	  of	  both	  drugs	  may	  mean	  that	  there	  is	  also	  some	  cross-­‐interaction	  between	  these	  enzymes	  and	  their	  substrates.	  	  At	  some	  undetermined	  level	  of	  concentration,	  it	  is	  possible	  to	  force	  an	  enzyme	  to	  metabolize	  a	  less	  preferable	  structure	  over	  the	  primary	  substrate.	  Beyond	  the	  possible	  overlap	  between	  steroid	  species	  and	  enzymes	  due	  to	  structural	  similarities,	  there	  is	  also	  some	  evidence	  that	  the	  administration	  of	  steroids	  can	  also	  alter	  the	  expression	  of	  P450	  enzymes.	  	  Studies	  examining	  the	  metabolites	  of	  common	  precursors	  in	  rats,	  including	  7α-­‐hydroxytestosterone,	  illustrated	  increased	  catabolism	  following	  high	  dose	  androstenedione	  [34].	  	  Conversely,	  a	  human	  study	  examined	  the	  effects	  of	  methylprednisolone	  administration	  on	  the	  activity	  of	  the	  CYP3A4	  enzyme	  and	  found	  that	  no	  alteration	  in	  activity	  could	  be	  found	  in	  short	  term	  high	  dose	  or	  long	  term	  low	  dose	  administration	  [124].	  	  Add	  to	  these	  equations	  any	  endogenous	  substrates	  created	  by	  wounding	  and	  the	  experimental	  process	  and	  there	  is	  at	  least	  the	  possibility	  that	  levels	  of	  one	  steroid	  may	  affect	  the	  catabolism	  of	  the	  other(s)	  by	  either	  the	  interference	  with	  enzyme	  binding	  or	  the	  increased	  expression	  of	  the	  enzyme	  itself.	  	  Lastly,	  one	  of	  the	  more	  important	  questions	  with	  regard	  to	  this	  study	  is	  how	  the	  events	  of	  injury	  and	  inflammation	  interact	  with	  the	  two	  steroidal	  agents	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(primarily	  methylprednisolone	  and	  AED),	  presumably	  to	  the	  benefit	  of	  the	  organism?	  	  As	  we	  have	  illustrated,	  there	  are	  separate	  but	  perhaps	  overlapping	  mechanisms	  for	  the	  catabolism	  of	  these	  compounds,	  and	  the	  mechanisms	  for	  the	  elimination	  of	  these	  compounds	  appear	  to	  be	  in	  place	  in	  both	  models,	  though	  perhaps	  to	  differing	  degrees.	  	  In	  addition,	  any	  perceived	  inequality	  due	  to	  the	  differences	  in	  wounding	  between	  the	  murine	  and	  rat	  models	  should	  not	  have	  any	  quantifiable	  difference,	  as	  the	  scale	  of	  wounding	  between	  the	  groups	  appears	  similar.	  	  However,	  it	  bears	  noting	  that	  there	  have	  been	  established	  relationships	  between	  the	  activity	  of	  the	  aforementioned	  p450	  enzymes	  and	  a	  state	  of	  inflammation.	  	  Dulos	  et	  al.	  has	  shown	  that	  the	  introduction	  of	  pro-­‐inflammatory	  cytokines	  increases	  mRNA	  levels	  of	  CYP7B,	  thus	  increasing	  catabolism	  of	  DHEA	  into	  the	  7-­‐α	  metabolite,	  which	  itself	  may	  contribute	  to	  the	  maintenance	  of	  chronic	  inflammation	  [125].	  	  	  In	  contrast,	  many	  more	  studies	  have	  indicated	  that	  infection	  and	  inflammation	  result	  in	  the	  reduction	  in	  capacity	  to	  eliminate	  drugs	  [126].	  	  This	  hypothesis	  has	  been	  reinforced	  many	  times,	  particularly	  in	  the	  rat	  model.	  	  No	  single	  mechanism	  has	  been	  attributable	  to	  this	  outcome;	  in	  fact	  reductions	  have	  been	  tied	  to	  repression	  of	  gene	  transcription,	  as	  well	  as	  protein	  turnover	  of	  cytochrome	  P450	  enzymes.	  	  These	  results	  are	  further	  attributable	  to	  exogenous	  as	  well	  as	  endogenous	  sources,	  including	  interferons,	  interleukins,	  and	  tumor	  necrosis	  factors.	  	  Therefore	  any	  difference	  in	  the	  expression	  of	  these	  signaling	  factors	  so	  prevalent	  within	  the	  immune	  system	  could	  exercise	  some	  effects	  on	  the	  catabolism	  of	  either	  the	  immunosupressor	  methylprednisolone,	  the	  immunomodulator	  androstenediol,	  or	  both.	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Conclusion	  These	  mini-­‐studies,	  as	  part	  of	  defining	  the	  parameters	  of	  a	  larger	  experiment,	  did	  in	  fact	  show	  some	  physiologic	  response	  to	  the	  drugs	  that	  were	  administered.	  	  While	  in	  some	  cases	  these	  differences	  were	  significant,	  we	  did	  not	  find	  any	  real	  difference	  in	  healing	  downstream	  of	  these	  changes.	  	  As	  discussed,	  there	  are	  many	  potential	  reasons	  that	  these	  results	  were	  different	  than	  those	  of	  previous	  experiments.	  Despite	  the	  disappointment	  of	  failing	  to	  show	  a	  difference	  in	  the	  rate	  of	  wound	  healing	  between	  the	  AED/DEPO	  and	  the	  DEPO	  only	  groups,	  it	  is	  perhaps	  from	  failure	  that	  we	  learn	  the	  most	  about	  how	  these	  agents	  exercise	  their	  influence.	  	  Ultimately,	  it	  seems	  that	  the	  levels	  of	  cytokine	  expression	  during	  these	  experiments	  gave	  the	  clearest	  indication	  that	  the	  model	  of	  trauma	  utilized	  here	  was	  not	  severe	  enough	  to	  induce	  expression	  of	  some	  of	  the	  most	  commonly	  measured	  pro-­‐inflammatory	  cytokines.	  	  While	  this	  threshold	  may	  be	  different	  than	  was	  necessary	  in	  earlier	  models,	  the	  rat	  appears	  to	  be	  more	  well	  positioned	  to	  resist	  a	  pro-­‐inflammatory	  state,	  and	  thus	  perhaps	  was	  not	  as	  well	  equipped	  to	  receive,	  or	  in	  need	  of,	  the	  immunomodulatory	  agents	  administered.	  Furthermore,	  the	  interaction	  between	  different	  exogenous	  and	  endogenous	  steroids	  raise	  significant	  questions	  with	  regard	  to	  how	  these	  compounds	  effects	  each	  other,	  as	  well	  as	  how	  they	  effect	  the	  metabolism	  of	  themselves	  and	  similar	  compounds.	  	  In	  addition,	  one	  of	  the	  most	  important	  lessons	  may	  be	  that	  systemic	  expression	  of	  inflammatory	  markers	  may	  not	  always	  be	  a	  good	  marker	  of	  local	  activity.	  	  These	  questions	  all	  bear	  consideration,	  however,	  they	  are	  perhaps	  only	  worth	  examining	  in	  a	  model	  in	  which	  there	  exists	  an	  inflammatory	  state	  in	  need	  of	  modulation.
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